CUMULATIVE
SUPPLEMENT 11

JAN'91-NOV'91



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

11TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

11TH EDITION

Cumulative Supplement

November 1991

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

11TH EDITION

CUMULATIVE SUPPLEMENT 11

NOVEMBER 1991

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 11th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Division of Blood and Blood Products and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Division of Blood and Blood Products lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product, along with the application number and product number (FDA's internal file number). All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item. A newly approved product is also identified by a lozenge (⌑) to the right of its strength which remains throughout all Cumulative Supplements for this edition.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line containing overstruck print. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the " ∋ " symbol to designate their non-marketed status. All products having a " ∋ " symbol in the 12th Cumulative Supplement of the 11th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 12th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 5, 1985 (50 FR 27688)
Tranylcypromine Sulfate	MAR 22, 1984 (49 FR 10708)

1.3 CHANGE OF A THERAPEUTIC EQUIVALENCY CODE FOR A DRUG ENTITY

Methylphenidate Hydrochloride:

In its initial considerations, the Agency did not classify methylphenidate hydrochloride (MPD) as having an actual or potential bioequivalence problem (42 FR 1624, January 7, 1977). MPD in oral tablet form (Ritalin™, manufactured by Ciba Pharmaceuticals) is a DESI drug product that was raised to the effective status on October 7, 1970 (35 FR 15771). MPD in tablet form remained single source until December 23, 1977 when it became available from MD Pharmaceutical. In the first and subsequent editions of the "Orange Book" this drug product has been coded coded **AA**.

Recently, FDA's Therapeutic Inequivalence Action Coordination Committee (TIACC) investigated a report from the Kaiser Permanente Medical Care Program in Oakland, California, suggesting therapeutic inequivalence regarding duration of action in a marketed lot of MD Pharmaceutical MPD tablets. Samples from MD Pharmaceutical and Ciba were tested in accordance with USP dissolution test procedures by an FDA field laboratory. Although both products met the single point USP criteria of not less than 75% of the labeled amount of MPD dissolved within 45 minutes, the dissolution profile of the MD Pharmaceutical product was much faster than that of the Ciba product.

Based on these in vitro dissolution data, FDA commissioned an in vivo bioequivalence study under its extramural contract research program. The bioequivalence study indicated that at one-half and three-fourths hours after administration of a single 20 mg dose, somewhat more of MD Pharmaceutical's product had been absorbed compared to Ciba's Ritalin. However, the MD Pharmaceutical MPD 20 mg tablets met FDA's criteria for rate and extent of absorption, and were considered to be bioequivalent to Ciba's Ritalin 20 mg tablets.

Because of the in vitro dissolution data coupled with new information discovered during the course of this evaluation, the FDA has proposed a change in the therapeutic equivalence code from **AA** to **BP** for listed MPD tablets. This change requires that firms submitting an ANDA for MPD tablets submit an acceptable in vivo bioequivalence study to gain approval in addition to submission of all previously required information.

Agency reasons for considering this change in the equivalence code is as follows:

1) Although early work suggested that MPD tablets are completely absorbed recent studies utilizing more specific techniques calculated the relative bioavailability to be 11 to 53%. (Chan et al: Pediatrics, **72**, 56-59, 1983). This raised concerns regarding possible approval of a superbioavailable drug product.

2) The current dl-MPD pharmacological activity derives primarily from the d isomer which may exhibit non-linear kinetics. (Srinivas et al: Journal of Pharmacology and Experimental Therapeutics, **241**, 300-306, 1987).

3) The previously cited in vitro dissolution data suggesting that substantial differences in in vitro dissolution may exist between different formulations of MPD.

The Agency invites written comments and scientific data regarding the Agency's proposal to change the therapeutic equivalence code for listed MPD oral tablets from **AA** to **BP**. The comment period will be 60 days from the first day in the monthly Supplement.

1.4 THE B* THERAPEUTIC EQUIVALENCE CODE

Drug products requiring further FDA investigation and review to determine therapeutic equivalence.

The code **B*** is assigned to products that were previously assigned an **A** or **B** code if FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

1.5 APPLICANT (NAME) CHANGES

Because it is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT (NAME) CHANGES

FORMER APPLICANT (NAME)	NEW APPLICANT (NAME)	ABBREVIATED NAME
CORD LABORATORIES INC	GENEVA PHARMACEUTICALS INC	GENEVA
GIST BROCADES	BROCADES PHARMA bv	BROCADES PHARMA
ICI PHARMACEUTICALS PR INC	IPR PHARMACEUTICALS INC	IPR
KENDALL MCGAW PHARMACEUTICALS	GENSIA PHARMACEUTICALS INC	GENSIA
PHARMACIA LABORATORIES DIV PHARMACIA INC	KABI PHARMACIA	KABI
REID ROWELL INC	SOLVAY PHARMACEUTICALS	SOLVAY

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1990) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1990	MAR 1991	JUN 1991	SEP 1991
DRUG PRODUCTS LISTED	10123	9953	9900	9869
SINGLE SOURCE	2030 (20.1%)	2090 (21.0%)	2110 (21.3%)	2103 (21.4%)
MULTISOURCE	8093 (79.9%)	7863 (79.0%)	7790 (78.7%)	7766 (78.6%)
THERAPEUTICALLY EQUIVALENT	7222 (71.3%)	7061 (71.0%)	6937 (70.1%)	6914 (70.0%)
NOT THERAPEUTICALLY EQUIVALENT	752 (7.4%)	660 (6.6%)	702 (7.1%)	706 (7.2%)
EXCEPTIONS[1]	119 (1.2%)	142 (1.4%)	151 (1.5%)	146 (1.4%)
NEW MOLECULAR ENTITIES APPROVED	--	5	4	3
NUMBER OF APPLICANTS	400	408	417	418

[1]Amino acid-containing products of varying composition (see Introduction, page 1-8 of the List).

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

/PROVAL #3/			
/AA/ /SOLVAY/	/325MG;30MG/	/N85685/001/
ə SOLVAY	325MG;30MG	N85685 001
/TYLENOL W/ CODEINE NO. 3/		
/AA/ /JOHNSON/RW/	/300MG;30MG/	/N87422/001/
ə JOHNSON RW	300MG;30MG	N87422 001
/TYLENOL W/ CODEINE NO. 4/		
/JOHNSON/RW/	/300MG;60MG/	/N87421/001/
ə JOHNSON RW	300MG;60MG	N87421 001

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

MIKART	650MG;60MG¤	N89363 001 SEP 25, 1991

ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 2

/AA/	/AM/THERAP/	/300MG;15MG/	/N89481/001/ /MAR/03,/1987/
	ə AM THERAP	300MG;15MG	N89481 001 MAR 03, 1987

ACETAMINOPHEN W/ CODEINE PHOSPHATE

/AA/	/PARKE/DAVIS/	/300MG;60MG/	/N87306/001/
	ə WARNER CHILCOTT	300MG;60MG	N87306 001
	/TYLENOL W/ CODEINE/		
/AA/	/JOHNSON/RW/	/325MG;15MG/	/N85056/002/
/AA/		/325MG;30MG/	/N85056/003/
		/325MG;7.5MG/	/N85056/001/
		/325MG;60MG/	/N85056/004/
	ə JOHNSON RW	325MG;7.5MG	N85056 001
	ə	325MG;15MG	N85056 002
	ə	325MG;30MG	N85056 003
	ə	325MG;60MG	N85056 004

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	MIKART	500MG;2.5MG	N89698 001 AUG 25, 1989
AA		500MG;7.5MG	N89699 001 AUG 25, 1989
		/500MG;2.5MG/	/N89698/001/ /AUG/25,/1989/
		/500MG;7.5MG/	/N89699/001/ /AUG/25,/1989/
/AA/	/PHARM/BASICS/	/500MG;5MG/	/N89291/001/ /MAY/29,/1987/
B*	PHARM BASICS	500MG;5MG	N89291 001 MAY 29, 1987

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	WATSON	500MG;2.5MG¤	N81079 001 AUG 30, 1991
AA		500MG;7.5MG¤	N81080 001 AUG 30, 1991
AA		750MG;7.5MG¤	N81083 001 AUG 30, 1991

VICODIN ES

AA	KNOLL	750MG;7.5MG	N89736 001 DEC 09, 1988
		/750MG;7.5MG/	/N89736/001/ /DEC/09,/1988/

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

/TYLOX-325/			
/JOHNSON/RW/	/325MG;5MG/	/N88246/001/ /NOV/08,/1984/
ə JOHNSON RW	325MG;5MG	N88246 001 NOV 08, 1984

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

/AB/	/BOLAR/	/325MG;50MG/	/N70398/001/ /DEC/18,/1986/
/AB/		/650MG;100MG/	/N70399/001/ /DEC/18,/1986/
	ə BOLAR	325MG;50MG	N70398 001 DEC 18, 1986
	ə	650MG;100MG	N70399 001 DEC 18, 1986
/AB/	/CHELSEA/	/325MG;50MG/	/N71336/001/ /DEC/11,/1986/
/AB/		/650MG;100MG/	/N71337/001/ /DEC/11,/1986/
B*	CHELSEA	325MG;50MG	N71336 001 DEC 11, 1986
B*		650MG;100MG	N71337 001 DEC 11, 1986

ACETAZOLAMIDE

TABLET; ORAL
ACETAZOLAMIDE

	∂ ALRA	250MG	N83320 001				
/∂/	/BANMAX/	/250MG/	/N83320/001/	> DLT >			
/AB/	/BOLAR/	/250MG/	/N84498/002/	> DLT >	/AN/	/QUAD/	/10%/ /N71740/001/ /AUG/11,/1987/
	∂ BOLAR	250MG	N84498 002	> DLT >			/20%/ /N71741/001/ /AUG/11,/1987/
				> ADD >		∂ QUAD	10% N71740 001 AUG 11, 1987
				> ADD >		∂	20% N71741 001 AUG 11, 1987

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC
/ORLEX/

/AT/	/NORWICH/EATON/	/2%/	/N86845/001/	
	∂ NORWICH EATON	2%	N86845 001	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC
/ORLEX HC/

/AT/	/NORWICH/EATON/	/2%;1%/	/N86844/001/	
	∂ NORWICH EATON	2%;1%	N86844 001	

ACETOHEXAMIDE

TABLET; ORAL
ACETOHEXAMIDE

/AB/	/PHARM/BASICS/	/250MG/	/N70753/001/ /NOV/03,/1986/	> ADD >			
/AB/		/500MG/	/N70754/001/ /NOV/03,/1986/	> ADD >	AB	COPLEY	EQ 2MG BASE¤ N72966 001 NOV 22, 1991
B*	PHARM BASICS	250MG	N70753 001 NOV 03, 1986	> ADD >	AB		EQ 4MG BASE¤ N72967 001 NOV 22, 1991
B*		500MG	N70754 001 NOV 03, 1986	> ADD >	AB	DANBURY	EQ 2MG BASE¤ N72629 001 JAN 31, 1991
					AB		EQ 4MG BASE¤ N72630 001 JAN 31, 1991
					AB	MYLAN	EQ 2MG BASE¤ N72893 001 JAN 17, 1991
					AB		EQ 4MG BASE¤ N72894 001 JAN 17, 1991
					AB	WATSON	EQ 2MG BASE¤ N72764 001 AUG 28, 1991
					AB		EQ 4MG BASE¤ N72765 001 AUG 28, 1991

ACETOPHENAZINE MALEATE

/TABLET;/ORAL/
/TINDAL/

/BP/	/SCHERING/	/20MG/	/N12254/002/	
	∂ SCHERING	20MG	N12254 002	

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL
ACETYLCYSTEINE

> DLT >	/AN/	/QUAD/	/10%/	/N71740/001/ /AUG/11,/1987/			
> DLT >			/20%/	/N71741/001/ /AUG/11,/1987/			
> DLT >		∂ QUAD	10%	N71740 001 AUG 11, 1987			
> ADD >		∂	20%	N71741 001 AUG 11, 1987			

ACYCLOVIR

TABLET; ORAL
ZOVIRAX

BURROUGHS WELLCOME	400MG¤	N20089 001 APR 30, 1991	
	800MG¤	N20089 002 APR 30, 1991	

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

> ADD >				
> ADD >	AN	COPLEY	EQ 0.5% BASE¤	N73307 001 NOV 27, 1991
> ADD >				

TABLET; ORAL
ALBUTEROL SULFATE

> ADD >	AB	COPLEY	EQ 2MG BASE¤	N72966 001 NOV 22, 1991
> ADD >	AB		EQ 4MG BASE¤	N72967 001 NOV 22, 1991
> ADD >	AB	DANBURY	EQ 2MG BASE¤	N72629 001 JAN 31, 1991
	AB		EQ 4MG BASE¤	N72630 001 JAN 31, 1991
	AB	MYLAN	EQ 2MG BASE¤	N72893 001 JAN 17, 1991
	AB		EQ 4MG BASE¤	N72894 001 JAN 17, 1991
	AB	WATSON	EQ 2MG BASE¤	N72764 001 AUG 28, 1991
	AB		EQ 4MG BASE¤	N72765 001 AUG 28, 1991

ALCOHOL

INJECTABLE; INJECTION
ALCOHOL 5% IN DEXTROSE 5%
/AP/ /CUTTER/ /5ML/100ML/ /N83483/001/
∂ CUTTER 5ML/100ML N83483 001

ALGLUCERASE

INJECTABLE; INJECTION
CEREDASE
GENZYME 80 UNITS/ML¤ N20057 003 APR 05, 1991

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL
/AB/ /BOLAR/ /300MG/ /N18241/002/ /NOV/16,/1984/
∂ BOLAR 300MG N18241 002 NOV 16, 1984
/AB/ /PUREPAC/ /100MG/ /N70579/001/ /APR/14,/1986/
/AB/ /300MG/ /N70580/001/ /APR/14,/1986/
∂ PUREPAC 100MG N70579 001 APR 14, 1986
∂ 300MG N70580 001 APR 14, 1986

ALPRAZOLAM

TABLET; ORAL
XANAX
/∂/UPJOHN/ /2MG/ /N18276/004/ /NOV/27,/1985/
UPJOHN 2MG N18276 004 NOV 27, 1985

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
AMANTADINE HCL
AA COPLEY 50MG/5ML¤ N73115 001 AUG 23, 1991

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE
AB GENEVA 5MG;50MG¤ N73357 001 NOV 27, 1991
AB MYLAN 5MG;50MG¤ N73209 001 OCT 31, 1991
AB ROYCE 5MG;50MG¤ N73334 001 JUL 19, 1991

AMINOCAPROIC ACID

INJECTABLE; INJECTION
AMINOCAPROIC ACID
> DLT >/AP/ /QUAD/ /250MG/ML/ /N70694/001/ /MAR/04,/1986/
> DLT >
> ADD > ∂ QUAD 250MG/ML N70694 001 MAR 04, 1986
> ADD >

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION
AMINOHIPPURATE SODIUM
> DLT >/AP/ /MSD/ /20%/ /N05619/001/
> ADD > MSD 20% N05619 001
> DLT >/AP/ /QUAD/ /20%/ /N89821/001/ /JUL/14,/1988/
> DLT >
> ADD > ∂ QUAD 20% N89821 001 JUL 14, 1988
> ADD >

AMINOPHYLLINE

INJECTABLE; INJECTION
AMINOPHYLLINE
AP GENSIA 25MG/ML¤ N81142 001 SEP 25, 1991
/AP/ /INTL/MEDICATION/ /25MG/ML/ /N87867/001/ /NOV/10,/1983/
/AP/ /25MG/ML/ /N87868/001/ /NOV/10,/1983/
∂ INTL MEDICATION 25MG/ML N87867 001 NOV 10, 1983
∂ 25MG/ML N87868 001 NOV 10, 1983
/AP/ /SOLOPAK/ /25MG/ML/ /N88429/001/ /MAY/30,/1985/
∂ SOLOPAK 25MG/ML N88429 001 MAY 30, 1985

AMINOPHYLLINE

TABLET; ORAL
AMINOPHYLLINE

BD	LANNETT	100MG	N84588 001
BD		200MG	N84588 002
/ə/		/100MG/	/N84588/001/
/ə/		/200MG/	/N84588/002/

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
/AMITID/

/AB/	/SQUIBB/	/10MG/	/N86454/001/
/AB/		/25MG/	/N86454/002/
/AB/		/50MG/	/N86454/003/
/AB/		/75MG/	/N86454/004/
/AB/		/100MG/	/N86454/005/
ə	SQUIBB	10MG	N86454 001
ə		25MG	N86454 002
ə		50MG	N86454 003
ə		75MG	N86454 004
ə		100MG	N86454 005

AMITRIPTYLINE HCL

/AB/	/BARR/	/10MG/	/N85744/001/
/AB/		/25MG/	/N85627/001/
/AB/		/50MG/	/N85745/001/
/AB/		/75MG/	/N85743/001/
/AB/		/100MG/	/N85742/002/
			/MAY/11,/1982/
/AB/		/150MG/	/N89423/001/
			/FEB/17,/1987/
ə	BARR	10MG	N85744 001
ə		25MG	N85627 001
ə		50MG	N85745 001
ə		75MG	N85743 001
ə		100MG	N85742 002
			MAY 11, 1982
ə		150MG	N89423 001
			FEB 17, 1987

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL

/AB/	/PHARM/BASICS/	/EQ 12.5MG BASE;5MG/	/N70477/001/ /JAN/12,/1988/
/AB/		/EQ 25MG BASE;10MG/	/N70478/001/ /JAN/12,/1988/
B*	PHARM BASICS	EQ 12.5MG BASE;5MG	N70477 001 JAN 12, 1988
B*		EQ 25MG BASE;10MG	N70478 001 JAN 12, 1988

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL

/AB/	/BOLAR/	/10MG;2MG/	/N70373/001/ /AUG/25,/1986/
/AB/		/10MG;4MG/	/N70375/001/ /AUG/25,/1986/
/AB/		/25MG;2MG/	/N70374/001/ /AUG/25,/1986/
/AB/		/25MG;4MG/	/N70376/001/ /AUG/25,/1986/
/AB/		/50MG;4MG/	/N70377/001/ /NOV/04,/1986/
ə	BOLAR	10MG;2MG	N70373 001 AUG 25, 1986
ə		10MG;4MG	N70375 001 AUG 25, 1986
ə		25MG;2MG	N70374 001 AUG 25, 1986
ə		25MG;4MG	N70376 001 AUG 25, 1986
ə		50MG;4MG	N70377 001 NOV 04, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HCL

/AB/	/CHELSEA/	/10MG;2MG/	/N71384/001/ /NOV/03,/1986/
/AB/		/10MG;4MG/	/N71386/001/ /NOV/03,/1986/
/AB/		/25MG;2MG/	/N71385/001/ /NOV/03,/1986/
/AB/		/25MG;4MG/	/N71387/001/ /NOV/03,/1986/
B*	CHELSEA	10MG;2MG	N71384 001 NOV 03, 1986
B*		10MG;4MG	N71386 001 NOV 03, 1986
B*		25MG;2MG	N71385 001 NOV 03, 1986
B*		25MG;4MG	N71387 001 NOV 03, 1986
/B*/		/50MG;4MG¤/	/N71558/001/ /MAR/02,/1987/
∂		50MG;4MG¤	N71558 001 MAR 02, 1987
AB	ROYCE	10MG;2MG¤	N73007 001 OCT 17, 1991
AB		10MG;4MG¤	N73009 001 OCT 17, 1991
AB		25MG;2MG¤	N73008 001 OCT 17, 1991
AB		25MG;4MG¤	N73010 001 OCT 17, 1991

AMOXAPINE

TABLET; ORAL

AMOXAPINE

AB	GENEVA	25MG¤	N72943 001 JUN 28, 1991
AB		50MG¤	N72944 001 JUN 28, 1991
AB		100MG¤	N72878 001 JUN 28, 1991
AB		150MG¤	N72879 001 JUN 28, 1991

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

/AP/	/INTL/MEDICATION/	/EQ 1GM BASE/VIAL/	/N62634/002/ /JAN/09,/1987/
/AP/		/EQ 2GM BASE/VIAL/	/N62634/003/ /JAN/09,/1987/
∂	INTL MEDICATION	EQ 1GM BASE/VIAL	N62634 002 JAN 09, 1987
∂		EQ 2GM BASE/VIAL	N62634 003 JAN 09, 1987

POLYCILLIN-N

AP	BRISTOL	EQ 10GM BASE/VIAL	N61395 006

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

PENBRITIN

/AB/	/WYETH/AYERST/	/EQ 250MG BASE/	/N60908/001/
/AB/		/EQ 500MG BASE/	/N60908/002/
∂	WYETH AYERST	EQ 250MG BASE	N60908 001
∂		EQ 500MG BASE	N60908 002

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 LYOPHILIZED

/AP/	/ARMOUR/	/100MG/VIAL;0.06MG/VIAL;/ /0.005MG/VIAL;15MG/VIAL;5UGM/VIAL;/ /0.4MG/VIAL;40MG/VIAL;4MG/VIAL;/ /3.6MG/VIAL;3MG/VIAL;1MG/VIAL;/ /10MG/VIAL/	/N18933/002/ /AUG/08,/1985/
AP	ASTRA	100MG/VIAL;0.06MG/VIAL; 0.005MG/VIAL;15MG/VIAL;5UGM/VIAL; 0.4MG/VIAL;40MG/VIAL;4MG/VIAL; 3.6MG/VIAL;3MG/VIAL;1MG/VIAL; 10MG/VIAL	N18933 002 AUG 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

MVC PLUS

/AP/	/ASCOT/	/10MG/ML;0.006MG/ML;0.5UGM/ML;/ /1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;/ /0.4MG/ML;0.36MG/ML;0.3MG/ML;/ /330 UNITS/ML;1 IU/ML/	/N18439/002/ /AUG/08,/1985/	
AP	STERIS	10MG/ML;0.006MG/ML;0.5UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML; 0.4MG/ML;0.36MG/ML;0.3MG/ML; 330 UNITS/ML;1 IU/ML	N18439 002 AUG 08, 1985	

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

/BUTALBITAL W/ ASPIRIN AND CAFFEINE/

/AB/	/CHELSEA/	/325MG;50MG;40MG/	/N86231/002/ /FEB/12,/1985/	

BUTALBITAL, ASPIRIN AND CAFFEINE

AB	CHELSEA	325MG;50MG;40MG	N86231 002 FEB 12, 1985	

TABLET; ORAL

/BUTALBITAL W/ ASPIRIN AND CAFFEINE/

/AB/	/CHELSEA/	/325MG;50MG;40MG/	/N86237/002/ /MAR/23,/1984/	

BUTALBITAL, ASPIRIN AND CAFFEINE

AB	CHELSEA	325MG;50MG;40MG	N86237 002 MAR 23, 1984	

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

B*	PAR	385MG;30MG;25MG	N71642 001 JUN 23, 1987	
/BX/		/385MG;30MG;25MG/	/N71642/001/ /JUN/23,/1987/	> ADD >

ORPHENGESIC FORTE

B*	PAR	770MG;60MG;50MG	N71643 001 JUN 23, 1987	> ADD >
/BX/		/770MG;60MG;50MG/	/N71643/001/ /JUN/23,/1987/	> ADD >

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

COMPOUND 65

@	ALRA	389MG;32.4MG;65MG	N84553 002 AUG 17, 1983
/@/	/BANMAX/	/389MG;32.4MG;65MG/	/N84553/002/ /AUG/17,/1983/

ASPIRIN; CARISOPRODOL

TABLET; ORAL

/CARISOPRODOL COMPOUND/

/AB/	/BOLAR/	/325MG;200MG/	/N88809/001/ /OCT/03,/1985/	
@	BOLAR	325MG;200MG	N88809 001 OCT 03, 1985	

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	GENEVA	50MG¤	N73025 001 SEP 17, 1991	
AB		100MG¤	N73026 001 SEP 17, 1991	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HCL AND ATROPINE SULFATE

/AA/	/HEATHER/	/0.025MG;2.5MG/	/N86798/001/	
@	HEATHER	0.025MG;2.5MG	N86798 001	
/AA/	/LOMOXATE CORD/	/0.025MG;2.5MG/	/N85311/002/	

LOMOX

AA	CORD	0.025MG;2.5MG	N85311 002	

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

	ANAQUEST	0.14MG/ML;10MG/ML¤	N19677 001 NOV 06, 1991	> ADD >
		0.14MG/ML;10MG/ML¤	N19678 001 NOV 06, 1991	> ADD >

>ADD> AZITHROMYCIN

>ADD> CAPSULE; ORAL
>ADD> ZITHROMAX
>ADD> PFIZER
>ADD>

250MG¤	N50670 001 NOV 01, 1991		

BACLOFEN

TABLET; ORAL
BACLOFEN

AB	DANBURY	10MG¤	N72824 001 SEP 18, 1991
AB		20MG¤	N72825 001 SEP 18, 1991
/AA/	/PHARM/BASICS/	/10MG/	/N71260/001/ /MAY/06,/1988/
/AA/		/20MG/	/N71261/001/ /MAY/06,/1988/
B*	PHARM BASICS	10MG	N71260 001 MAY 06, 1988
B*		20MG	N71261 001 MAY 06, 1988

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL
LOTENSIN
CIBA

EQ 5MG BASE¤	N19851 001 JUN 25, 1991	
EQ 10MG BASE¤	N19851 002 JUN 25, 1991	
EQ 20MG BASE¤	N19851 003 JUN 25, 1991	
EQ 40MG BASE¤	N19851 004 JUN 25, 1991	

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE

/AA/	/PHARM/BASICS/	/0.5MG/	/N89211/001/ /JUN/14,/1988/
/AA/		/1MG/	/N89212/001/ /JUN/14,/1988/
/AA/		/2MG/	/N89213/001/ /JUN/14,/1988/
B*	PHARM BASICS	0.5MG	N89211 001 JUN 14, 1988
B*		1MG	N89212 001 JUN 14, 1988
B*		2MG	N89213 001 JUN 14, 1988

BERACTANT

SUSPENSION; INTRATRACHEAL
SURVANTA
ROSS

25MG/ML¤	N20032 001 JUL 01, 1991	

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

>DLT> /BETHANECHOL CHLORIDE/
>DLT>/AP/ /QUAD/ /5MG/ML/ /N89815/001/
>DLT> /APR/12,/1988/
>ADD> ∂ QUAD 5MG/ML N89815 001
>ADD> APR 12, 1988

URECHOLINE

>DLT>/AP/	/MSD/	/5MG/ML/	/N06536/001/
>ADD>	MSD	5MG/ML	N06536 001

TABLET; ORAL
BETHANECHOL CHLORIDE

/AA/	/BOLAR/	/5MG/	/N85230/002/
/AA/		/10MG/	/N85228/001/
/AA/		/25MG/	/N85229/001/
/AA/		/50MG/	/N87397/002/
∂	BOLAR	5MG	N85230 002
∂		10MG	N85228 001
∂		25MG	N85229 001
∂		50MG	N87397 001

DUVOID

/AA/	/NORWICH/EATON/	/10MG/	/N86262/001/
/AA/		/25MG/	/N85882/002/
/AA/		/25MG/	/N86263/001/
/AA/		/50MG/	/N85882/003/

BETHANECHOL CHLORIDE

TABLET; ORAL
DUVOID

AA	ROBERTS	10MG	N86262 001
AA		25MG	N86263 001
AA		50MG	N85882 003

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE

> DLT > /AP/	/QUAD/	/50MG/ML/	/N71181/001/ /FEB/16,/1988/
> DLT >			
> ADD >	∂ QUAD	50MG/ML	N71181 001 FEB 16, 1988
> ADD >			

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

	/ABBOTT/	/800MG/100ML/	/N19008/001/ /APR/16,/1986/
	∂ ABBOTT	800MG/100ML	N19008 001 APR 16, 1986

BROMPHENIRAMINE MALEATE

TABLET; ORAL
BROMPHENIRAMINE MALEATE

/AA/	/PAR/	/4MG/	/N87009/001/
	∂ PAR	4MG	N87009 001
/AA/	/VITARINE/	/4MG/	/N85850/001/
	∂ VITARINE	4MG	N85850 001

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR;ORAL
BIPHETAP

	/PHARM BASICS/	/4MG/5ML;25MG/5ML/	/N88687/001/ /SEP/26,/1984/
	∂ PHARM BASICS	4MG/5ML;25MG/5ML	N88687 001 SEP 26, 1984

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPRENEX

	/NORWICH/EATON/	/EQ/0.3MG/BASE/ML/	/N18401/001/
	R AND C	EQ 0.3MG BASE/ML	N18401 001

BUPROPION HYDROCHLORIDE

TABLET; ORAL
WELLBUTRIN

	/BURROUGHS/WELLCOME/	/50MG/	/N18644/001/ /DEC/30,/1985/
	∂ BURROUGHS WELLCOME	50MG	N18644 001 DEC 30, 1985

BUTABARBITAL SODIUM

TABLET; ORAL
BUTABARBITAL SODIUM

/AA/	/CORD/	/15MG/	/N84292/003/ /FEB/09,/1982/
/AA/		/30MG/	/N84272/002/
	∂ CORD	15MG	N84292 003 FEB 09, 1982
	∂	30MG	N84272 002
/AA/	/WHITE/TOWNE/PAULSEN/	/15MG/	/N83325/002/
	∂ WHITE TOWNE PAULSEN	15MG	N83325 002

CALCITONIN, SALMON

INJECTABLE; INJECTION
CALCIMAR

AP	RHONE POULENC RORER	200 IU/ML	N17769 001

MIACALCIN

AP	SANDOZ	200 IU/ML¤	N17808 002 MAR 29, 1991

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION
BSS PLUS

> ADD >	AT	ALCON	0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML	N18469 001
> ADD >				
> ADD >				
> ADD >		ENDOSOL PLUS		
> ADD >	AT	ENTRAVISION	0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML¤	N20079 001 NOV 27, 1991
> ADD >				
> ADD >				
> ADD >				

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

/INJECTABLE;/INJECTION/
/ACETATED/RINGER'S/IN/PLASTIC/CONTAINER/
/MCGAW/ /20MG/100ML;30MG/100ML;380MG/100ML;/ /N18725/001/
/600MG/100ML/ /NOV/29,/1982/

	ə MCGAW	20MG/100ML;30MG/100ML;380MG/100ML; 600MG/100ML	N18725 001 NOV 29, 1982

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION
CALCIUM GLUCEPTATE

/AP/	/ABBOTT/	/EQ 90MG CALCIUM/5ML/	/N83159/001/	
	ə ABBOTT	EQ 90MG CALCIUM/5ML	N83159 001	

CARBAMAZEPINE

TABLET; ORAL
CARBAMAZEPINE

/AB/	/PHARM/BASICS/	/200MG/	/N70300/001/ /MAY/15,/1986/	
B*	PHARM BASICS	200MG	N70300 001 MAY 15, 1986	

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL
SINEMET CR

	MSD	50MG;200MG¤	N19856 001 MAY 30, 1991

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

/AA/	/BOLAR/	/350MG/	/N85433/001/	
	ə BOLAR	350MG	N85433 001	
AA	MUTUAL PHARM	350MG¤	N89346 001 OCT 17, 1991	

CEFADROXIL

CAPSULE; ORAL
ULTRACEF

/AB/	/BRISTOL/	/EQ 500MG BASE/	/N62378/001/ /MAR/16,/1982/	
	ə BRISTOL	EQ 500MG BASE	N62378 001 MAR 16, 1982	

POWDER FOR RECONSTITUTION; ORAL
ULTRACEF

/AB/	/BRISTOL/	/EQ 125MG BASE/5ML/	/N62376/001/ /MAR/16,/1982/	
/AB/		/EQ 250MG BASE/5ML/	/N62376/002/ /MAR/16,/1982/	
/AB/		/EQ 500MG BASE/5ML/	/N62376/003/ /MAR/16,/1982/	
	ə BRISTOL	EQ 125MG BASE/5ML	N62376 001 MAR 16, 1982	
	ə	EQ 250MG BASE/5ML	N62376 002 MAR 16, 1982	
	ə	EQ 500MG BASE/5ML	N62376 003 MAR 16, 1982	

TABLET; ORAL
ULTRACEF

/AB/	/BRISTOL/	/EQ 1GM BASE/	/N62408/001/ /AUG/31,/1982/	
	ə BRISTOL	EQ 1GM BASE	N62408 001 AUG 31, 1982	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
ANCEF IN PLASTIC CONTAINER

	BAXTER	EQ 10MG BASE/ML¤	N63002 001 MAR 28, 1991
		EQ 20MG BASE/ML¤	N63002 002 MAR 28, 1991

CEPHALEXIN

POWDER FOR RECONSTITUTION; ORAL
CEPHALEXIN

AB	SQUIBB MARK	EQ 125MG BASE/5ML¤	N62986 001 APR 18, 1991

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

/CEPHALOTHIN/			
/AP/ /INTL/MEDICATION/	/EQ 1GM BASE/VIAL/	/N62426/002/	/MAY/03,/1985/
/AP/	/EQ 2GM BASE/VIAL/	/N62426/003/	/MAY/03,/1985/
/AP/	/EQ 4GM BASE/VIAL/	/N62426/004/	/MAY/03,/1985/
	/EQ/500MG/BASE/VIAL/	/N62426/001/	/MAY/03,/1985/
ə INTL MEDICATION	EQ 500MG BASE/VIAL	N62426 001	MAY 03, 1985
ə	EQ 1GM BASE/VIAL	N62426 002	MAY 03, 1985
ə	EQ 2GM BASE/VIAL	N62426 003	MAY 03, 1985
ə	EQ 4GM BASE/VIAL	N62426 004	MAY 03, 1985

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

BAXTER	EQ 20MG BASE/ML¤	N62422 005	JUL 16, 1991
	EQ 40MG BASE/ML¤	N62422 006	JUL 16, 1991

CEPHRADINE

CAPSULE; ORAL

/VELOSEF '250'/			
/AB/ /ERSANA/	/250MG/	/N50548/001/	
ə ERSANA	250MG	N50548 001	
/VELOSEF '500'/			
/AB/ /ERSANA/	/500MG/	/N50548/002/	
ə ERSANA	500MG	N50548 002	

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL			
/AB/ /SUPERPHARM/	/5MG/	/N88987/001/	/APR/25,/1985/
/AB/	/10MG/	/N88986/001/	/APR/25,/1985/
/AB/	/25MG/	/N88988/001/	/APR/25,/1985/
ə SUPERPHARM	5MG	N88987 001	APR 25, 1985
ə	10MG	N88986 001	APR 25, 1985
ə	25MG	N88988 001	APR 25, 1985
LYGEN			
ə ALRA	5MG	N85107 001	
ə	10MG	N85009 001	
ə	25MG	N85108 001	
/ə/BANMAX/	/5MG/	/N85107/001/	
/ə/	/10MG/	/N85009/001/	
/ə/	/25MG/	/N85108/001/	

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE			
/AB/ /BOLAR/	/250MG/	/N85165/001/	
/AB/	/500MG/	/N84026/001/	/SEP/01,/1982/
ə BOLAR	250MG	N85165 001	
ə	500MG	N84026 001	SEP 01, 1982
/B*/ /CHELSEA/	/500MG¤/	/N86796/001/	/AUG/15,/1983/
ə CHELSEA	500MG¤	N86796 001	AUG 15, 1983

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

/CHLOROTHIAZIDE/W/RESERPINE/			
/BP/ /BOLAR/	/500MG;0.125MG/	/N88151/001/	/JUN/09,/1983/
ə BOLAR	500MG;0.125MG	N88151 001	JUN 09, 1983

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION
CHLORPHENIRAMINE MALEATE

/AP/	/LEMMON/	/10MG/ML/	/N83593/001/
AP	STERIS	10MG/ML	N83593 001

TABLET; ORAL
/ANTAGONATE/

/AA/	/MILES/	/4MG/	/N83381/001/
	∂ MILES	4MG	N83381 001

CHLORPHENIRAMINE MALEATE

/AA/	/VITARINE/	/4MG/	/N85837/001/
	∂ VITARINE	4MG	N85837 001

/PHENETRON/

/AA/	/LANNETT/	/4MG/	/N80846/001/
	∂ LANNETT	4MG	N80846 001

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLORPROMAZINE HCL

/AP/	/LEMMON/	/25MG/ML/	/N85591/001/
AP	STERIS	25MG/ML	N85591 001

CHLORPROPAMIDE

TABLET; ORAL
CHLORPROPAMIDE

/AB/	/BOLAR/	/100MG/	/N88608/001/ /APR/12,/1984/
/AB/		/250MG/	/N88568/001/ /APR/12,/1984/
	∂ BOLAR	100MG	N88608 001 APR 12, 1984
	∂	250MG	N88568 001 APR 12, 1984
/AB/	/PHARM/BASICS/	/100MG/	/N88708/001/ /AUG/30,/1984/
/AB/		/250MG/	/N88709/001/ /AUG/30,/1984/
B*	PHARM BASICS	100MG	N88708 001 AUG 30, 1984
B*		250MG	N88709 001 AUG 30, 1984

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE

/AB/	/BOLAR/	/25MG/	/N87050/001/
/AB/		/50MG/	/N87029/001/
	∂ BOLAR	25MG	N87050 001
	∂	50MG	N87029 001
/AB/	/SUPERPHARM/	/25MG/	/N87473/001/ /FEB/09,/1983/
	∂ SUPERPHARM	25MG	N87473 001 FEB 09, 1983

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE

AA	DANBURY	500MG¤	N81019 001 JUL 29, 1991

CLARITHROMYCIN

TABLET; ORAL
BIAXIN
ABBOTT

250MG¤		N50662 001 OCT 31, 1991
500MG¤		N50662 002 OCT 31, 1991

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
TAVIST D

	/DORSEY/	/EQ/1MG/BASE;75MG/	/N18298/001/ /DEC/15,/1982/
	SANDOZ	EQ 1MG BASE;75MG	N18298 001 DEC 15, 1982

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLINDAMYCIN HCL

AB	DANBURY	EQ 75MG BASE¤	N63082 001 JUL 31, 1991
AB		EQ 150MG BASE¤	N63083 001 JUL 31, 1991

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

/AP/	/LEMMON/	/EQ 150MG BASE/ML/	/N62900/001/ /JUN/08,/1988/	
/AP/		/EQ 150MG BASE/ML/	/N63079/001/ /MAR/05,/1990/	
AP	STERIS	EQ 150MG BASE/ML	N62900 001 JUN 08, 1988	
AP		EQ 150MG BASE/ML	N63079 001 MAR 05, 1990	

CLIOQUINOL; HYDROCORTISONE

CREAM; TOPICAL
VIOFORM-HYDROCORTISONE

	CIBA	3%;0.5%	N10412 002
		3%;1%	N10412 001

OINTMENT; TOPICAL
VIOFORM-HYDROCORTISONE

ə	CIBA	3%;0.5%	N10412 004
		3%;1%	N10412 003

CLOFIBRATE

CAPSULE; ORAL
CLOFIBRATE

AB	NOVOPHARM	500MG*	N72600 001 JUL 25, 1991

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HCL

/AB/	/BOLAR/	/0.1MG/	/N70395/001/ /MAR/23,/1987/	
/AB/		/0.2MG/	/N70396/001/ /MAR/23,/1987/	
/AB/		/0.3MG/	/N70397/001/ /MAR/23,/1987/	
ə	BOLAR	0.1MG	N70395 001 MAR 23, 1987	
ə		0.2MG	N70396 001 MAR 23, 1987	
ə		0.3MG	N70397 001 MAR 23, 1987	

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HCL

/AB/	/DURAMED/	/0.1MG/	/N71103/001/ /AUG/14,/1986/	
/AB/		/0.2MG/	/N71102/001/ /AUG/14,/1986/	
/AB/		/0.3MG/	/N71101/001/ /AUG/14,/1986/	
ə	DURAMED	0.1MG	N71103 001 AUG 14, 1986	
ə		0.2MG	N71102 001 AUG 14, 1986	
ə		0.3MG	N71101 001 AUG 14, 1986	

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

/AB/	/PHARM BASICS/	/3.75MG/	/N71242/001/ /MAY/20,/1987/	
/AB/		/7.5MG/	/N71243/001/ /MAY/20,/1987/	
/AB/		/15MG/	/N71244/001/ /MAY/20,/1987/	
B*	PHARM BASICS	3.75MG	N71242 001 MAY 20, 1987	
B*		7.5MG	N71243 001 MAY 20, 1987	
B*		15MG	N71244 001 MAY 20, 1987	
/AB/	/PUREPAC/	/3.75MG/	/N71924/001/ /APR/25,/1988/	
ə	PUREPAC	3.75MG	N71924 001 APR 25, 1988	
/AB/	/SEARLE/	/3.75MG/	/N71727/001/ /DEC/18,/1987/	
/AB/		/7.5MG/	/N71728/001/ /DEC/18,/1987/	
/AB/		/15MG/	/N71729/001/ /DEC/18,/1987/	
ə	SEARLE	3.75MG	N71727 001 DEC 18, 1987	
ə		7.5MG	N71728 001 DEC 18, 1987	
ə		15MG	N71729 001 DEC 18, 1987	

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM

/AB/	/AM THERAP/	/3.75MG/	/N71747/001/	/JUN/09,/1987/
/AB/		/7.5MG/	/N71748/001/	/JUN/09,/1987/
/AB/		/15MG/	/N71749/001/	/JUN/09,/1987/
∂	AM THERAP	3.75MG	N71747 001	JUN 09, 1987
∂		7.5MG	N71748 001	JUN 09, 1987
∂		15MG	N71749 001	JUN 09, 1987

CLOTRIMAZOLE

CREAM; VAGINAL
/GYNE-LOTRIMIN/

/AT/	/SCHERING/	/1%/	/N18052/001/

TABLET; VAGINAL
/GYNE-LOTRIMIN/

/AT/	/SCHERING/	/100MG/	/N17717/001/

COLCHICINE; PROBENECID

TABLET; ORAL
/PROBENECID/W//COLCHICINE/

/BP/	/BOLAR/	/0.5MG;500MG/	/N83221/001/
∂	BOLAR	0.5MG;500MG	N83221 001

CORTISONE ACETATE

INJECTABLE; INJECTION
CORTISONE ACETATE

/BP/	/LEMMON/	/25MG/ML/	/N85677/001/
/BP/		/50MG/ML/	/N85677/002/
BP	STERIS	25MG/ML	N85677 001
BP		50MG/ML	N85677 002

CYANOCOBALAMIN

INJECTABLE; INJECTION
COBAVITE

/AP/	/LEMMON/	/0.1MG/ML/	/N83013/001/
/AP/		/1MG/ML/	/N83064/001/

CYANOCOBALAMIN

INJECTABLE; INJECTION
COBAVITE

AP	STERIS	0.1MG/ML	N83013 001
AP		1MG/ML	N83064 001
	CYANOCOBALAMIN		
	AKORN	1MG/ML	N87969 001 NOV 10, 1983
/AP/	/LEMMON/	/0.1MG/ML/	/N83126/001/
/AP/		/1MG/ML/	/N83126/002/
/AP/	/LYPHOMED/	/0.03MG/ML/	/N80510/003/
/AP/		/0.1MG/ML/	/N80510/001/
/AP/		/1MG/ML/	/N80510/002/
∂	LYPHOMED	0.03MG/ML	N80510 003
∂		0.1MG/ML	N80510 001
∂		1MG/ML	N80510 002
AP	STERIS	0.1MG/ML	N83120 001
AP		1MG/ML	N83120 002
	DODECAMIN		
/AP/	/AKORN/	/1MG/ML/	/N87969/001/ NOV/10,/1983/

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL

>ADD>	AB	GENEVA	10MG‡	N72854 001 NOV 19, 1991
>ADD>	AB	MYLAN	10MG‡	N73144 001 MAY 31, 1991
>ADD>	AB	WATSON	10MG‡	N73143 001 NOV 27, 1991

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
AK-PENTOLATE

AT	AKORN	1%	N85555 001
	/CYCLOPENTOLATE HCL/		
/AT/	/AKORN/	/1%/	/N85555/001/
	CYCLOPENTOLATE HCL		
AT	STERIS	1%‡	N89162 001 JAN 24, 1991

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HCL

/AA/	/NASKA/	/2MG/5ML/	/N89021/001/ /DEC/21,/1987/
ə NASKA		2MG/5ML	N89021 001 DEC 21, 1987

TABLET; ORAL

CYPROHEPTADINE HCL

/AA/	/BOLAR/	/4MG/	/N85245/001/
ə BOLAR		4MG	N85245 001

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

>DLT >/AP/	/QUAD/	/100MG/VIAL/	/N71248/001/ /DEC/30,/1987/
>DLT >			
>DLT >/AP/		/500MG/VIAL/	/N71249/001/ /DEC/30,/1987/
>DLT >			
>ADD > ə	QUAD	100MG/VIAL	N71248 001 DEC 30, 1987
>ADD >			
>ADD > ə		500MG/VIAL	N71249 001 DEC 30, 1987
>ADD >			

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

>DLT >/AP/	/QUAD/	/100MG/VIAL/	/N70821/001/ /OCT/09,/1986/
>DLT >			
>DLT >/AP/		/200MG/VIAL/	/N70822/001/ /OCT/09,/1986/
>DLT >			
>ADD > ə	QUAD	100MG/VIAL	N70821 001 OCT 09, 1986
>ADD >			
>ADD > ə		200MG/VIAL	N70822 001 OCT 09, 1986
>ADD >			
>DLT >		/500MG/VIAL/	/N71563/001/ /MAY/06,/1988/
>DLT >			
>ADD > ə		500MG/VIAL	N71563 001 MAY 06, 1988
>ADD >			

DANAZOL

CAPSULE; ORAL

DANAZOL

/AB/	/AM/THERAP/	/200MG/	/N71569/001/ /DEC/30,/1987/
B*	AM THERAP	200MG	N71569 001 DEC 30, 1987

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL

ENDURONYL

/BP/	/ABBOTT/	/0.25MG;5MG/	/N12775/001/
	ABBOTT	0.25MG;5MG	N12775 001

ENDURONYL FORTE

/BP/	/ABBOTT/	/0.5MG;5MG/	/N12775/002/
	ABBOTT	0.5MG;5MG	N12775 002

/METHYCLOTHIAZIDE/AND/DESERPIDINE/

/BP/	/BOLAR/	/0.25MG;5MG/	/N88486/001/ /AUG/10,/1984/
/BP/		/0.5MG;5MG/	/N88452/001/ /AUG/10,/1984/
ə BOLAR		0.25MG;5MG	N88486 001 AUG 10, 1984
ə		0.5MG;5MG	N88452 001 AUG 10, 1984

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HCL

/AB/	/PHARM/BASICS/	/25MG/	/N71864/001/ /SEP/09,/1987/
/AB/		/50MG/	/N71865/001/ /SEP/09,/1987/
/AB/		/75MG/	/N71866/001/ /SEP/09,/1987/
/AB/		/100MG/	/N71867/001/ /SEP/09,/1987/
B*	PHARM BASICS	25MG	N71864 001 SEP 09, 1987
B*		50MG	N71865 001 SEP 09, 1987
B*		75MG	N71866 001 SEP 09, 1987
B*		100MG	N71867 001 SEP 09, 1987

DESMOPRESSIN ACETATE

SOLUTION; NASAL
CONCENTRAID

BX	FERRING	0.01%	N19776 001	DEC 26, 1990
		/0.01%/	/N19776/001/	/DEC/26,/1990/

DDAVP

BX	RHONE POULENC RORER	0.01%	N17922 001
		/0.01%/	/N17922/001/

DEXAMETHASONE

TABLET; ORAL
DEXAMETHASONE

/BP/	/BOLAR/	/0.75MG/	/N84457/001/
	ə BOLAR	0.75MG	N84457 001
/BP/	/CORD/	/0.75MG/	/N80399/001/
	ə CORD	0.75MG	N80399 001

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
/DEXACEN-4/

/AP/	/CENTRAL/PHARMS/	/EQ 4MG PHOSPHATE/ML/	/N84342/001/	
	ə CENTRAL PHARMS	EQ 4MG PHOSPHATE/ML	N84342 001	
	DEXAMETHASONE SODIUM PHOSPHATE			
/AP/	/LEMMON/	/EQ 4MG PHOSPHATE/ML/	/N84355/001/	
>DLT>/AP/	/QUAD/	/EQ 4MG PHOSPHATE/ML/	/N89280/001/	
>DLT>			/MAR/18,/1987/	
>DLT>/AP/		/EQ 10MG PHOSPHATE/ML/	/N89281/001/	
>DLT>			/MAR/18,/1987/	
>DLT>/AP/		/EQ 20MG PHOSPHATE/ML/	/N89282/001/	
>DLT>			/MAR/18,/1987/	
>DLT>/AP/		/EQ 24MG PHOSPHATE/ML/	/N89372/001/	
>DLT>			/MAR/18,/1987/	
>ADD>	ə QUAD	EQ 4MG PHOSPHATE/ML	N89280 001	MAR 18, 1987
>ADD>				
>ADD>	ə	EQ 10MG PHOSPHATE/ML	N89281 001	MAR 18, 1987
>ADD>				
>ADD>	ə	EQ 20MG PHOSPHATE/ML	N89282 001	MAR 18, 1987
>ADD>				
>ADD>	ə	EQ 24MG PHOSPHATE/ML	N89372 001	MAR 18, 1987
>ADD>				
AP	STERIS	EQ 4MG PHOSPHATE/ML	N84355 001	
	HEXADROL			
>DLT>/AP/	/ORGANON/	/EQ 20MG PHOSPHATE/ML/	/N14694/004/	
>ADD>	ORGANON	EQ 20MG PHOSPHATE/ML	N14694 004	

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC
DEXAIR

AT	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	N88433 001	DEC 15, 1983
/AT/	/PHARMAFAIR/	/EQ 0.1% PHOSPHATE/	/N88433/001/	/DEC/15,/1983/

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 10% IN PLASTIC CONTAINER

/AP/	/CUTTER/	/10GM/100ML/	/N18504/001/
	ə CUTTER	10GM/100ML	N18504 001
	DEXTROSE 50% IN PLASTIC CONTAINER		
AP	BAXTER	50GM/100ML*	N20047 001 JUL 02, 1991
	DEXTROSE 60% IN PLASTIC CONTAINER		
AP	BAXTER	60GM/100ML*	N20047 002 JUL 02, 1991
	DEXTROSE 70% IN PLASTIC CONTAINER		
AP	BAXTER	70GM/100ML*	N20047 003 JUL 02, 1991

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

/AP/	/MCGAW/	/5GM/100ML;220MG/100ML;/ /450MG/100ML/	/N18268/002/	
	MCGAW	5GM/100ML;220MG/100ML; 450MG/100ML	N18268 002	

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

/AP/	/CUTTER/	/5GM/100ML;200MG/100ML/	/N18399/001/	
	ə CUTTER	5GM/100ML;200MG/100ML	N18399 001	
	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
/AP/	/ABBOTT/	/5GM/100ML;300MG/100ML/	/N17799/001/	
	ABBOTT	5GM/100ML;300MG/100ML	N17799 001	
/AP/	/CUTTER/	/5GM/100ML;300MG/100ML/	/N18501/001/	
	ə CUTTER	5GM/100ML;300MG/100ML	N18501 001	
	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
/AP/	/CUTTER/	/5GM/100ML;450MG/100ML/	/N18400/001/	
	ə CUTTER	5GM/100ML;450MG/100ML	N18400 001	

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

	DIATRIZOATE-60			
/AP/	/INTL/MEDICATION/	/52%;8%/		/N88166/001/
				/JUN/17,/1983/
	∂ INTL MEDICATION	52%;8%		N88166 001
				JUN 17, 1983

DIATRIZOATE SODIUM

INJECTABLE; INJECTION

	MD-50			
/AP/	/MALLINCKRODT/	/50%/		/N87075/001/
	∂ MALLINCKRODT	50%		N87075 001

DIAZEPAM

INJECTABLE; INJECTION

	DIAZEPAM			
/AP/	/LEMMON/	/5MG/ML/		/N70911/001/
				/AUG/28,/1986/
/AP/		/5MG/ML/		/N70912/001/
				/AUG/28,/1986/
/AP/		/5MG/ML/		/N70930/001/
				/DEC/01,/1986/
AP	STERIS	5MG/ML		N70911 001
				AUG 28, 1986
AP		5MG/ML		N70912 001
				AUG 28, 1986
AP		5MG/ML		N70930 001
				DEC 01, 1986

TABLET; ORAL

	DIAZEPAM			
/A/	/SUPERPHARM/	/2MG/		/N70644/001/
				/DEC/11,/1985/
/A/		/5MG/		/N70643/001/
				/DEC/11,/1985/
/A/		/10MG/		/N70644/001/
				/DEC/11,/1985/

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

	VOLTAREN			
	CIBA	0.1%¤		N20037 001
				MAR 28, 1991

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

	DICYCLOMINE HCL			
/AB/	/BOLAR/	/10MG/		/N83179/001/
				/FEB/12,/1986/
	∂ BOLAR	10MG		N83179 001
				FEB 12, 1986

TABLET; ORAL

	DICYCLOMINE HCL			
/AB/	/BOLAR/	/20MG/		/N84361/001/
				/FEB/06,/1986/
	∂ BOLAR	20MG		N84361 001
				FEB 06, 1986

DIDANOSINE

POWDER FOR RECONSTITUTION; ORAL

	VIDEX			
	BRISTOL MYERS SQUIBB	10MG/ML¤		N20156 001
				OCT 09, 1991
		100MG/PACKET¤		N20155 003
				OCT 09, 1991
		167MG/PACKET¤		N20155 004
				OCT 09, 1991
		250MG/PACKET¤		N20155 005
				OCT 09, 1991
		375MG/PACKET¤		N20155 006
				OCT 09, 1991

TABLET, CHEWABLE; ORAL

	VIDEX			
	BRISTOL MYERS SQUIBB	25MG¤		N20154 002
				OCT 09, 1991
		50MG¤		N20154 003
				OCT 09, 1991
		100MG¤		N20154 004
				OCT 09, 1991
		150MG¤		N20154 005
				OCT 09, 1991

DIETHYLSTILBESTROL

TABLET; ORAL

	STILBESTROL			
/BP/	/TABLICAPS/	/0.5MG/		/N83004/001/
	TABLICAPS	0.5MG		N83004 001

DIETHYLSTILBESTROL

TABLET; ORAL
/STILBETIN/

/BP/	/SQUIBB/	/0.5MG/	/N04056/008/
/BP/		/1MG/	/N04056/009/
/BP/		/5MG/	/N04056/010/
		/0.1MG/	/N04056/007/
		/0.25MG/	/N04056/017/
	∂ SQUIBB	0.1MG	N04056 007
	∂	0.25MG	N04056 017
	∂	0.5MG	N04056 008
	∂	1MG	N04056 009
	∂	5MG	N04056 010

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION
CARDIZEM

	MARION MERRELL DOW	25MG/VIAL¤	N20027 001 OCT 24, 1991
		50MG/VIAL¤	N20027 002 OCT 24, 1991

DIMENHYDRINATE

INJECTABLE; INJECTION
DIMENHYDRINATE

/AP/	/LEMMON/	/50MG/ML/	/N83531/001/
AP	STERIS	50MG/ML	N83531 001

LIQUID; ORAL
DIMENHYDRINATE

	∂ ALRA	12.5MG/4ML	N80715 001
	/∂/BANMAX/	/12.5MG/4ML/	/N80715/001/

/TABLET;/ORAL/
/DIMENHYDRINATE/

/AA/	/CHELSEA/	/50MG/	/N85166/001/
	∂ CHELSEA	50MG	N85166 001

TABLET; ORAL
DIMENHYDRINATE

>ADD>	∂ HEATHER	50MG	N80841 001

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

	∂ ALRA	25MG	N80519 004
	∂	50MG	N80519 003
	/∂/BANMAX/	/50MG/	/N80519/003/

ELIXIR; ORAL
DIPHENHYDRAMINE HCL

/AA/	/KV/	/12.5MG/5ML/	/N85621/001/
	∂ KV	12.5MG/5ML	N85621 001

INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL

/AP/	/ELKINS/SINN/	/50MG/ML/	/N83183/001/
	∂ ELKINS SINN	50MG/ML	N83183 001
/AP/	/LEMMON/	/10MG/ML/	/N83533/001/
AP	STERIS	10MG/ML	N83533 001

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE

AB	GENEVA	25MG¤	N86944 002 APR 16, 1991
AB	LEDERLE	25MG¤	N88999 001 FEB 05, 1991
AB		50MG¤	N89000 001 FEB 05, 1991
AB		75MG¤	N89001 001 FEB 05, 1991

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL
DISOPYRAMIDE PHOSPHATE

/AB/	/BOLAR/	/EQ 100MG BASE/	/N70240/001/ /FEB/02,/1986/
/AB/		/EQ 150MG BASE/	/N70241/001/ /FEB/02,/1986/
	∂ BOLAR	EQ 100MG BASE	N70240 001 FEB 02, 1986
	∂	EQ 150MG BASE	N70241 001 FEB 02, 1986

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

	DISOPYRAMIDE PHOSPHATE		
B*	CHELSEA	EQ 100MG BASE	N71020 001 DEC 01, 1986
B*		EQ 150MG BASE	N71021 001 DEC 01, 1986
/BX/		/EQ/100MG/BASE/	/N71020/001/ /DEC/01,/1986/
/BX/		/EQ/150MG/BASE/	/N71021/001/ /DEC/01,/1986/
/AB/	/MYLAN/	/EQ 100MG BASE/	/N70138/001/ /JUN/14,/1985/
/AB/		/EQ 150MG BASE/	/N70139/001/ /JUN/14,/1985/
	ə MYLAN	EQ 100MG BASE	N70138 001 JUN 14, 1985
	ə	EQ 150MG BASE	N70139 001 JUN 14, 1985

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DOBUTREX		
	LILLY	EQ 12.5MG BASE/ML	N17820 002
		/EQ/250MG/BASE/VIAL/	/N17820/002/

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DOPAMINE HCL		
AP	GENSIA	40MG/ML¤	N72999 001 OCT 23, 1991
AP		80MG/ML¤	N73000 001 OCT 23, 1991
/AP/	/SOLOPAK/	/40MG/ML/	/N70011/001/ /AUG/29,/1985/
	ə SOLOPAK	40MG/ML	N70011 001 AUG 29, 1985

DOXACURIUM CHLORIDE

INJECTABLE; INJECTION

	NUROMAX		
	BURROUGHS WELLCOME	EQ 1MG BASE/ML¤	N19946 001 MAR 07, 1991

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

	DOXEPIN HCL		
/AB/	/BARR/	/EQ 25MG BASE/	/N71502/001/ /FEB/18,/1988/
/AB/		/EQ 50MG BASE/	/N71653/001/ /FEB/18,/1988/
/AB/		/EQ 75MG BASE/	/N71654/001/ /FEB/18,/1988/
/AB/		/EQ 100MG BASE/	/N71521/001/ /FEB/18,/1988/
	ə BARR	EQ 25MG BASE	N71502 001 FEB 18, 1988
	ə	EQ 50MG BASE	N71653 001 FEB 18, 1988
	ə	EQ 75MG BASE	N71654 001 FEB 18, 1988
	ə	EQ 100MG BASE	N71521 001 FEB 18, 1988
/B*/	/CHELSEA/	/EQ/10MG/BASE¤/	/N70952/001/ /MAR/04,/1987/
/B*/		/EQ/25MG/BASE¤/	/N70953/001/ /MAY/15,/1986/
/B*/		/EQ/50MG/BASE¤/	/N70954/001/ /MAY/15,/1986/
/B*/		/EQ/75MG/BASE¤/	/N71763/001/ /FEB/09,/1988/
/B*/		/EQ/100MG/BASE¤/	/N70955/001/ /MAY/15,/1986/
/B*/		/EQ/150MG/BASE¤/	/N71764/001/ /FEB/09,/1988/
	ə CHELSEA	EQ 10MG BASE¤	N70952 001 MAR 04, 1987
	ə	EQ 25MG BASE¤	N70953 001 MAY 15, 1986
	ə	EQ 50MG BASE¤	N70954 001 MAY 15, 1986
	ə	EQ 75MG BASE¤	N71763 001 FEB 09, 1988
	ə	EQ 100MG BASE¤	N70955 001 MAY 15, 1986
	ə	EQ 150MG BASE¤	N71764 001 FEB 09, 1988
/AB/	/PUREPAC/	/EQ 75MG BASE/	/N72385/001/ /SEP/08,/1988/
/AB/		/EQ 150MG BASE/	/N72387/001/ /SEP/08,/1988/
	ə PUREPAC	EQ 75MG BASE	N72386 001 SEP 08, 1988
	ə	EQ 150MG BASE	N72387 001 SEP 08, 1988

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL

AB	ROYCE	EQ 10MG BASE¤	N72985 001 MAR 29, 1991	
AB		EQ 25MG BASE¤	N72986 001 MAR 29, 1991	
AB		EQ 50MG BASE¤	N72987 001 MAR 29, 1991	

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN PFS

AP	ADRIA	2MG/ML	N50629 001 DEC 23, 1987	> DLT >	
AP		200MG/100ML	N50629 002 MAY 03, 1988	> ADD >	
AP		2MG/ML¤	N63165 001 JAN 30, 1991	> ADD >	
AP		200MG/100ML¤	N63165 002 JAN 30, 1991	> ADD >	
	/2MG/ML/	/N50629/002/ /MAY/03,/1988/	> ADD >		

DOXORUBICIN HCL

AP	CETUS BEN VENUE	2MG/ML	N62975 001 MAR 17, 1989		

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

/AB/	/SUPERPHARM/	/EQ 50MG BASE/	/N62469/001/ /OCT/31,/1984/
/AB/		/EQ 100MG BASE/	/N62469/002/ /OCT/31,/1984/
	ə SUPERPHARM	EQ 50MG BASE	N62469 001 OCT 31, 1984
	ə	EQ 100MG BASE	N62469 002 OCT 31, 1984

TABLET; ORAL

DOXYCYCLINE HYCLATE

/AB/	/CHELSEA/	/EQ 100MG BASE/	/N62392/002/ /MAR/31,/1983/
	ə CHELSEA	EQ 100MG BASE	N62392 002 MAR 31, 1983

DOXYLAMINE SUCCINATE

/TABLET;/ORAL/

/DOXYLAMINE SUCCINATE/

/AA/	/COPLEY/	/25MG/	/N88966/001/ /OCT/08,/1985/

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

/AP/	/ASTRA/	/2.5MG/ML/	/N72020/001/ /OCT/19,/1988/		
	ə ASTRA	2.5MG/ML	N72020 001 OCT 19, 1988		
/AP/	/QUAD/	/2.5MG/ML/	/N71942/001/ /AUG/17,/1988/	> DLT >	
	ə QUAD	2.5MG/ML	N71942 001 AUG 17, 1988	> DLT >	
				> ADD >	
AP	STERIS	2.5MG/ML¤	N73520 001 NOV 27, 1991	> ADD >	
AP		2.5MG/ML¤	N73521 001 NOV 27, 1991	> ADD >	
AP		2.5MG/ML¤	N73523 001 NOV 27, 1991	> ADD >	

EDETATE DISODIUM

INJECTABLE; INJECTION

DISODIUM EDETATE

/AP/	/LEMMON/	/150MG/ML/	/N84356/001/
AP	STERIS	150MG/ML	N84356 001

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL W/ EPINEPHRINE

/2/	/LEMMON/	/0.01MG/ML;1%/	/N85463/001/
ə	STERIS	0.01MG/ML;1%	N85463 001

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES

/AB/	/BOLAR/	/1MG/	/N86433/001/ /MAY/27,/1982/
	ə BOLAR	1MG	N86433 001 MAY 27, 1982

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES

AB	MUTUAL PHARM	1MG¤	N81113 001 OCT 31, 1991

TABLET; SUBLINGUAL

/DEAPRIL-ST/

/AA/	/BRISTOL/MYERS/SQUIBB/	1MG/	/N85020/001/
	ə BRISTOL MYERS SQUIBB	1MG	N85020 002

ERGOLOID MESYLATES

/AA/	/BOLAR/	/0.5MG/	/N84930/001/	
/AA/		/1MG/	/N85177/001/	
	ə BOLAR	0.5MG	N84930 001	>DLT >/AO/
	ə	1MG	N85177 001	>DLT >
/AA/	/KV/	/0.5MG/	/N86265/001/	>ADD >
/AA/		/1MG/	/N86264/001/	>ADD >
	ə KV	0.5MG	N86265 001	
	ə	1MG	N86264 001	

ERYTHROMYCIN

GEL; TOPICAL

E/GEL

	/FULTON/	/2%¤/	/N63107/001/ /AUG/23,/1991/

EMGEL

AT	GLAXO	2%¤	N63107 001 AUG 23, 1991

ERYGEL

AT	HERBERT	2%	N50617 001 OCT 21, 1987

SOLUTION; TOPICAL

ERYTHROMYCIN

AT	CLAY PARK	2%¤	N63038 001 JAN 11, 1991
/AT/	/LILLY/	/2%/	/N50532/001/
	ə LILLY	2%	N50532 001

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

/AB/	/NASKA/	/EQ 400MG BASE/5ML/	/N62674/001/ /MAR/10,/1987/
	ə NASKA	EQ 400MG BASE/5ML	N62674 001 MAR 10, 1987

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

	/DUPONT/	/100MG/ML/	/N19386/003/ /DEC/31,/1986/
	ə DUPONT	100MG/ML	N19386 003 DEC 31, 1986

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

ESTRADIOL CYPIONATE

	/QUAD/	/5MG/ML/	/N89310/001/ /FEB/09,/1987/	
	ə QUAD	5MG/ML	N89310 001 FEB 09, 1987	

ESTROGENS, CONJUGATED

TABLET; ORAL

CONJUGATED ESTROGENS

/BP/	/CHELSEA/	/1.25MG/	/N85601/001/
/BP/		/2.5MG/	/N85626/001/
/ə/		/0.625MG/	/N85600/001/
/ə/	/CORD/	/0.3MG/	/N86070/001/
/ə/		/0.625MG/	/N83761/001/
/ə/		/1.25MG/	/N83763/001/
/ə/		/2.5MG/	/N83762/001/
/ə/	/DURAMED/	/0.3MG¤/	/N85432/001/
/ə/		/0.625MG¤/	/N83272/001/
/ə/		/1.25MG¤/	/N83294/001/
/ə/		/2.5MG¤/	/N83295/001/
/ə/	/HEATHER/	/0.625MG/	/N83366/001/
/ə/		/1.25MG/	/N83368/001/
/ə/		/2.5MG/	/N84550/001/
/ə/	/PRIVATE/FORM/	/0.625MG/	/N83384/001/
/ə/		/1.25MG/	/N83592/001/
/ə/		/2.5MG/	/N85908/001/
/BP/	/ZENITH/	/0.3MG/	/N88569/001/ /NOV/29,/1984/
/BP/		/0.625MG/	/N83373/001/
/BP/		/1.25MG/	/N83601/001/
/BP/		/2.5MG/	/N83602/001/
	ə ZENITH	0.3MG	N88569 001 NOV 29, 1984
	ə	0.625MG	N83373 001
	ə	1.25MG	N83601 001
	ə	2.5MG	N83602 001

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL

/MILPREN-200/

/BS/ /WALLACE/ /0.45MG;200MG/ /N11045/002/

@ WALLACE 0.45MG;200MG N11045 002

/MILPREN-400/

/BS/ /WALLACE/ /0.45MG;400MG/ /N11045/001/

@ WALLACE 0.45MG;400MG N11045 001

PMB 200

/BS/ /WYETH/AYERST/ /0.45MG;200MG/ /N10971/005/

WYETH AYERST 0.45MG;200MG N10971 005

PMB 400

/BS/ /WYETH/AYERST/ /0.45MG;400MG/ /N10971/003/

WYETH AYERST 0.45MG;400MG N10971 003

ESTROGENS, ESTERIFIED

TABLET; ORAL

/AMNESTROGEN/

/BS/ /SQUIBB/ /0.625MG/ /N83266/002/

/BS/ /1.25MG/ /N83266/003/

/BS/ /2.5MG/ /N83266/004/

@ SQUIBB 0.625MG N83266 002

@ 1.25MG N83266 003

@ 2.5MG N83266 004

/ESTERIFIED/ESTROGENS/

/BS/ /PRIVATE/FORM/ /2.5MG/ /N85907/001/

@ PRIVATE FORM 2.5MG N85907 001

/EVEX/

/BS/ /SYNTEX/ /0.625MG/ /N84215/001/

/BS/ /1.25MG/ /N83376/002/

@ SYNTEX 0.625MG N84215 001

@ 1.25MG N83376 002

/FEMOGEN/

/BS/ /PRIVATE/FORM/ /0.625MG/ /N85076/001/

@ PRIVATE FORM 0.625MG N85076 001

ESTROPIPATE

TABLET; ORAL

OGEN

AB ABBOTT 0.75MG N83220 001

AB 1.5MG N83220 002

ORTHO-EST

AB JOHNSON RW 0.75MG¤ N89567 001
FEB 27, 1991

AB 1.5MG¤ N89582 001
JUL 17, 1991

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

/NORETHINDRONE AND ETHINYL ESTRADIOL/

/AB/ /WATSON/ /0.035MG;0.5MG AND 1MG/ /N71043/001/
/APR/01,/1988/

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

AB WATSON 0.035MG;0.5MG AND 1MG N71043 001
APR 01, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

WATSON 0.035MG;0.5MG AND 1MG¤ N71041 001
SEP 24, 1991

TABLET; ORAL-28

/NORETHINDRONE AND ETHINYL ESTRADIOL/

/AB/ /WATSON/ /0.035MG;0.5MG AND 1MG/ /N71044/001/
/APR/01,/1988/

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

AB WATSON 0.035MG;0.5MG AND 1MG N71044 001
APR 01, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

WATSON 0.035MG;0.5MG AND 1MG¤ N71042 001
SEP 24, 1991

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

/TABLET;/ORAL-28/

/NORLESTRIN/28/1/50/

/PARKE/DAVIS/ /0.05MG;1MG/ /N16723/001/

TABLET; ORAL-28

NORLESTRIN 28 1/50

@ PARKE DAVIS 0.05MG;1MG N16723 001

ETODOLAC

CAPSULE; ORAL

LODINE

WYETH AYERST 200MG¤ N18922 002
JAN 31, 1991

300MG¤ N18922 003
JAN 31, 1991

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

PLENDIL

MSD	5MG¤	N19834 001	
		JUL 26, 1991	
	10MG¤	N19834 002	
		JUL 26, 1991	

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

AB	DANBURY	EQ 200MG BASE¤	N72981 001
			AUG 19, 1991
AB		EQ 300MG BASE¤	N72982 001
			AUG 19, 1991
AB	WARNER CHILCOTT	EQ 200MG BASE¤	N72946 001
			APR 30, 1991
AB		EQ 300MG BASE¤	N72472 001
			APR 30, 1991

TABLET; ORAL

FENOPROFEN CALCIUM

/AB/	/PHARM/BASICS/	/EQ 600MG BASE/	/N72362/001/
			/JUN/16,/1988/
	∂ PHARM BASICS	EQ 600MG BASE	N72362 001
			JUN 16, 1988

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

AP	STERLING	EQ 0.05MG BASE/ML¤	N72786 001
			SEP 24, 1991

FIBRINOGEN, I-125

INJECTABLE; INJECTION

	/IBRIN/		
	/AMERSHAM/	/154/UCI/VIAL/	/N17879/001/
	∂ AMERSHAM	154 UCI/VIAL	N17879 001

FLOXURIDINE

INJECTABLE; INJECTION

>DLT>	/FLOXURIDINE/		
>DLT>/AP/	/QUAD/	/500MG/VIAL/	/N71055/001/
>DLT>			/AUG/24,/1987/

FLOXURIDINE

INJECTABLE; INJECTION

>DLT>	/FLOXURIDINE/		
>ADD>	∂ QUAD	500MG/VIAL	N71055 001
>ADD>			AUG 24, 1987
	FUDR		
>DLT>/AP/	/ROCHE/	/500MG/VIAL/	/N16929/001/
>ADD>	ROCHE	500MG/VIAL	N16929 001

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

	BERLEX	50MG/VIAL¤	N20038 001
			APR 18, 1991

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

	/FLUOCET/		
/AT/	/NMC/	/0.01%/	/N88361/001/
			/JAN/16,/1984/
	FLUOCINOLONE ACETONIDE		
AT	NMC	0.01%	N88361 001
			JAN 16, 1984

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

AB	TARO	0.05%	N19117 001
			JUN 26, 1984
AB	TICAN	0.05%	N72494 001
			JAN 19, 1989
	/VASODERM/		
/AB/	/TARO/	/0.05%/	/N19117/001/
			/JUN/26,/1984/
	/VASODERM-E/		
/AB/	/TICAN/	/0.05%/	/N72494/001/
			/JAN/19,/1989/

FLUOROURACIL

INJECTABLE; INJECTION
ADRUCIL

AP	ADRIA	50MG/ML¤	N40023 001 OCT 18, 1991
AP		50MG/ML¤	N81222 001 JUN 28, 1991
AP		50MG/ML¤	N81225 001 AUG 28, 1991

FLUOROURACIL

>DLT >/AP/	/QUAD/	/50MG/ML/	/N89368/001/ /FEB/03,/1987/
>DLT >/AP/		/50MG/ML/	/N89455/001/ /FEB/03,/1987/
>ADD >	ə QUAD	50MG/ML	N89368 001 FEB 03, 1987
>ADD >	ə	50MG/ML	N89455 001 FEB 03, 1987
/AP/	/SOLOPAK/	/50MG/ML/	/N88766/001/ /DEC/28,/1984/
	ə SOLOPAK	50MG/ML	N88766 001 DEC 28, 1984

FLUOXETINE HYDROCHLORIDE

SOLUTION; ORAL
PROZAC

	LILLY	EQ 20MG BASE/5ML¤	N20101 001 APR 24, 1991

FLUOXYMESTERONE

TABLET; ORAL
FLUOXYMESTERONE

/BP/	/BOLAR/	/2MG/	/N88260/001/ /DEC/06,/1983/
/BP/		/5MG/	/N88265/001/ /DEC/06,/1983/
/BP/		/10MG/	/N88309/001/ /DEC/06,/1983/
	ə BOLAR	2MG	N88260 001 DEC 06, 1983
	ə	5MG	N88265 001 DEC 06, 1983
	ə	10MG	N88309 001 DEC 06, 1983

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION
FLUPHENAZINE

>DLT >/AQ/	/QUAD/	/25MG/ML/	/N70762/001/ /FEB/20,/1986/
>DLT >			
>ADD >	ə QUAD	25MG/ML	N70762 001 FEB 20, 1986
>ADD >			

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
FLUPHENAZINE HCL

AA	COPLEY	5MG/ML¤	N73058 001 AUG 30, 1991

INJECTABLE; INJECTION
FLUPHENAZINE HCL

>DLT >/AP/	/QUAD/	/2.5MG/ML/	/N89800/001/ /JUN/08,/1988/
>DLT >			
>ADD >	ə QUAD	2.5MG/ML	N89800 001 JUN 08, 1988
>ADD >			

TABLET; ORAL
FLUPHENAZINE HCL

/AB/	/BOLAR/	/1MG/	/N88555/001/ /DEC/18,/1987/
/AB/		/2.5MG/	/N88544/001/ /DEC/18,/1987/
/AB/		/5MG/	/N88527/001/ /DEC/18,/1987/
/AB/		/10MG/	/N88550/001/ /DEC/18,/1987/
	ə BOLAR	1MG	N88555 001 DEC 18, 1987
	ə	2.5MG	N88544 001 DEC 18, 1987
	ə	5MG	N88527 001 DEC 18, 1987
	ə	10MG	N88550 001 DEC 18, 1987

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
FLURAZEPAM HCL

AB	GENEVA	15MG¤	N71716 001 JUL 31, 1991
AB		30MG¤	N71717 001 JUL 31, 1991

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
FLURAZEPAM HCL

/AB/	/PHARM/BASICS/	/15MG/	/N70562/001/ /JUL/09/1987/	
/AB/		/30MG/	/N70563/001/ /JUL/09/1987/	
B*	PHARM BASICS	15MG	N70562 001 JUL 09, 1987	
B*		30MG	N70563 001 JUL 09, 1987	

FOSCARNET SODIUM

INJECTABLE; INJECTION
FOSCAVIR

	ASTRA	24MG/ML¤	N20068 001 SEP 27, 1991

FOSINOPRIL SODIUM

TABLET; ORAL
MONOPRIL

	BRISTOL MYERS SQUIBB	10MG¤	N19915 002 MAY 16, 1991
		20MG¤	N19915 003 MAY 16, 1991

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

/AP/	/SOLOPAK/	/10MG/ML/	/N70023/001/ /FEB/05/1986/
	ə SOLOPAK	10MG/ML	N70023 001 FEB 05, 1986
AP	STERLING	10MG/ML¤	N72080 001 AUG 13, 1991

SOLUTION; ORAL
FUROSEMIDE

AA	PHARM BASICS	10MG/ML	N70655 001 OCT 02, 1987

/AA/	/HYDROSEMIDE/ /PHARM/BASICS/	/10MG/ML/	/N70655/001/ /OCT/02/1987/

GALLIUM NITRATE

INJECTABLE; INJECTION
GANITE

	FUJISAWA	25MG/ML¤	N19961 002 JAN 17, 1991

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE

>ADD>	AP	GENSIA	EQ 10MG BASE/ML¤	N63149 001 NOV 21, 1991
>ADD>				
>ADD>	AP		EQ 40MG BASE/ML¤	N63106 002 NOV 21, 1991
>ADD>				

SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE

/AT/	/PACO/	/EQ 3MG BASE/ML/	/N62932/001/ /NOV/07/1988/
	ə PACO	EQ 3MG BASE/ML	N62932 001 NOV 07, 1988

GENTIAN VIOLET

/TAMPON;/VAGINAL/
/GENAPAX/

	/KEY/PHARMS/	/5MG/	/N85017/001/
	ə KEY PHARMS	5MG	N85017 001

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION
GLUCAGON

>DLT>	/AP/	/LILLY/	/EQ 1MG BASE/VIAL/	/N12122/002/
>ADD>		LILLY	EQ 1MG BASE/VIAL	N12122 002
>DLT>	/AP/	/QUAD/	/EQ 1MG BASE/VIAL/	/N71023/001/ /MAR/04/1987/
>DLT>				
>ADD>		ə QUAD	EQ 1MG BASE/VIAL	N71023 001 MAR 04, 1987
>ADD>				

GLUTETHIMIDE

TABLET; ORAL
/DORIDEN/

/AA/	/RHONE/POULENC/RORER/	/250MG/	/N09519/002/
/AA/		/500MG/	/N09519/005/
	ə RHONE POULENC RORER	250MG	N09519 002
	ə	500MG	N09519 005

GLUTETHIMIDE

TABLET; ORAL
GLUTETHIMIDE

/AA/	/CHELSEA/	/500MG/	/N85763/001/	
	ə CHELSEA	500MG	N85763 001	

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE

AP	GENSIA	0.2MG/ML*	N81169 001	
			SEP 10, 1991	
>DLT> /AP/	/QUAD/	/0.2MG/ML/	/N89397/001/	
>DLT>			/DEC/09,/1986/	
>ADD>	ə QUAD	0.2MG/ML	N89397 001	
>ADD>			DEC 09, 1986	

TABLET; ORAL
GLYCOPYRROLATE

/AA/	/BOLAR/	/1MG/	/N85562/001/	
	ə BOLAR	1MG	N85562 001	

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION
CHORIONIC GONADOTROPIN

>DLT> /AP/	/QUAD/	/5,000 UNITS/VIAL/	/N89312/001/	
>DLT>			/DEC/04,/1986/	
>DLT> /AP/		/5,000 UNITS/VIAL/	/N89313/001/	
>DLT>			/DEC/04,/1986/	
>DLT> /AP/		/10,000 UNITS/VIAL/	/N89314/001/	
>DLT>			/DEC/04,/1986/	
>DLT> /AP/		/10,000 UNITS/VIAL/	/N89315/001/	
>DLT>			/DEC/04,/1986/	
>DLT> /AP/		/20,000 UNITS/VIAL/	/N89316/001/	
>DLT>			/DEC/04,/1986/	
>ADD>	ə QUAD	5,000 UNITS/VIAL	N89312 001	
>ADD>			DEC 04, 1986	
>ADD>	ə	5,000 UNITS/VIAL	N89313 001	
>ADD>			DEC 04, 1986	
>ADD>	ə	10,000 UNITS/VIAL	N89314 001	
>ADD>			DEC 04, 1986	
>ADD>	ə	10,000 UNITS/VIAL	N89315 001	
>ADD>			DEC 04, 1986	
>ADD>	ə	20,000 UNITS/VIAL	N89316 001	
>ADD>			DEC 04, 1986	

GUANETHIDINE MONOSULFATE

TABLET; ORAL
/GUANETHIDINE MONOSULFATE/

/AB/	/BOLAR/	/EQ 10MG SULFATE/	/N86113/001/	
			/MAR/26,/1985/	
/AB/		/EQ 25MG SULFATE/	/N86114/001/	
			/MAR/26,/1985/	
	ə BOLAR	EQ 10MG SULFATE	N86113 001	
			MAR 26, 1985	
	ə	EQ 25MG SULFATE	N86114 001	
			MAR 26, 1985	

ISMELIN

/AB/	/CIBA/	/EQ 10MG SULFATE/	/N12329/001/	
/AB/		/EQ 25MG SULFATE/	/N12329/002/	
	CIBA	EQ 10MG SULFATE	N12329 001	
		EQ 25MG SULFATE	N12329 002	

HALOBETASOL PROPIONATE

CREAM; TOPICAL
ULTRAVATE
/BRISTOL/MYERS/SQUIBB/0.05%/ /N19967/001/ /DEC/27,/1990/

WESTWOOD SQUIBB	0.05%	N19967 001
		DEC 27, 1990

OINTMENT; TOPICAL
ULTRAVATE
/BRISTOL/MYERS/SQUIBB/0.05%/ /N19968/001/ /DEC/17,/1990/

WESTWOOD SQUIBB	0.05%	N19968 001
		DEC 17, 1990

HALOPERIDOL

TABLET; ORAL

		HALOPERIDOL		
/AB/	/BOLAR/	/0.5MG/	/N71571/001/ /JUN/03,/1988/
/AB/		/1MG/	/N71572/001/ /JUN/03,/1988/
/AB/		/2MG/	/N71573/001/ /JUN/03,/1988/
/AB/		/5MG/	/N71374/001/ /JUN/03,/1988/
/AB/		/10MG/	/N71375/001/ /JUN/03,/1988/
/AB/		/20MG/	/N71376/001/ /JUN/03,/1988/
	@ BOLAR	0.5MG	N71571 001 JUN 03, 1988
	@	1MG	N71572 001 JUN 03, 1988
	@	2MG	N71573 001 JUN 03, 1988
	@	5MG	N71374 001 JUN 03, 1988
	@	10MG	N71375 001 JUN 03, 1988
	@	20MG	N71376 001 JUN 03, 1988
AB	DANBURY	10MG¤	N72113 001 AUG 27, 1991
AB		20MG¤	N72353 001 AUG 27, 1991

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

		HALOPERIDOL		
/AP/	/LEMMON/	/EQ 5MG BASE/ML/	/N70713/001/ /MAY/17,/1988/
/AP/		/EQ 5MG BASE/ML/	/N70714/001/ /MAY/17,/1988/
/AP/		/EQ 5MG BASE/ML/	/N70744/001/ /MAY/17,/1988/
>DLT >/AP/	/QUAD/	/EQ 5MG BASE/ML/	/N71082/001/ /JAN/02,/1987/
>DLT > >ADD > >ADD >	@ QUAD	EQ 5MG BASE/ML	N71082 001 JAN 02, 1987
/AP/	/SOLOPAK/	/EQ 5MG BASE/ML/	/N70802/001/ /DEC/14,/1987/
	@ SOLOPAK	EQ 5MG BASE/ML	N70802 001 DEC 14, 1987

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

		HALOPERIDOL		
AP	STERIS	EQ 5MG BASE/ML	N70713 001 MAY 17, 1988
AP		EQ 5MG BASE/ML	N70714 001 MAY 17, 1988
AP		EQ 5MG BASE/ML	N70744 001 MAY 17, 1988

HEPARIN SODIUM

INJECTABLE; INJECTION

		HEPARIN LOCK FLUSH		
/AP/	/INTL/MEDICATION/	/10 UNITS/ML/	/N86357/001/
	@ INTL MEDICATION	10 UNITS/ML	N86357 001
		/500/UNITS/ML/	/N86357/002/
	@	500 UNITS/ML	N86357 002
/AP/	/SOLOPAK/	/100 UNITS/ML/	/N87959/001/ /APR/20,/1983/
	@ SOLOPAK	100 UNITS/ML	N87959 001 APR 20, 1983

		HEPARIN SODIUM		
/AP/	/LYPHOMED/	/5,000 UNITS/ML/	/N17029/002/
	@ LYPHOMED	5,000 UNITS/ML	N17029 002
	/HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%/		
/AP/	/ABBOTT/	/10,000 UNITS/100ML/	/N18911/006/ /JAN/30,/1985/
	@ ABBOTT	10,000 UNITS/100ML	N18911 006 JAN 30, 1985
	/HEPARIN SODIUM 25000 UNITS IN SODIUM CHLORIDE 0.5% IN/ /PLASTIC CONTAINER/		
/AP/	/MCGAW/	/5,000 UNITS/100ML/	/N19135/001/ /MAR/29,/1985/
	@ MCGAW	5,000 UNITS/100ML	N19135 001 MAR 29, 1985

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

		HYDRALAZINE HCL		
/AP/	/SOLOPAK/	/20MG/ML/	/N88517/001/ /AUG/22,/1985/
/AP/		/20MG/ML/	/N88518/001/ /APR/20,/1984/
	@ SOLOPAK	20MG/ML	N88517 001 AUG 22, 1985
	@	20MG/ML	N88518 001 APR 20, 1984

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HCL

/AA/	/CHELSEA/	/25MG/	/N85532/001/ /MAY/24,/1982/
/AA/		/50MG/	/N85533/002/ /MAY/25,/1982/
	∂ CHELSEA	25MG	N85532 002 MAY 24, 1982
	∂	50MG	N85533 002 MAY 25, 1982

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

/AB/	/BOLAR/	/25MG;25MG/	/N85457/001/ /MAR/04,/1982/
/AB/		/50MG;50MG/	/N85446/001/ /MAR/04,/1982/
/AB/		/100MG;50MG/	/N85440/001/ /MAR/04,/1982/
	∂ BOLAR	25MG;25MG	N85457 001 MAR 04, 1982
	∂	50MG;50MG	N85446 001 MAR 04, 1982
	∂	100MG;50MG	N85440 001 MAR 04, 1982

TABLET; ORAL

APRESOLINE-ESIDRIX

/AB/	/CIBA/	/25MG;15MG/	/N12026/002/
	CIBA	25MG;15MG	N12026 002

/HYDROCHLOROTHIAZIDE/W/HYDRALAZINE/

/BP/	/BOLAR/	/25MG;15MG/	/N85373/001/
	∂ BOLAR	25MG;15MG	N85373 001

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

/HYDROCHLOROTHIAZIDE/W/RESERPINE/AND/HYDRALAZINE/

/BP/	/BOLAR/	/25MG;15MG;0.1MG/	/N83770/001/
	∂ BOLAR	25MG;15MG;0.1MG	N83770 001

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

	∂ ALRA	25MG	N86369 001
	∂	50MG	N83554 001
	/∂/BANMAX/	/25MG/	/N86369/001/
	/∂/	/50MG/	/N83554/001/
/AB/	/BOLAR/	/25MG/	/N83458/001/
/AB/		/50MG/	/N83456/001/
/AB/		/100MG/	/N85099/001/
	∂ BOLAR	25MG	N83458 001
	∂	50MG	N83456 001
	∂	100MG	N85099 001

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

/AB/	/BOLAR/	/15MG;250MG/	/N70365/001/ /MAR/19,/1986/
/AB/		/25MG;250MG/	/N70366/001/ /APR/16,/1986/
/AB/		/30MG;500MG/	/N70367/001/ /MAR/19,/1986/
/AB/		/50MG;500MG/	/N70368/001/ /APR/16,/1986/
	∂ BOLAR	15MG;250MG	N70365 001 MAR 19, 1986
	∂	25MG;250MG	N70366 001 APR 16, 1986
	∂	30MG;500MG	N70367 001 MAR 19, 1986
	∂	50MG;500MG	N70368 001 APR 16, 1986

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDROCHLOROTHIAZIDE W/ RESERPINE

/BP/	/BOLAR/	/25MG;0.125MG/	/N85317/001/
/BP/		/50MG;0.125MG/	/N83666/001/
	∂ BOLAR	25MG;0.125MG	N85317 001
	∂	50MG;0.125MG	N83666 001

RESERPINE AND HYDROCHLOROTHIAZIDE

/BP/	/CORD/	/50MG;0.125MG/	/N88200/001/ /JAN/31,/1984/
	∂ CORD	50MG;0.125MG	N88200 001 JAN 31, 1984

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

/AB/ /SUPERPHARM/ /25MG;25MG/ /N89137/001/ /AUG/26,/1985/

∂ SUPERPHARM 25MG;25MG N89137 001 AUG 26, 1985

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

/AB/ /BOLAR/ /25MG;25MG/ /N85974/001/

∂ BOLAR 25MG;25MG N85974 001

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

AB SKF 25MG;50MG N16042 002

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB GENEVA 25MG;50MG N73191 001 JUL 31, 1991

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

B* PAR 50MG;75MG N72337 001 MAY 11, 1988

/BX/ /50MG;75MG/ /N72337/001/ /MAY/11,/1988/

HYDROCORTISONE

CREAM; TOPICAL

ANUSOL HC

AT PARKE DAVIS 2.5%* N88250 001 JUN 06, 1984

/H-CORT/

/AT/ /PHARMS/ASSOC/ /0.5%/ /N86823/001/

∂ PHARMS ASSOC 0.5% N86823 001

/HC '41/

/AT/ /MILES/ /0.5%/ /N80438/001/

∂ MILES 0.5% N80438 001

/HC '44/

/AT/ /MILES/ /1%/ /N80438/002/

∂ MILES 1% N80438 002

HYDROCORTISONE

AT BAUSCH AND LOMB 1% N87838 001 JUL 28, 1982

/AT/ /NASKA/ /1%/ /N89706/001/ /MAR/10,/1988/

∂ NASKA 1% N89706 001 MAR 10, 1988

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

/AT/ /PHARMAFAIR/ /1%/ /N87838/001/ /JUL/28,/1982/

/AT/ /WHITE/TOWNE/PAULSEN/ /1%/ /N80496/002/

∂ WHITE TOWNE PAULSEN 1% N80496 002

PENECORT

/AT/ /PARKE/DAVIS/ /2.5%*/ /N88250/001/ /JUN/06,/1984/

SYNACORT

/AT/ /SYNTEX/ /0.5%/ /N87459/001/

∂ SYNTEX 0.5% N87459 001

LOTION; TOPICAL

HYDROCORTISONE

/AT/ /NASKA/ /1%/ /N89705/001/ /APR/25,/1988/

∂ NASKA 1% N89705 001 APR 25, 1988

/LOTION;/TOPICAL/

/TEXACORT/

/AT/ /COOPERCARE/ /1%/ /N80425/001/

OINTMENT; TOPICAL

HYDROCORTISONE

/AT/ /NASKA/ /1%/ /N89704/001/ /MAR/10,/1988/

∂ NASKA 1% N89704 001 MAR 10, 1988

SOLUTION; TOPICAL

PENECORT

AT HERBERT 1% N88214 001 JUN 06, 1984

TEXACORT

AT GENDERM 1% N80425 001

TABLET; ORAL

HYDROCORTISONE

/BP/ /PUREPAC/ /20MG/ /N80395/001/

∂ PUREPAC 20MG N80395 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

OTOCORT

/AT/ /LEMMON/ /1%;EQ 3.5MG BASE/ML;/ /10,000 UNITS/ML/ /N60736/002/

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

OTOCORT

AT	STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60730 002

SUSPENSION; OTIC

OTOCORT

/AT/	/LEMMON/	/1%;EQ 3.5MG BASE/ML;/ /10,000 UNITS/ML/	/N62521/001/ /JUL/11,/1985/
AT	STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62521 001 JUL 11, 1985

HYDROCORTISONE ACETATE

CREAM; TOPICAL

HYDROCORTISONE ACETATE

AT	CENCI	1%	N80419 001 JAN 25, 1982
/AT/	/LIFE/LABS/	/1%/	/N80419/001/ /JAN/25,/1982/

INJECTABLE; INJECTION

HYDROCORTISONE ACETATE

/BP/	/LEMMON/	/25MG/ML/	/N83759/001/
/BP/		/50MG/ML/	/N83759/002/
BP	STERIS	25MG/ML	N83759 001
BP		50MG/ML	N83759 002

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

/HYDROCORTISONE/BUTYRATE/

/a/	/GIST/	/0.1%/	/N18514/001/ /MAR/31,/1982/
	/LOCOID/ /OWEN/GALDERMA/	/0.1%/	/N18795/001/ /JAN/07,/1983/

LOCOID

	BROCADES PHARMA	0.1%	N18514 001 MAR 31, 1982
a	OWEN GALDERMA	0.1%	N18795 001 JAN 07, 1983

HYDROCORTISONE BUTYRATE

SOLUTION; TOPICAL

/HYDROCORTISONE BUTYRATE/

/AT/	/GIST/	/0.1%/	/N19116/001/ /FEB/25,/1987/
	/LOCOID/ /OWEN/GALDERMA/	/0.1%/	/N19819/001/ /SEP/15,/1988/

LOCOID

	BROCADES PHARMA	0.1%	N19116 001 FEB 25, 1987
a	OWEN GALDERMA	0.1%	N19819 001 SEP 15, 1988

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

>DLT>		/HYDROCORTISONE SODIUM PHOSPHATE/		
>DLT>/AP/		/QUAD/	/EQ 50MG BASE/ML/	/N89581/001/ /MAY/28,/1987/
>DLT>				
>ADD>		a QUAD	EQ 50MG BASE/ML	N89581 001 MAY 28, 1987
>ADD>				
		HYDROCORTONE		
>DLT>/AP/		/MSD/	/EQ 50MG BASE/ML/	/N12052/001/
>ADD>		MSD	EQ 50MG BASE/ML	N12052 001

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

HYDROCORTISONE SODIUM SUCCINATE

/AP/	/LYPHOMED/	/EQ 100MG BASE/VIAL/	/N88667/001/ /JUN/08,/1984/
/AP/		/EQ 100MG BASE/VIAL/	/N88712/001/ /JUN/08,/1984/
/AP/		/EQ 250MG BASE/VIAL/	/N88668/001/ /JUN/08,/1984/
/AP/		/EQ 500MG BASE/VIAL/	/N88669/001/ /JUN/08,/1984/
/AP/		/EQ 1GM BASE/VIAL/	/N88670/001/ /JUN/08,/1984/
	a LYPHOMED	EQ 100MG BASE/VIAL	N88667 001 JUN 08, 1984
	a	EQ 100MG BASE/VIAL	N88712 001 JUN 08, 1984
	a	EQ 250MG BASE/VIAL	N88668 001 JUN 08, 1984
	a	EQ 500MG BASE/VIAL	N88669 001 JUN 08, 1984
	a	EQ 1GM BASE/VIAL	N88670 001 JUN 08, 1984

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

HYDROFLUMETHIAZIDE AND RESERPINE

B*	PHARM BASICS	50MG;0.125MG	N88195 001	OCT 26, 1983
/BP/		/50MG;0.125MG/	/N88195/001/	/OCT/26,/1983/
	/HYDROFLUMETHIAZIDE/W//RESERPINE/			
/BP/	/BOLAR/	/25MG;0.125MG/	/N88127/001/	/MAR/22,/1983/
/BP/		/50MG;0.125MG/	/N88110/001/	/MAR/22,/1983/
	@ BOLAR	25MG;0.125MG	N88127 001	MAR 22, 1983
	@	50MG;0.125MG	N88110 001	MAR 22, 1983
	SALUTENSIN-DEMI			
/BP/	/BRISTOL/	/25MG;0.125MG/	/N12359/004/	
	BRISTOL	25MG;0.125MG	N12359 004	

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

HYDROCOBALAMIN

/AP/	/LEMMON/	/1MG/ML/	/N85528/001/
AP	STERIS	1MG/ML	N85528 001

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

/DURA-LUTIN/

/AO/	/STERIS/	/125MG/ML/	/N17439/001/
/AO/		/250MG/ML/	/N17439/002/

HYDROXYPROGESTERONE CAPROATE

>DLT>	/AO/	/QUAD/	/125MG/ML/	/N89330/001/
>DLT>				/JAN/02,/1987/
>DLT>	/AO/		/250MG/ML/	/N89331/001/
>DLT>				/JAN/02,/1987/
>ADD>		@ QUAD	125MG/ML	N89330 001 JAN 02, 1987
>ADD>		@	250MG/ML	N89331 001 JAN 02, 1987
	AO	STERIS	125MG/ML	N17439 001
	AO		250MG/ML	N17439 002

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL

/AP/	/LEMMON/	/25MG/ML/	/N87274/001/	
/AP/		/50MG/ML/	/N87274/002/	
AP	STERIS	25MG/ML	N87274 001	
AP		50MG/ML	N87274 002	

TABLET; ORAL

HYDROXYZINE HCL

/AB/	/BARR/	/10MG/	/N88409/001/	/NOV/15,/1983/
/AB/		/25MG/	/N87857/001/	/APR/18,/1983/
/AB/		/50MG/	/N87860/001/	/APR/18,/1983/
/AB/		/100MG/	/N87862/001/	/APR/18,/1983/
	@ BARR	10MG	N88409 001	NOV 15, 1983
	@	25MG	N87857 001	APR 18, 1983
	@	50MG	N87860 001	APR 18, 1983
	@	100MG	N87862 001	APR 18, 1983
/AB/	/PHARM/BASICS/	/10MG/	/N89121/001/	/MAR/20,/1986/
/AB/		/25MG/	/N89122/001/	/MAR/20,/1986/
/AB/		/50MG/	/N89123/001/	/MAR/20,/1986/
B*	PHARM BASICS	10MG	N89121 001	MAR 20, 1986
B*		25MG	N89122 001	MAR 20, 1986
B*		50MG	N39123 001	MAR 20, 1986

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

/AB/	/BOLAR/	/EQ 25MG HCL/	/N86698/001/	
/AB/		/EQ 50MG HCL/	/N86695/001/	
/AB/		/EQ 100MG HCL/	/N86697/001/	
	@ BOLAR	EQ 25MG HCL	N86698 001	
	@	EQ 50MG HCL	N86695 001	
	@	EQ 100MG HCL	N36697 001	
AB	DANBURY	EQ 25MG HCL*	N81165 001	JUL 31, 1991

HYDROXYZINE PAMOATE

CAPSULE; ORAL

	HYDROXYZINE PAMOATE		
AB	GENEVA	EQ 25MG HCL¤	N81127 001 JUN 28, 1991
AB		EQ 50MG HCL¤	N81128 001 JUN 28, 1991
AB		EQ 100MG HCL¤	N81129 001 JUN 28, 1991
/AB/	/SUPERPHARM/	/EQ 25MG HCL/	/N89031/001/ /JAN/02,/1987/
/AB/		/EQ 50MG HCL/	/N89032/001/ /JAN/02,/1987/
/AB/		/EQ 100MG HCL/	/N89033/001/ /JAN/02,/1987/
	ə SUPERPHARM	EQ 25MG HCL	N89031 001 JAN 02, 1987
	ə	EQ 50MG HCL	N89032 001 JAN 02, 1987
	ə	EQ 100MG HCL	N89033 001 JAN 02, 1987
/AB/	/VANGARD/	/EQ 25MG HCL/	/N88392/001/ /SEP/19,/1983/
	ə VANGARD	EQ 25MG HCL	N88392 001 SEP 19, 1983

IBUPROFEN

SUSPENSION; ORAL

	RUFEN		
BX	BOOTS	100MG/5ML	N19784 001 DEC 18, 1989

TABLET; ORAL

	IBUPROFEN		
/B*/	/CHELSEA/	/400MG¤/	/N70038/001/ /SEP/06,/1985/
/B*/		/600MG¤/	/N70041/001/ /SEP/06,/1985/
/B*/		/800MG¤/	/N71911/001/ /OCT/13,/1987/
	ə CHELSEA	400MG	N70038 001 SEP 06, 1985
	ə	600MG	N70041 001 SEP 06, 1985
	ə	800MG	N71911 001 OCT 13, 1987
/BX/	/SUPERPHARM/	/400MG/	/N70708/001/ /APR/25,/1986/

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

	IMIPRAMINE HCL		
/AB/	/BOLAR/	/10MG/	/N85220/001/
/AB/		/25MG/	/N84252/002/
/AB/		/50MG/	/N85221/001/
	ə BOLAR	10MG	N85220 001
	ə	25MG	N84252 002
	ə	50MG	N85221 001
	PRAMINE		
	ə ALRA	10MG	N83827 001
	ə	25MG	N83827 002
	ə	50MG	N83827 003
/ə/	/BANMAX/	/10MG/	/N83827/001/
/ə/		/25MG/	/N83827/002/
/ə/		/50MG/	/N83827/003/

INDOMETHACIN

CAPSULE; ORAL

	INDOMETHACIN		
/AB/	/BOLAR/	/25MG/	/N70784/001/ /AUG/20,/1986/
/AB/		/50MG/	/N70785/001/ /AUG/20,/1986/
	ə BOLAR	25MG	N70784 001 AUG 20, 1986
	ə	50MG	N70785 001 AUG 20, 1986
AB	DANBURY	25MG¤	N72996 001 JUL 31, 1991
AB		50MG¤	N72997 001 JUL 31, 1991
/AB/	/ROXANE/	/25MG/	/N70353/001/ /JUN/18,/1985/
/AB/		/50MG/	/N70354/001/ /JUN/18,/1985/
	ə ROXANE	25MG	N70353 001 JUN 18, 1985
	ə	50MG	N70354 001 JUN 18, 1985
/AB/	/SUPERPHARM/	/25MG/	/N70487/001/ /OCT/10,/1986/
/AB/		/50MG/	/N70488/001/ /OCT/10,/1986/
	ə SUPERPHARM	25MG	N70487 001 OCT 10, 1986
	ə	50MG	N70488 001 OCT 10, 1986

IOPAMIDOL

INJECTABLE; INJECTION

ISOVUE-M 200

SQUIBB	41%	N18735 001	
		DEC 31, 1985	

ISOVUE-200

/SQUIBB/	/41%/	/N18735/001/	
		/DEC/31,/1985/	
SQUIBB	41%	N18735 006	
		JUL 07, 1987	

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

ISOETHARINE HCL

/AN/	/ARMOUR/	/0.125%/	/N89615/001/	
			/JUN/13,/1991/	
/AN/		/0.167%/	/N89616/001/	
			/JUN/13,/1991/	
/AN/		/0.2%/	/N89617/001/	
			/JUN/13,/1991/	
/AN/		/0.25%/	/N89618/001/	
			/JUN/13,/1991/	
		/0.062%/	/N89614/001/	
			/JUN/13,/1991/	
AN	ASTRA	0.125%	N89615 001	
			JUN 13, 1991	
AN		0.167%	N89616 001	
			JUN 13, 1991	
AN		0.2%	N89617 001	
			JUN 13, 1991	
AN		0.25%	N89618 001	
			JUN 13, 1991	
		0.062%	N89614 001	
			JUN 13, 1991	

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION

BRONKOMETER

/BN/	/STERLING/	/0.34MG/BASE/INH/	/N12339/007/	
BN	STERLING	0.34MG/INH	N12339 007	

ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

>DLT >/AP/	/QUAD/	/100MG/ML/	/N89816/001/		
>DLT >			/OCT/28,/1988/		
>ADD >	ə QUAD	100MG/ML	N89816 001		
>ADD >			OCT 28, 1988		

HYDRAZID

>DLT >/AP/	/SQUIBB/	/100MG/ML/	/N86662/001/		
>ADD >	SQUIBB	100MG/ML	N08662 001		

SYRUP; ORAL

/RINTFON/

/AA/	/ROCHE/	/50MG/5ML/	/N88420/001/		
	ə ROCHE	50MG/5ML	N08420 001		

TABLET; ORAL

ISONIAZID

/AA/	/BOLAR/	/100MG/	/N80401/001/		
/AA/		/300MG/	/N83178/001/		
	ə BOLAR	100MG	N80401 001		
	ə	300MG	N83178 001		
AA	ZENITH	300MG	N83610 001		

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN SULFATE

/AP/	/INTL/MEDICATION/	/EQ 500MG BASE/2ML/	/N62466/001/		
			/SEP/30,/1983/		
/AP/		/EQ 1GM BASE/3ML/	/N62466/002/		
			/SEP/30,/1983/		
	ə INTL MEDICATION	EQ 500MG BASE/2ML	N62466 001		
			SEP 30, 1983		
	ə	EQ 1GM BASE/3ML	N62466 002		
			SEP 30, 1983		

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALAR

>DLT >/AP/	/PARKE/DAVIS/	/EQ 10MG BASE/ML/	/N16812/001/		
>DLT >/AP/		/EQ 50MG BASE/ML/	/N16812/002/		
>DLT >/AP/		/EQ 100MG BASE/ML/	/N16812/003/		
>ADD >	PARKE DAVIS	EQ 10MG BASE/ML	N16812 001		
>ADD >		EQ 50MG BASE/ML	N16812 002		
>ADD >		EQ 100MG BASE/ML	N16812 003		

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HCL

> DLT >	/AP/	/QUAD/	/EQ 10MG BASE/ML/	/N71949/001/ /APR/11,/1988/
> DLT >				
> DLT >	/AP/		/EQ 50MG BASE/ML/	/N71950/001/ /APR/11,/1988/
> DLT >				
> DLT >	/AP/		/EQ 100MG BASE/ML/	/N71951/001/ /APR/11,/1988/
> DLT >				
> ADD >		a QUAD	EQ 10MG BASE/ML	N71949 001 APR 11, 1988
> ADD >				
> ADD >		a	EQ 50MG BASE/ML	N71950 001 APR 11, 1988
> ADD >				
> ADD >		a	EQ 100MG BASE/ML	N71951 001 APR 11, 1988
> ADD >				

KETOCONAZOLE

/SUSPENSION;ORAL/

/NIZORAL/

/JANSSEN/ /100MG/5ML/ /N70767/001/ /NOV/07,/1986/

a JANSSEN 100MG/5ML N70767 001 NOV 07, 1986

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

> DLT >	/AP/	/QUAD/	/EQ 5MG BASE/ML/	/N89503/001/ /OCT/05,/1987/
> DLT >				
> DLT >	/AP/		/EQ 5MG BASE/ML/	/N89504/001/ /DEC/22,/1987/
> DLT >				
> DLT >	/AP/		/EQ 50MG BASE/VIAL/	/N89496/001/ /MAR/05,/1987/
> DLT >				
> DLT >	/AP/		/EQ 100MG BASE/VIAL/	/N89636/001/ /DEC/24,/1987/
> DLT >				
> ADD >		a QUAD	EQ 5MG BASE/ML	N89503 001 OCT 05, 1987
> ADD >				
> ADD >		a	EQ 5MG BASE/ML	N89504 001 DEC 22, 1987
> ADD >				
> ADD >		a	EQ 50MG BASE/VIAL	N89496 001 MAR 05, 1987
> ADD >				
> ADD >		a	EQ 100MG BASE/VIAL	N89636 001 DEC 24, 1987
> ADD >				

WELLCOVORIN

> DLT >	/AP/	/BURROUGHS/WELLCOME/	/EQ 5MG BASE/ML/	/N87439/001/ /OCT/19,/1982/
> DLT >				
> ADD >		BURROUGHS WELLCOME	EQ 5MG BASE/ML	N87439 001 OCT 19, 1982
> ADD >				

LEVONORGESTREL

IMPLANT; IMPLANTATION

/LEVONORGESTREL/SYSTEM/

	/WYETH/AYERST/	/36MG/IMPLANT/	/N20088/001/ /DEC/10,/1990/
	NORPLANT SYSTEM WYETH AYERST	36MG/IMPLANT	N20088 001 DEC 10, 1990

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL

/AP/	/CUTTER/	/1%/	/N80414/001/	
/AP/		/2%/	/N80414/002/	
	a CUTTER	1%	N80414 001	
	a	2%	N80414 002	
/AP/	/ELKINS/SINN/	/0.5%/	/N85131/001/	
/AP/		/4%/	/N84626/001/	
	a ELKINS SINN	0.5%	N85131 001	
	a	4%	N84626 001	
/a/	/LEMMON/	/1%/	/N83627/001/	
/a/		/2%/	/N83627/002/	
	a STERIS	1%	N83627 001	
	a	2%	N83627 002	

SOLUTION; TOPICAL

LIDOCAINE HCL

/AT/	/PACO/	/4%/	/N89688/001/ /JUN/30,/1989/	
	a PACO	4%	N89688 001 JUN 30, 1989	

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOMYCIN HCL

AP	STERIS	EQ 300MG BASE/ML*	N63180 001 APR 16, 1991

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

/AB/	/SKF/	/EQ 0.025MG BASE/	/N10379/002/
	SKF	EQ 0.025MG BASE	N10379 002

LIOTHYRONINE SODIUM

TABLET; ORAL
/LIOTHYRONINE SODIUM/
/AB/ /BOLAR/ /EQ 0.025MG BASE/ /N85755/001/ /JAN/25,/1982/
∂ BOLAR EQ 0.025MG BASE N85755 001 JAN 25, 1982

LITHIUM CARBONATE

CAPSULE; ORAL
LITHIUM CARBONATE
/AB/ /BOLAR/ /300MG/ /N70407/001/ /MAR/19,/1987/
∂ BOLAR 300MG N70407 001 MAR 19, 1987
/AB/ /PHARM/BASICS/ /300MG/ /N72542/001/ /FEB/01,/1989/
B* PHARM BASICS 300MG N72542 001 FEB 01, 1989

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
IMODIUM
AB JANSSEN 2MG N17690 001
AB 2MG N17694 001
LOPERAMIDE HCL
AB MYLAN 2MG‡ N72741 001 SEP 18, 1991
AB NOVOPHARM 2MG‡ N73122 001 AUG 30, 1991
> ADD > AB ROXANE 2MG‡ N73080 001 NOV 27, 1991
> ADD >

LORAZEPAM

CONCENTRATE; ORAL
LORAZEPAM INTENSOL
ROXANE 2MG/ML‡ N72755 001 JUN 28, 1991

LORAZEPAM

TABLET; ORAL
LORAZEPAM
/BX/ /AM THERAP/ /0.5MG/ /N70727/001/ /MAR/07,/1986/
/BX/ /1MG/ /N70728/001/ /MAR/07,/1986/
/BX/ /2MG/ /N70729/001/ /MAR/07,/1986/
∂ AM THERAP 0.5MG N70727 001 MAR 07, 1986
∂ 1MG N70728 001 MAR 07, 1986
∂ 2MG N70729 001 MAR 07, 1986
AB MUTUAL PHARM 0.5MG‡ N72553 001 MAR 29, 1991
AB 1MG‡ N72554 001 MAR 29, 1991
AB 2MG‡ N72555 001 MAR 29, 1991
/AB/ /PHARM/BASICS/ /1MG/ /N70539/001/ /DEC/22,/1986/
/AB/ /2MG/ /N70540/001/ /DEC/22,/1986/
B* PHARM BASICS 1MG N70539 001 DEC 22, 1986
B* 2MG N70540 001 DEC 22, 1986
AB ROYCE 0.5MG‡ N72926 001 OCT 31, 1991
AB 1MG‡ N72927 001 OCT 31, 1991
AB 2MG‡ N72928 001 OCT 31, 1991

LOVASTATIN

TABLET; ORAL
MEVACOR
MSD 10MG‡ N19643 002 MAR 28, 1991

MANNITOL

INJECTABLE; INJECTION
MANNITOL 10%
/AP/ /CUTTER/ /10GM/100ML/ /N16472/002/
∂ CUTTER 10GM/100ML N16472 002

INJECTABLE; INJECTION

MANNITOL 10%

/AP/	/CUTTER/	/10GM/100ML/	/N16472/002/
∂ CUTTER		10GM/100ML	N16472 002

MANNITOL

INJECTABLE; INJECTION

MANNITOL 15%

/AP/	/CUTTER/	/15GM/100ML/	/N16472/005/
∂ CUTTER		15GM/100ML	N16472 005

MANNITOL 20%

/AP/	/CUTTER/	/20GM/100ML/	/N16472/004/
∂ CUTTER		20GM/100ML	N16472 004

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

MAPROTILINE HCL

/AB/	/BOLAR/	/25MG/	/N71943/001/ /DEC/30,/1987/
/AB/		/50MG/	/N71944/001/ /DEC/30,/1987/
/AB/		/75MG/	/N71945/001/ /DEC/30,/1987/
∂ BOLAR		25MG	N71943 001 DEC 30, 1987
∂		50MG	N71944 001 DEC 30, 1987
∂		75MG	N71945 001 DEC 30, 1987

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

/AB/	/PHARM/BASICS/	/EQ 50MG BASE/	/N71007/001/ /MAR/25,/1988/
/AB/		/EQ 100MG BASE/	/N71008/001/ /MAR/25,/1988/
B* PHARM BASICS		EQ 50MG BASE	N71007 001 MAR 25, 1988
B*		EQ 100MG BASE	N71008 001 MAR 25, 1988

MEGESTROL ACETATE

TABLET; ORAL

MEGESTROL ACETATE

B*	PHARM BASICS	20MG	N70646 001 OCT 02, 1987
B*		40MG	N70647 001 OCT 02, 1987
/BX/		/20MG/	/N70646/001/ /OCT/02,/1987/
/BX/		/40MG/	/N70647/001/ /OCT/02,/1987/

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HCL

/AP/	/ELKINS/SINN/	/25MG/ML/	/N88279/001/ /JUN/15,/1984/
/AP/		/50MG/ML/	/N88280/001/ /JUN/15,/1984/
/AP/		/75MG/ML/	/N88281/001/ /JUN/15,/1984/
/AP/		/100MG/ML/	/N88282/001/ /JUN/15,/1984/
∂ ELKINS SINN		25MG/ML	N88279 001 JUN 15, 1984
∂		50MG/ML	N88280 001 JUN 15, 1984
∂		75MG/ML	N88281 001 JUN 15, 1984
∂		100MG/ML	N88282 001 JUN 15, 1984

MEPROBAMATE

TABLET; ORAL

BAMATE

∂ ALRA		200MG	N80380 001
∂		400MG	N80380 002
/∂/BANMAX/		/200MG/	/N80380/001/
/∂/		/400MG/	/N80380/002/

MESTRANOL; NORETHYNODREL

/TABLET;/ORAL-21/

/ENOVID-E/21/

/SEARLE/		/0.1MG;2.5MG/	/N10976/007/
∂ SEARLE		0.1MG;2.5MG	N10976 007

METAPROTERENOL SULFATE

SYRUP; ORAL
METAPROTERENOL SULFATE

AA	COPLEY	10MG/5ML¤	N73034 001 AUG 30, 1991

TABLET; ORAL
METAPROTERENOL SULFATE

/AB/	/AM THERAP/	/10MG/	/N72054/001/ /JUN/23,/1988/
/AB/		/20MG/	/N72055/001/ /JUN/23,/1988/
	ə AM THERAP	10MG	N72054 001 JUN 23, 1988
	ə	20MG	N72055 001 JUN 23, 1988
AB	DANBURY	10MG¤	N73013 001 JAN 31, 1991
AB		20MG¤	N72795 001 JAN 31, 1991
/AB/	/PHARM/BASICS/	/10MG/	/N71013/001/ /JAN/25,/1988/
/AB/		/20MG/	/N71014/001/ /JAN/25,/1988/
B*	PHARM BASICS	10MG	N71013 001 JAN 25, 1988
B*		20MG	N71014 001 JAN 25, 1988

METARAMINOL BITARTRATE

INJECTABLE; INJECTION
METARAMINOL BITARTRATE

/AP/	/BRISTOL/	/EQ 10MG BASE/ML/	/N80431/001/
AP	LYPHOMED	EQ 10MG BASE/ML	N80431 001

METHADONE HYDROCHLORIDE

/TABLET;/EFFERVESCENT;/ORAL/
/WESTADONE/
/VITARINE/

	/2.5MG/	/N17108/001/
	/5MG/	/N17108/002/
	/10MG/	/N17108/003/
	/40MG/	/N17108/004/
ə VITARINE	2.5MG	N17108 001
ə	5MG	N17108 002
ə	10MG	N17108 003
ə	40MG	N17108 004

METHANTHELINE BROMIDE

TABLET; ORAL
BANTHINE

AA	SCHIAPPARELLI SEARLE	50MG	N07390 001
/AA/	/SEARLE/	/50MG/	/N07390/001/

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL

/AA/	/BOLAR/	/500MG/	/N83605/001/
/AA/		/750MG/	/N83605/002/
	ə BOLAR	500MG	N83605 001
	ə	750MG	N83605 002

METHOTREXATE SODIUM

INJECTABLE; INJECTION
FOLEX PFS

AP	ADRIA	EQ 25MG BASE/ML¤	N81242 001 AUG 23, 1991
	METHOTREXATE		
/AP/	/LEDERLE/	/EQ 2.5MG BASE/ML/	/N11719/004/
	LEDERLE	EQ 2.5MG BASE/ML	N11719 004
	METHOTREXATE SODIUM		
/AP/	/LYPHOMED/	/EQ 2.5MG BASE/ML/	/N89323/001/ /JUN/13,/1986/
/AP/		/EQ 25MG BASE/ML/	/N89322/001/ /JUN/13,/1986/
	ə LYPHOMED	EQ 2.5MG BASE/ML	N89323 001 JUN 13, 1986
	ə	EQ 25MG BASE/ML	N89322 001 JUN 13, 1986

METHOTREXATE SODIUM

INJECTABLE; INJECTION
METHOTREXATE SODIUM

>DLT>	/AP/	/QUAD/	/EQ 25MG BASE/ML/	/N89308/001/ /JUL/10,/1986/
>DLT>				
>DLT>	/AP/		/EQ 25MG BASE/ML/	/N89309/001/ /JUL/10,/1986/
>DLT>				
>DLT>	/AP/		/EQ 20MG BASE/VIAL/	/N89293/001/ /JUL/10,/1986/
>DLT>				
>DLT>	/AP/		/EQ 50MG BASE/VIAL/	/N89294/001/ /JUL/10,/1986/
>DLT>				
>DLT>	/AP/		/EQ 100MG BASE/VIAL/	/N89295/001/ /JUL/10,/1986/
>DLT>				
>DLT>	/AP/		/EQ 250MG BASE/VIAL/	/N89296/001/ /JUL/10,/1986/
>DLT>				
>ADD>		ə QUAD	EQ 25MG BASE/ML	N89308 001 JUL 10, 1986
>ADD>				
>ADD>		ə	EQ 25MG BASE/ML	N89309 001 JUL 10, 1986
>ADD>				
>ADD>		ə	EQ 20MG BASE/VIAL	N89293 001 JUL 10, 1986
>ADD>				
>ADD>		ə	EQ 50MG BASE/VIAL	N89294 001 JUL 10, 1986
>ADD>				
>ADD>		ə	EQ 100MG BASE/VIAL	N89295 001 JUL 10, 1986
>ADD>				
>ADD>		ə	EQ 250MG BASE/VIAL	N89296 001 JUL 10, 1986
>ADD>				

METHYCLOTHIAZIDE

TABLET; ORAL
METHYCLOTHIAZIDE

/AB/	/BOLAR/	/2.5MG/	/N85487/001/ /MAR/11,/1982/
/AB/		/5MG/	/N85476/001/ /MAR/11,/1982/
	ə BOLAR	2.5MG	N85487 001 MAR 11, 1982
	ə	5MG	N85476 001 MAR 11, 1982
/AB/	/PHARM/BASICS/	/5MG/	/N88745/001/ /MAR/21,/1985/
B*	PHARM BASICS	5MG	N88745 001 MAR 21, 1985

METHYLDOPA

TABLET; ORAL
METHYLDOPA

/AB/	/BOLAR/	/125MG/	/N70245/001/ /FEB/25,/1986/
/AB/		/250MG/	/N70246/001/ /FEB/25,/1986/
/AB/		/500MG/	/N70247/001/ /FEB/25,/1986/
	ə BOLAR	125MG	N70245 001 FEB 25, 1986
	ə	250MG	N70246 001 FEB 25, 1986
	ə	500MG	N70247 001 FEB 25, 1986
/AB/	/ROXANE/	/125MG/	/N70192/001/ /APR/25,/1986/
/AB/		/250MG/	/N70193/001/ /APR/25,/1986/
/AB/		/500MG/	/N70194/001/ /APR/25,/1986/
	ə ROXANE	125MG	N70192 001 APR 25, 1986
	ə	250MG	N70193 001 APR 25, 1986
	ə	500MG	N70194 001 APR 25, 1986

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
METHYLDOPATE HCL

>ADD>	AP	GENSIA	50MG/ML*	N72974 001 NOV 22, 1991
>ADD>				
>DLT>	/AP/	/QUAD/	/50MG/ML/	/N71024/001/ /SEP/18,/1986/
>DLT>				
>ADD>		ə QUAD	50MG/ML	N71024 001 SEP 18, 1986
>ADD>				

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE ACETATE

/ə/	/LEMMON/	/20MG/ML/	/N87248/001/
/ə/		/40MG/ML/	/N85374/001/
/ə/		/80MG/ML/	/N86507/001/
	ə STERIS	20MG/ML	N87248 001
	ə	40MG/ML	N85374 001
	ə	80MG/ML	N86507 001

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-METHAPRED

AP	ABBOTT	EQ 40MG BASE/VIAL¤	N89573 001 FEB 22, 1991
AP		EQ 125MG BASE/VIAL¤	N89574 001 FEB 22, 1991
AP		EQ 500MG BASE/VIAL¤	N89575 001 FEB 22, 1991
AP		EQ 1GM BASE/VIAL¤	N89576 001 FEB 22, 1991

METHYLPREDNISOLONE SODIUM SUCCINATE

/AP/	/LYPHOMED/	/EQ 40MG BASE/VIAL/	/N88676/001/ /JUN/08,/1984/
/AP/		/EQ 125MG BASE/VIAL/	/N88677/001/ /JUN/08,/1984/
/AP/		/EQ 500MG BASE/VIAL/	/N88678/001/ /JUN/08,/1984/
/AP/		/EQ 500MG BASE/VIAL/	/N89186/001/ /MAR/28,/1986/
/AP/		/EQ 1GM BASE/VIAL/	/N88679/001/ /JUN/08,/1984/
/AP/		/EQ 1GM BASE/VIAL/	/N89188/001/ /MAR/28,/1986/
	ə LYPHOMED	EQ 40MG BASE/VIAL	N88676 001 JUN 08, 1984
	ə	EQ 125MG BASE/VIAL	N88677 001 JUN 08, 1984
	ə	EQ 500MG BASE/VIAL	N88678 001 JUN 08, 1984
	ə	EQ 500MG BASE/VIAL	N89186 001 MAR 28, 1986
	ə	EQ 1GM BASE/VIAL	N88679 001 JUN 08, 1984
	ə	EQ 1GM BASE/VIAL	N89188 001 MAR 28, 1986
>DLT >/AP/	/QUAD/	/EQ 40MG BASE/VIAL/	/N89264/001/ /JAN/22,/1986/
>DLT >			
>DLT >/AP/		/EQ 125MG BASE/VIAL/	/N89265/001/ /JAN/22,/1986/
>DLT >			
>DLT >/AP/		/EQ 500MG BASE/VIAL/	/N89266/001/ /JAN/22,/1986/
>DLT >			
>DLT >/AP/		/EQ 1GM BASE/VIAL/	/N89267/001/ /JAN/22,/1986/
>DLT >			
>ADD >	ə QUAD	EQ 40MG BASE/VIAL	N89264 001 JAN 22, 1986
>ADD >			
>ADD >	ə	EQ 125MG BASE/VIAL	N89265 001 JAN 22, 1986
>ADD >			
>ADD >	ə	EQ 500MG BASE/VIAL	N89266 001 JAN 22, 1986
>ADD >			
>ADD >	ə	EQ 1GM BASE/VIAL	N89267 001 JAN 22, 1986
>ADD >			

METHYLTESTOSTERONE

TABLET; BUCCAL/SUBLINGUAL
/METANDREN/

/AB/	/CIBA/	/5MG/	/N03240/004/
/AB/		/10MG/	/N03240/005/
	ə CIBA	5MG	N03240 004
	ə	10MG	N03240 005
	METHYLTESTOSTERONE		
/BP/	/PHARM/BASICS/	/10MG/	/N80271/001/
	ə PHARM BASICS	10MG	N80271 001

TABLET; ORAL
/METANDREN/

/AB/	/CIBA/	/10MG/	/N03240/001/
/AB/		/25MG/	/N03240/003/
	ə CIBA	10MG	N03240 001
	ə	25MG	N03240 003

METHYPRYLON

TABLET; ORAL
NOLUDAR

	/ROCHE/	/50MG/	/N09660/002/
	ə ROCHE	50MG	N09660 002

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	ABBOTT	EQ 10MG BASE/2ML¤	N73117 001 JAN 17, 1991
AP		EQ 10MG BASE/2ML¤	N73118 001 JAN 17, 1991
>ADD > AP	GENSIA	EQ 10MG BASE/2ML¤	N73135 001 NOV 27, 1991
>ADD >			
>DLT >/AP/	/QUAD/	/EQ 10MG BASE/2ML/	/N70671/001/ /MAY/27,/1986/
>DLT >			
>ADD >	ə QUAD	EQ 10MG BASE/2ML	N70671 001 MAY 27, 1986
>ADD >			
/AP/	/SOLOPAK/	/EQ 10MG BASE/2ML/	/N70622/001/ /MAR/02,/1987/
	ə SOLOPAK	EQ 10MG BASE/2ML	N70622 001 MAR 02, 1987

SYRUP; ORAL
METOCLOPRAMIDE HCL

/AA/	/PACO/	/EQ 5MG BASE/5ML/	/N71665/001/ /DEC/05,/1988/
	ə PACO	EQ 5MG BASE/5ML	N71665 001 DEC 05, 1988

METOCLOPRAMIDE HYDROCHLORIDE

SYRUP; ORAL

	METOCLOPRAMIDE HCL		
AA	PHARMS ASSOC	EQ 5MG BASE/5ML¤	N72744 001 MAY 28, 1991

TABLET; ORAL

	METOCLOPRAMIDE HCL		
/AB/	/BARR/	/EQ 10MG BASE/	/N70660/001/ /FEB/10,/1987/
ə	BARR	EQ 10MG BASE	N70660 001 FEB 10, 1987
/AB/	/BOLAR/	/EQ 10MG BASE/	/N70363/001/ /MAR/02,/1987/
ə	BOLAR	EQ 10MG BASE	N70363 001 MAR 02, 1987
AB	LEDERLE	EQ 10MG BASE¤	N72639 001 MAY 09, 1991
/AB/	/MARTEC/	/EQ 10MG BASE/	/N70598/001/ /FEB/02,/1987/
/AB/	/PHARM/BASICS/	/EQ 10MG BASE/	/N70339/001/ /JUL/29,/1985/
B*	PHARM BASICS	EQ 10MG BASE	N70339 001 JUL 29, 1985
AB	SCHERING	EQ 10MG BASE	N70598 001 FEB 02, 1987

METOCURINE IODIDE

INJECTABLE; INJECTION

	METOCURINE IODIDE		
>DLT>			
>DLT>/AP/	/QUAD/	/2MG/ML/	/N89443/001/ /JUN/01,/1988/
>DLT>			
>ADD>	ə QUAD	2MG/ML	N89443 001 JUN 01, 1988
>ADD>			
	METUBINE IODIDE		
>DLT>/AP/	/LILLY/	/2MG/ML/	/N06632/003/
>ADD>	LILLY	2MG/ML	N06632 003

METRONIDAZOLE

INJECTABLE; INJECTION

	METRONIDAZOLE		
/AP/	/INTL/MEDICATION/	/500MG/100ML/	/N70064/001/ /MAY/08,/1985/
ə	INTL MEDICATION	500MG/100ML	N70004 001 MAY 08, 1985
AP	STERIS	500MG/100ML	N70042 001 DEC 20, 1984

METRONIDAZOLE

INJECTABLE; INJECTION

	METRYL IV		
/AP/	/STERIS/	/500MG/100ML/	/N70042/001/ /DEC/20,/1984/

TABLET; ORAL

	METRONIDAZOLE		
/AB/	/SUPERPHARM/	/250MG/	/N70006/001/ /DEC/11,/1984/
/AB/		/500MG/	/N70009/001/ /DEC/11,/1984/
ə	SUPERPHARM	250MG	N70008 001 DEC 11, 1984
ə		500MG	N70009 001 DEC 11, 1984

MICONAZOLE NITRATE

	/CREAM;/VAGINAL/ /MONISTAT 7/		
/AT/	/JOHNSON/RW/	/2%/	/N17456/001/

	/SUPPOSITORY;/VAGINAL/ /MONISTAT 7/		
/AT/	/JOHNSON/RW/	/100MG/	/N18526/001/ /MAR/15,/1982/

MILRINONE LACTATE

	/INJECTABLE;/INJECTION/ /MILRINONE/LACTATE/		
	/STERLING/	/EQ/1MG/BASE/ML/	/N19436/001/ /DEC/31,/1987/
ə	STERLING	EQ 1MG BASE/ML	N19436 001 DEC 31, 1987

MINOXIDIL

TABLET; ORAL

	MINOXIDIL		
/AB/	/PHARM/BASICS/	/2.5MG/	/N71537/001/ /DEC/16,/1988/
B*	PHARM BASICS	2.5MG	N71537 001 DEC 16, 1988

MORPHINE SULFATE

INJECTABLE; INJECTION

INFUMORPH

	ELKINS SINN	10MG/ML¤	N18565 003 JUL 19, 1991
		25MG/ML¤	N18565 004 JUL 19, 1991

MORPHINE SULFATE

AP	STERIS	0.5MG/ML¤	N73373 001 SEP 30, 1991
AP		0.5MG/ML¤	N73375 001 SEP 30, 1991
AP		1MG/ML¤	N73374 001 SEP 30, 1991
AP		1MG/ML¤	N73376 001 SEP 30, 1991

TABLET, EXTENDED RELEASE; ORAL

MS CONTIN

BC	PURDUE FREDERICK	30MG	N19516 001 MAY 29, 1987
BC		60MG	N19516 002 APR 08, 1988
BC		100MG	N19516 004 JAN 16, 1990

ORAMORPH SR

BC	ROXANE LABS	30MG¤	N19977 001 AUG 15, 1991
BC		60MG¤	N19977 002 AUG 15, 1991
BC		100MG¤	N19977 003 AUG 15, 1991

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE

>DLT >/AP/	/QUAD/	/10MG/ML/	/N70692/001/	
>DLT >			/MAR/25,/1986/	
>DLT >/AP/		/20MG/ML/	/N70693/001/	
>DLT >			/MAR/25,/1986/	
>ADD >	ə QUAD	10MG/ML	N70692 001 MAR 25, 1986	
>ADD >				
>ADD >	ə	20MG/ML	N70693 001 MAR 25, 1986	
>ADD >				

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

/AP/	/ELKINS/SINN/	/0.4MG/ML/	/N70496/001/	
			/OCT/22,/1985/	
	ə ELKINS SINN	0.4MG/ML	N70496 001 OCT 22, 1985	

NALOXONE HCL

/AP/	/LYPHOMED/	/1MG/ML/	/N71604/001/	
			/DEC/16,/1988/	
	ə LYPHOMED	1MG/ML	N71604 001 DEC 16, 1988	
>DLT >/AP/	/QUAD/	/0.02MG/ML/	/N70678/001/	
>DLT >			/DEC/18,/1986/	
>DLT >/AP/		/0.4MG/ML/	/N70679/001/	
>DLT >			/DEC/18,/1986/	
>DLT >/AP/		/1MG/ML/	/N70680/001/	
>DLT >			/DEC/18,/1986/	
>ADD >	ə QUAD	0.02MG/ML	N70678 001 DEC 18, 1986	
>ADD >				
>ADD >	ə	0.4MG/ML	N70679 001 DEC 18, 1986	
>ADD >				
>ADD >	ə	1MG/ML	N70680 001 DEC 18, 1986	
>ADD >				

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

/AD/	/LENMON/	/50MG/ML/	/N87548/001/	
			/OCT/06,/1983/	
/AD/		/50MG/ML/	/N88554/001/	
			/FEB/10,/1986/	
/AD/		/100MG/ML/	/N87549/001/	
			/OCT/06,/1983/	
>DLT >/AD/	/QUAD/	/50MG/ML/	/N89248/001/	
>DLT >			/JUN/25,/1986/	
>DLT >/AD/		/100MG/ML/	/N89249/001/	
>DLT >			/JUN/25,/1986/	
>DLT >/AD/		/200MG/ML/	/N89250/001/	
>DLT >			/JUN/25,/1986/	
>ADD >	ə QUAD	50MG/ML	N89248 001 JUN 25, 1986	
>ADD >				
>ADD >	ə	100MG/ML	N89249 001 JUN 25, 1986	
>ADD >				
>ADD >	ə	200MG/ML	N89250 001 JUN 25, 1986	
>ADD >				

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE

AO	STERIS	50MG/ML	N87598 001 OCT 06, 1983
AO		50MG/ML	N88554 001 FEB 10, 1986
AO		100MG/ML	N87599 001 OCT 06, 1983

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION
NANDROLONE PHENPROPIONATE

> DLT >	/AO/	/QUAD/	/25MG/ML/	/N89297/001/ /OCT/01/1986/
> DLT >	/AO/		/50MG/ML/	/N89298/001/ /OCT/01/1986/
> ADD >		∂ QUAD	25MG/ML	N89297 001 OCT 01, 1986
> ADD >		∂	50MG/ML	N89298 001 OCT 01, 1986

NEOMYCIN SULFATE

TABLET; ORAL
NEOMYCIN SULFATE

/AA/	/ROXANE/	/EQ 350MG BASE/	/N62173/001/
	∂ ROXANE	EQ 350MG BASE	N62173 001

NIACIN

TABLET; ORAL
NIACIN

/AA/	/WEST/WARD/	/500MG/	/N83718/001/
	∂ WEST WARD	500MG	N83718 001

NICOTINE

> ADD >		FILM, EXTENDED RELEASE; TRANSDERMAL		
> ADD >		HABITROL		
> ADD >	BC	CIBA GEIGY	7MG/24HR¤	N20076 001 NOV 27, 1991
> ADD >	BC		14MG/24HR¤	N20076 002 NOV 27, 1991
> ADD >	BC		21MG/24HR¤	N20076 003 NOV 27, 1991

NICOTINE

> ADD >		FILM, EXTENDED RELEASE; TRANSDERMAL		
> ADD >		NICODERM		
> ADD >	BC	MARION MERRELL DOW	7MG/24HR¤	N20165 001 NOV 07, 1991
> ADD >	BC		14MG/24HR¤	N20165 002 NOV 07, 1991
> ADD >	BC		21MG/24HR¤	N20165 003 NOV 07, 1991

NIFEDIPINE

CAPSULE; ORAL
NIFEDIPINE

AB	CHASE	20MG¤	N73421 001 JUN 19, 199
AB	SCHERER	10MG¤	N73250 001 OCT 08, 1991

NITROFURAZONE

CREAM; TOPICAL
FURACIN

/NORWICH/EATON/	/0.2%/	/N83789/001/
ROBERTS	0.2%	N83789 001

POWDER; TOPICAL
FURACIN

/NORWICH/EATON/	/0.2%/	/N83791/001/
ROBERTS	0.2%	N83791 001

NITROGLYCERIN

INJECTABLE; INJECTION
NITRO-BID

> DLT >	/AP/	/MARION/MERRELL/DOW/	/10MG/ML/	/N71159/001/ /FEB/28/1990/
> ADD >		MARION MERRELL DOW	10MG/ML	N71159 001 FEB 28, 1990

NITROGLYCERIN

/AP/	/LYPHOMED/	/5MG/ML/	/N71203/001/ /MAY/08/1990/
	∂ LYPHOMED	5MG/ML	N71203 001 MAY 08, 1990

NITROGLYCERIN

INJECTABLE; INJECTION

NITROGLYCERIN

>DLT >/AP/	/QUAD/	/5MG/ML/	/N71094/001/	
>DLT >			/JUL/31,/1987/	
>DLT >/AP/		/10MG/ML/	/N71095/001/	
>DLT >			/JUL/31,/1987/	
>ADD >	ə QUAD	5MG/ML	N71094 001	
>ADD >			JUL 31, 1987	
>ADD >	ə	10MG/ML	N71095 001	
>ADD >			JUL 31, 1987	
/AP/	/SOLOPAK/	/5MG/ML/	/N70634/001/	
	ə SOLOPAK	5MG/ML	/JUN/19,/1986/	
	/NITROL/		N70634 001	
/AP/	/RORER/URBAN/	/0.8MG/ML/	JUN 19, 1986	
	ə RORER	0.8MG/ML	/N18774/001/	
			/JAN/19,/1983/	
	NITROSTAT		N18774 001	
/AP/	/PARKE/DAVIS/	/0.8MG/ML/	JAN 19, 1983	
	PARKE DAVIS	0.8MG/ML	/N18588/001/	
			N18588 001	

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

CHIBROXIN			
MSD	0.3%	N19757 001	
		JUN 17, 1991	

NYSTATIN

CREAM; TOPICAL

/CANDEX/			
/AT/ /MILES/	/100,000 UNITS/GM/	/N61810/001/	
ə MILES	100,000 UNITS/GM	N61810 001	

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ZOFRAN			
GLAXO	EQ 2MG BASE/ML	N20007 001	
		JAN 04, 1991	

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

NORFLEX

/AB/	/3M/	/100MG/	/N12157/001/	
	3M	100MG	N12157 001	
	/ORPHENADRINE CITRATE/			
/AB/	/BOLAR/	/100MG/	/N84303/001/	
	ə BOLAR	100MG	N84303 001	

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

/AP/	/ELKINS/SINN/	/EQ 250MG BASE/VIAL/	/N62711/001/
/AP/		/EQ 500MG BASE/VIAL/	/FEB/03,/1989/
/AP/		/EQ 1GM BASE/VIAL/	/N62711/002/
/AP/		/EQ 2GM BASE/VIAL/	/FEB/03,/1989/
/AP/		/EQ 4GM BASE/VIAL/	/N62711/003/
/AP/		/EQ 10GM BASE/VIAL/	/FEB/03,/1989/
	ə ELKINS SINN	EQ 250MG BASE/VIAL	/N62711/004/
	ə	EQ 500MG BASE/VIAL	/FEB/03,/1989/
	ə	EQ 1GM BASE/VIAL	/N62711/005/
	ə	EQ 2GM BASE/VIAL	/FEB/03,/1989/
	ə	EQ 4GM BASE/VIAL	/N62711/006/
	ə	EQ 10GM BASE/VIAL	/FEB/03,/1989/
			N62711 001
			FEB 03, 1989
			N62711 002
			FEB 03, 1989
			N62711 003
			FEB 03, 1989
			N62711 004
			FEB 03, 1989
			N62711 005
			FEB 03, 1989
			N62711 006
			FEB 03, 1989

OXANDROLONE

/TABLET;/ORAL/			
/ANAVAR/			
/ə/SEARLE/	/2.5MG/	/N13718/001/	
TABLET; ORAL			
OXANDRIN			
GYNEX	2.5MG	N13718 001	

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM

B*	CHELSEA	10MG	N71661 001	
			MAR 02, 1988	
B*		15MG	N71662 001	
			MAR 02, 1988	
B*		30MG	N71663 001	
			MAR 02, 1988	
/BX/		/10MG/	/N71661/001/	
			/MAR/02,/1988/	
/BX/		/15MG/	/N71662/001/	
			/MAR/02,/1988/	
/BX/		/30MG/	/N71663/001/	
			/MAR/02,/1988/	

OXTRIPHYLLINE

TABLET, DELAYED RELEASE; ORAL
CHOLEDYL

/AB/	/PARKE/DAVIS/	/100MG/	/N09268/003/	
/AB/		/200MG/	/N09268/007/	
	PARKE DAVIS	200MG	N09268 007	
		100MG	N09268 003	

/OXTRIPHYLLINE/

/AB/	/BOLAR/	/100MG/	/N87866/001/	
			/AUG/25,/1983/	
/AB/		/200MG/	/N87835/001/	
			/AUG/25,/1983/	
	ə BOLAR	100MG	N87866 001	
			AUG 25, 1983	
	ə	200MG	N87835 001	
			AUG 25, 1983	

OXYBUTYNIN CHLORIDE

TABLET; ORAL
OXYBUTYNIN CHLORIDE

/AB/	/BOLAR/	/5MG/	/N72485/001/	
			/APR/19,/1989/	
	ə BOLAR	5MG	N72485 001	
			APR 19, 1989	

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
AREDIA

	CIBA GEIGY	30MG/VIAL¤	N20036 001	
			OCT 31, 1991	

PANCURONIUM BROMIDE

INJECTABLE; INJECTION
PANCURONIUM BROMIDE

			> DLT >	
/AP/	/QUAD/	/1MG/ML/	/N72209/001/	
			/JUN/03,/1988/	
			> DLT >	
		/2MG/ML/	/N72208/001/	
			/JUN/03,/1988/	
			> ADD >	
	ə QUAD	1MG/ML	N72209 001	
			JUN 03, 1988	
			> ADD >	
	ə	2MG/ML	N72208 001	
			JUN 03, 1988	

PENTOBARBITAL SODIUM

CAPSULE; ORAL
SODIUM PENTOBARBITAL

/AA/	/CHELSEA/	/100MG/	/N85791/001/
	ə CHELSEA	100MG	N85791 001
/AA/	/WYETH/AYERST/	/100MG/	/N83239/001/
	ə WYETH AYERST	100MG	N83239 001

PENTOSTATIN

INJECTABLE; INJECTION
NIPENT

PARKE DAVIS	10MG/VIAL¤	N20122 001
		OCT 11, 1991

PERPHENAZINE

TABLET; ORAL
PERPHENAZINE

B*	CHELSEA	8MG	N89700 001
			DEC 23, 1987
/BX/		/8MG/	/N89706/001/
			/DEC/23,/1987/

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
PHENDIMETRAZINE TARTRATE

BC	VITARINE	105MG	N18074 001
/3/		/105MG/	/N18074/001/
/SPRX-105/			
/BC/	/SOLVAY/	/105MG/	/N88024/001/
			/DEC/22,/1982/
	ə SOLVAY	105MG	N88024 001
			DEC 22, 1982

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

/AA/	/CORD/	/35MG/	/N86365/001/	
	∂ CORD	35MG	N86365 001	
AA	MIKART	35MG¤	N89452 001	
			OCT 30, 1991	

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM

/AP/	/SOLOPAK/	/50MG/ML/	/N88521/001/	
	∂ SOLOPAK	50MG/ML	/DEC/18,/1984/	
			N88521 001	
			DEC 18, 1984	

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL
PINDAC

	LEO	12.5MG	N19456 001	
			DEC 28, 1989	
		25MG	N19456 002	
			DEC 28, 1989	
	/LILLY/	/12.5MG/	/N19456/001/	
			/DEC/28,/1989/	
		/25MG/	/N19456/002/	
			/DEC/28,/1989/	

PIPERAZINE CITRATE

SYRUP; ORAL
PIPERAZINE CITRATE

/AA/	/BARRE/	/EQ 500MG BASE/5ML/	/N80774/001/	
	∂ BARRE	EQ 500MG BASE/5ML	N80774 001	

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

POWDER FOR RECONSTITUTION; ORAL
NULYTELY

	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT; 11.2GM/BOT¤	N19797 001	
			APR 22, 1991	

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
COLYTE

>DLT>	/AA/	/REED/AND/CARNRICK/	/227.1GM/PACKET;2.82GM/PACKET;/ /6.36GM/PACKET;5.53GM/PACKET;/ /21.5GM/PACKET/	/N18983/004/ /OCT/26,/1984/	
>DLT>					
>DLT>					
>DLT>					
>ADD>	AA	REED AND CARNRICK	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT¤	N18983 010 JAN 31, 1989	
>ADD>		∂	227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET	N18983 004 OCT 26, 1984	
>ADD>					
>ADD>					
>ADD>					
>ADD>					
>ADD>		COLYTE-FLAVORED			
>ADD>	AA	REED AND CARNRICK	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT¤	N18983 008 NOV 14, 1991	
>ADD>					
>ADD>					
>ADD>	AA		240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT¤	N18983 009 NOV 14, 1991	
>ADD>					
>ADD>					
		GLYCOPREP			
	AA	GOLDLINE	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N72319 001 DEC 23, 1988	
	/AA/	/SUPERPHARM/	/236GM/BOT;2.97GM/BOT;6.74GM/BOT;/ /5.86GM/BOT;22.74GM/BOT/	/N72319/001/ /DEC/23,/1988/	

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

/AP/	/CUTTER/	/1MEQ/ML/	/N80195/002/	
/AP/		/2MEQ/ML/	/N80195/001/	
/AP/		/3MEQ/ML/	/N80195/003/	
	∂ CUTTER	1MEQ/ML	N80195 002	
	∂	2MEQ/ML	N80195 001	
	∂	3MEQ/ML	N80195 003	
/AP/	/ELKINS/SINN/	/2MEQ/ML/	/N80203/001/	
	∂ ELKINS SINN	2MEQ/ML	N80203 001	
/AP/	/LEMMON/	/2MEQ/ML/	/N62268/001/	
/AP/		/3MEQ/ML/	/N62210/001/	
/AP/	/LILLY/	/2MEQ/ML/	/N07865/002/	
	∂ LILLY	2MEQ/ML	N07865 002	
AP	STERIS	2MEQ/ML	N86208 001	
AP		3MEQ/ML	N86210 001	

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION
PRALIDOXIME CHLORIDE

>DLT >/AP/	/QUAD/	/1GM/VIAL/	/N72224/001/
>DLT >			/NOV/23,/1988/
>ADD >	∂ QUAD	1GM/VIAL	N72224 001
>ADD >			NOV 23, 1988

PROTOPAM CHLORIDE

>DLT >/AP/	/WYETH/AYERST/	/1GM/VIAL/	/N14134/001/
>ADD >	WYETH AYERST	1GM/VIAL	N14134 001

PRAVASTATIN SODIUM

TABLET; ORAL
PRAVACHOL

	BRISTOL MYERS SQUIBB	10MG¤	N19898 002
			OCT 31, 1991
		20MG¤	N19898 003
			OCT 31, 1991

PRAZEPAM

CAPSULE; ORAL
PRAZEPAM

/AB/	/PHARM/BASICS/	/5MG/	/N70427/001/
			/NOV/06,/1987/
/AB/		/10MG/	/N70428/001/
			/NOV/06,/1987/
B*	PHARM BASICS	5MG	N70427 001
			NOV 06, 1987
B*		10MG	N70428 001
			NOV 06, 1987

PREDNICARBATE

OINTMENT; TOPICAL
DERMATOP

	HOECHST ROUSSEL	0.1%¤	N19568 001
			SEP 23, 1991

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
PREDNISOLONE ACETATE

/BP/	/CENTRAL/PHARMS/	/25MG/ML/	/N84717/001/
	∂ CENTRAL PHARMS	25MG/ML	N84717 001
/BP/	/LEMMON/	/25MG/ML/	/N83654/001/
/BP/		/50MG/ML/	/N85781/001/

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
PREDNISOLONE ACETATE

BP	STERIS	25MG/ML	N83654 001
BP		50MG/ML	N85781 001

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC
PREDNISOLONE SODIUM PHOSPHATE

AT	STERIS	EQ 0.11% PHOSPHATE¤	N81043 001
			OCT 24, 1991
AT		EQ 0.9% PHOSPHATE¤	N81044 001
			OCT 24, 1991

PREDNISONE

TABLET; ORAL
/DELTA-DOME/

/BX/	/MILES/	/5MG/	/N80293/001/
	∂ MILES	5MG	N80293 001
	PREDNICEN-M		
AB	CENTRAL PHARMS	5MG	N84655 001
/BX/		/5MG/	/N84655/001/
	PREDNISONE		
/BX/	/AM/THERAP/	/5MG/	/N89387/001/
			/NOV/06,/1986/
/BX/		/10MG/	/N89388/001/
			/NOV/06,/1986/
/BX/		/20MG/	/N89389/001/
			/NOV/06,/1986/
	∂ AM THERAP	5MG	N89387 001
			NOV 06, 1986
	∂	10MG	N89388 001
			NOV 06, 1986
	∂	20MG	N89389 001
			NOV 06, 1986
/BX/	/BARR/	/50MG/	/N86596/001/
	∂ BARR	50MG	N86596 001

PREDNISONE

TABLET; ORAL

PREDNISONE

AB	ROXANE	1MG	N87800 001 APR 22, 1982
AB		2.5MG	N87801 001 APR 22, 1982
AB		10MG	N84122 001
AB		20MG	N87342 001
AB		50MG	N84283 001
/BX/		/20MG/	/N17109/001/
	/∂/	/1MG/	/N87800/001/
	/∂/	/2.5MG/	/APR/22,/1982/ /N87801/001/
	/∂/	/10MG/	/APR/22,/1982/ /N84122/001/
	∂	20MG	N17109 001
	/∂/	/20MG/	/N87342/001/
	/∂/	/50MG/	/N84283/001/

PRIMIDONE

TABLET; ORAL

PRIMIDONE

/AB/	/BOLAR/	/250MG/	/N85052/001/
	∂ BOLAR	250MG	N85052 001

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HCL

/AB/	/BOLAR/	/250MG/	/N83795/001/
/AB/		/500MG/	/N84357/001/
	∂ BOLAR	250MG	N83795 001
	∂	500MG	N84357 001

INJECTABLE; INJECTION

PROCAINAMIDE HCL

>DLT >/AB/	/QUAD/	/100MG/ML/	/N89255/001/
>DLT >			/MAY/30,/1986/
>DLT >/AB/		/500MG/ML/	/N89257/001/
>DLT >			/MAY/30,/1986/
>ADD >	∂ QUAD	100MG/ML	N89256 001 MAY 30, 1986
>ADD >			
>ADD >	∂	500MG/ML	N89257 001 MAY 30, 1986
>ADD >			

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HCL

/AB/	/WARNER/CHILCOTT/	/100MG/ML/	/N89528/001/ /MAY/03,/1988/
/AB/		/500MG/ML/	/N89529/001/ /MAY/03,/1988/
	∂ WARNER CHILCOTT	100MG/ML	N89528 001 MAY 03, 1988
	∂	500MG/ML	N89529 001 MAY 03, 1988

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HCL

/AB/	/BOLAR/	/1GM/	/N89520/001/ /JAN/15,/1987/
	∂ BOLAR	1GM	N89520 001 JAN 15, 1987

PROCAN SR

/AB/	/PARKE/DAVIS/	/1GM/	/N88489/001/ /JAN/16,/1985/
	PARKE DAVIS	1GM	N88489 001 JAN 16, 1985

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HCL

/AB/	/CUTTER/	/1%/	/N80415/001/
/AP/		/2%/	/N80415/002/
	∂ CUTTER	1%	N80415 001
	∂	2%	N80415 002
/AB/	/LEMMON/	/1%/	/N83535/001/
/AP/		/2%/	/N83535/002/
AP	STERIS	1%	N83535 001
AP		2%	N83535 002

PROCHLORPERAZINE EDISYLATE

/CONCENTRATE;/ORAL/

/PROCHLORPERAZINE/EDISYLATE/

	/PHARM/BASICS/	/EQ/10MG/BASE/ML/	/N88598/001/ /OCT/25,/1984/
	∂ PHARM BASICS	EQ 10MG BASE/ML	N88598 001 OCT 25, 1984

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

>DLT >	/AP/	/QUAD/	/EQ 5MG BASE/ML/	/N89637/001/ /FEB/01,/1988/
>DLT >				
>DLT >	/AP/		/EQ 5MG BASE/ML/	/N89638/001/ /FEB/01,/1988/
>DLT >				
>ADD >		ə QUAD	EQ 5MG BASE/ML	N89637 001 FEB 01, 1988
>ADD >				
>ADD >		ə	EQ 5MG BASE/ML	N89638 001 FEB 01, 1988
>ADD >				

SYRUP; ORAL

COMPAZINE

/AA/	/SKF/	/EQ 5MG BASE/5ML/	/N11188/001/
	SKF	EQ 5MG BASE/5ML	N11188 001

/PROCHLORPERAZINE EDISYLATE/

/AA/	/PHARM/BASICS/	/EQ 5MG BASE/5ML/	/N88597/001/ /OCT/25,/1984/
	ə PHARM BASICS	EQ 5MG BASE/5ML	N88597 001 OCT 25, 1984

PROCHLORPERAZINE MALEATE

TABLET; ORAL

/PROCHLORPERAZINE/

/AB/	/BOLAR/	/EQ 5MG BASE/	/N85580/001/
/AB/		/EQ 10MG BASE/	/N85178/001/
/AB/		/EQ 25MG BASE/	/N85579/001/
	ə BOLAR	EQ 5MG BASE	N85580 001
	ə	EQ 10MG BASE	N85178 001
	ə	EQ 25MG BASE	N85579 001

PROCHLORPERAZINE MALEATE

/AB/	/DURAMED/	/EQ 5MG BASE/	/N89484/001/ /JAN/20,/1987/
/AB/		/EQ 10MG BASE/	/N89485/001/ /JAN/20,/1987/
/AB/		/EQ 25MG BASE/	/N89486/001/ /JAN/20,/1987/
B*	DURAMED	EQ 5MG BASE	N89484 001 JAN 20, 1987
B*		EQ 10MG BASE	N89485 001 JAN 20, 1987
B*		EQ 25MG BASE	N89486 001 JAN 20, 1987

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HCL

/AP/	/LEMMON/	/25MG/ML/	/N83532/001/
/AP/		/50MG/ML/	/N83532/002/
AP	STERIS	25MG/ML	N83532 001
AP		50MG/ML	N83532 002

SUPPOSITORY; RECTAL

/PROMETHAZINE HCL/

/BR/	/G AND W/	/50MG/	/N87165/001/ /AUG/14,/1987/
	PROMETHEGAN		
BR	G AND W	50MG	N87165 001 AUG 14, 1987

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HCL

ə ALRA	65MG	N83184 001
/ə/BANMAX/	/65MG/	/N83184/001/

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

PROPRANOLOL HCL

/AP/	/SOLOPAK/	/1MG/ML/	/N70135/001/ /APR/15,/1986/
	ə SOLOPAK	1MG/ML	N70135 001 APR 15, 1986

SOLUTION; ORAL

PROPRANOLOL HCL

/AA/	/PHARM/BASICS/	/20MG/5ML/	/N71984/001/ /MAR/03,/1989/
/AA/		/40MG/5ML/	/N71985/001/ /MAR/03,/1989/
	ə PHARM BASICS	20MG/5ML	N71984 001 MAR 03, 1989
	ə	40MG/5ML	N71985 001 MAR 03, 1989
/AA/	/ROXANE/	/20MG/5ML/	/N70979/001/ /MAY/15,/1987/
/AA/		/40MG/5ML/	/N70690/001/ /MAY/15,/1987/
	ROXANE	20MG/5ML	N70979 001 MAY 15, 1987
		40MG/5ML	N70690 001 MAY 15, 1987

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

/AB/	/BOLAR/	/10MG/	/N70378/001/ /MAR/19,/1987/		
/AB/		/20MG/	/N70379/001/ /MAR/19,/1987/		
/AB/		/40MG/	/N70380/001/ /MAR/19,/1987/		
/AB/		/60MG/	/N70381/001/ /MAR/19,/1987/		
/AB/		/80MG/	/N70382/001/ /MAR/19,/1987/		
	∂ BOLAR	10MG	N70378 001 MAR 19, 1987		
	∂	20MG	N70379 001 MAR 19, 1987		
	∂	40MG	N70380 001 MAR 19, 1987		
	∂	60MG	N70381 001 MAR 19, 1987		
	∂	80MG	N70382 001 MAR 19, 1987		
/AB/	/DURAMED/	/40MG/	/N70368/001/ /SEP/09,/1985/		
/AB/		/60MG/	/N70369/001/ /OCT/01,/1986/		
/AB/		/80MG/	/N70310/001/ /SEP/09,/1985/	>DLT<	
B*	DURAMED	40MG	N70308 001 SEP 09, 1985	>DLT<	
B*		60MG	N70309 001 OCT 01, 1986	>ADD<	
B*		80MG	N70310 001 SEP 09, 1985	>ADD<	
/AB/	/MARTEC/	/10MG/	/N70120/001/ /AUG/06,/1985/		
/AB/		/20MG/	/N70121/001/ /AUG/06,/1985/		
/AB/		/40MG/	/N70122/001/ /AUG/06,/1985/		
/AB/		/60MG/	/N70123/001/ /OCT/29,/1986/		
/AB/		/80MG/	/N70124/001/ /AUG/06,/1985/		

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	SCHERING	10MG	N70120 001 AUG 06, 1985
AB		20MG	N70121 001 AUG 06, 1985
AB		40MG	N70122 001 AUG 06, 1985
AB		60MG	N70123 001 OCT 29, 1986
AB		80MG	N70124 001 AUG 06, 1985
/AB/	/SUPERPHARM/	/40MG/	/N71517/001/ /JUN/08,/1988/
/AB/		/80MG/	/N71518/001/ /JUN/08,/1988/
	∂ SUPERPHARM	40MG	N71517 001 JUN 08, 1988
	∂	80MG	N71518 001 JUN 08, 1988

PROTAMINE SULFATE

INJECTABLE; INJECTION
PROTAMINE SULFATE

/QUAD/	/50MG/VIAL/	/N89307/001/ /MAY/30,/1986/
∂ QUAD	50MG/VIAL	N89307 001 MAY 30, 1986

PSEUDOEPHEDRINE HYDROCHLORIDE; TERFENADINE

TABLET, EXTENDED RELEASE; ORAL
SELDANE-D
MERRELL DOW 120MG;60MG N19664 001 AUG 19, 1991

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL
PYRIDOSTIGMINE BROMIDE

KALI DUPHAR	30MG	N89572 001 NOV 27, 1990
/PUREPAC/	/30MG/	/N89572/001/ /NOV/27,/1990/

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION
PYRIDOXINE HCL

/AP/	/LEMMON/	/100MG/ML/	/N83760/001/	
AP	STERIS	100MG/ML	N83760 001	

PYRILAMINE MALEATE

TABLET; ORAL
PYRILAMINE MALEATE

/AA/	/CHELSEA/	/25MG/	/N85231/001/	
	∂ CHELSEA	25MG	N85231 001	
/AA/	/RICHLYN/	/25MG/	/N80808/001/	
	RICHLYN	25MG	N80808 001	

QUAZEPAM

TABLET; ORAL
DORAL

	BAKER CUMMINS	7.5MG	N18708 003 FEB 26, 1987
		15MG	N18708 001 DEC 27, 1985
	/DORMALIN/		
	/BAKER/CUMMINS/	/7.5MG/	/N18708/003/ /FEB/26,/1987/
		/15MG/	/N18708/001/ /DEC/27,/1985/

> ADD > QUINAPRIL HYDROCHLORIDE

> ADD > TABLET; ORAL
> ADD > ACCUPRIL

> ADD >	PARKE DAVIS	EQ 5MG BASE¤	N19885 001 NOV 19, 1991
> ADD >		EQ 10MG BASE¤	N19885 002 NOV 19, 1991
> ADD >		EQ 20MG BASE¤	N19885 003 NOV 19, 1991
> ADD >		EQ 40MG BASE¤	N19885 004 NOV 19, 1991

QUINESTROL

TABLET; ORAL
ESTROVIS

PARKE DAVIS	0.1MG	N16768 002

QUINIDINE GLUCONATE

/TABLET;/ORAL/
/QUINACT/

	/BERLEX/	/266MG/	/N85978/001/
		/400MG/	/N86099/001/
	∂ BERLEX	266MG	N85978 001
	∂	400MG	N86099 001

TABLET, EXTENDED RELEASE; ORAL
/QUINAMM/

/AB/	/BOLAR/	/324MG/	/N87448/001/
	∂ BOLAR	324MG	N87448 001

QUINIDINE GLUCONATE

/AB/	/ROXANE/	/324MG/	/N88431/001/ /JAN/06,/1984/
	∂ ROXANE	324MG	N88431 001 JAN 06, 1984

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

/AB/	/VANGARD/	/200MG/	/N87909/001/ /JUL/13,/1982/
	∂ VANGARD	200MG	N87909 001 JUL 13, 1982

QUINORA

/AB/	/KEY/PHARMS/	/200MG/	/N83576/001/
	∂ KEY PHARMS	200MG	N83576 001

RAMIPRIL

CAPSULE; ORAL
ALTACE

	HOECHST ROUSSEL	1.25MG¤	N19901 001 JAN 28, 1991
		2.5MG¤	N19901 002 JAN 28, 1991
		5MG¤	N19901 003 JAN 28, 1991
		10MG¤	N19901 004 JAN 28, 1991

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
ZANTAC IN PLASTIC CONTAINER
/GLAXO/ /EQ/50MG/BASE/100ML/ /N19593/001/ /DEC/17,/1986/
∂ GLAXO EQ 50MG BASE/100ML N19593 001 DEC 17, 1986
EQ 1MG BASE/ML¤ N19593 002 SEP 27, 1991

RAUWOLFIA SERPENTINA

TABLET; ORAL
RAUWOLFIA SERPENTINA
BP DANBURY 50MG N80907 001
/∂/ /50MG/ /N80907/001/

RESERPINE

TABLET; ORAL
RESERPINE
/BP/ /WHITE/TOWNE/PAULSEN/ /0.1MG/ /N80723/001/
/BP/ /0.25MG/ /N80723/002/
∂ WHITE TOWNE PAULSEN 0.1MG N80723 001
∂ 0.25MG N80723 002
/1MG/ /N80723/003/
∂ 1MG N80723 003

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HCL
AP ABBOTT 10MG/ML¤ N71618 001 FEB 28, 1991
AP 15MG/ML¤ N71619 001 FEB 28, 1991
>DLT >/AP/ /QUAD/ /15MG/ML/ /N70701/001/ /OCT/06,/1986/
>DLT >
>ADD >
>ADD > ∂ QUAD 15MG/ML N70701 001 OCT 06, 1986

RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 30MG/100ML¤ N71438 001 JAN 22, 1991

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECOBARBITAL SODIUM
/AA/ /WYETH/AYERST/ /100MG/ /N86390/001/
∂ WYETH AYERST 100MG N86390 001

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE
AT CLAY PARK 2.5%¤ N89996 001 JAN 10, 1991

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
SODIUM NITROPRUSSIDE
/AP/ /LYPHOMED/ /50MG/VIAL/ /N70031/001/ /JAN/17,/1985/
∂ LYPHOMED 50MG/VIAL N70031 001 JAN 17, 1985

SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE
/AB/ /BOLAR/ /25MG/ /N86898/002/ /MAR/02,/1982/
∂ BOLAR 25MG N86898 002 MAR 02, 1982

SUCCIMER

CAPSULE; ORAL
CHEMET
MCNEIL 100MG¤ N19998 002 JAN 30, 1991

SULFAMETHOXAZOLE

TABLET; ORAL
SULFAMETHOXAZOLE
/AB/ /BOLAR/ /500MG/ /N85053/001/
∂ BOLAR 500MG N85053 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

COTRIM

/AP/	/STERIS/	/80MG/ML;16MG/ML	/N71556/001/	/DEC/17,/1987/
> DLT >	/SULFAMETHOPRIM/			
> DLT > /AP/	/QUAD/	/80MG/ML;16MG/ML/	/N71341/001/	/AUG/07,/1987/
> DLT >				
> ADD >	@ QUAD	80MG/ML;16MG/ML	N71341 001	AUG 07, 1987
> ADD >				

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP	GENSIA	80MG/ML;16MG/ML¤	N73303 001 OCT 31, 1991
AP	STERIS	80MG/ML;16MG/ML	N71556 001 DEC 17, 1987

SUSPENSION; ORAL

COTRIM PEDIATRIC

AB	LEMMON	200MG/5ML;40MG/5ML	N70028 001 OCT 29, 1985
	/SULFAMETHOXAZOLE AND TRIMETHOPRIM/		
/AB/	/PLANTEX/	/200MG/5ML;40MG/5ML/	/N70028/001/ /OCT/29,/1985/

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

/AB/	/PHARM/BASICS/	/400MG;80MG/	/N70203/001/ /NOV/08,/1985/
/AB/		/800MG;160MG/	/N70204/001/ /NOV/08,/1985/
B*	PHARM BASICS	400MG;80MG	N70203 001 NOV 08, 1985
B*		800MG;160MG	N70204 001 NOV 08, 1985
AB	ROXANE	400MG;80MG¤	N72768 001 AUG 30, 1991

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

AB	ROXANE LABS	800MG;160MG¤	N72769 001 AUG 30, 1991

SULFANILAMIDE

CREAM; VAGINAL

SULFANILAMIDE

AT	LEMMON	15%	N88718 001 SEP 19, 1985
	/VAGITROL/		
/AT/	/LEMMON/	/15%/	/N88718/001/ /SEP/19,/1985/

SULFASALAZINE

TABLET, DELAYED RELEASE; ORAL

AZULFIDINE EN-TABS

	KABI	500MG	N07073 002 APR 06, 1983
/AB/	/PHARMACIA/	/500MG/	/N07073/002/ /APR/06,/1983/
	/SULFASALAZINE/		
/BE/	/BOLAR/	/500MG/	/N88052/001/ /MAY/24,/1983/
	@ BOLAR	500MG	N88052 001 MAY 24, 1983

SULFISOXAZOLE

TABLET; ORAL

SOXAZOLE

	@ ALRA	500MG	N80366 001
/2/	/BANMAX/	/500MG/	/N80366/001/

SULINDAC

TABLET; ORAL

SULINDAC

AB	GENEVA	150MG¤	N72712 001 AUG 30, 1991
AB		200MG¤	N72713 001 AUG 30, 1991
AB	LEDERLE	150MG¤	N73261 001 SEP 06, 1991
AB		200MG¤	N73262 001 SEP 06, 1991
AB	MUTUAL PHARM	150MG¤	N72050 001 APR 17, 1991
AB		200MG¤	N72051 001 APR 17, 1991
AB	WARNER CHILCOTT	150MG¤	N72710 001 MAR 25, 1991
AB		200MG¤	N72711 001 MAR 25, 1991

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

ULTRATAG

	MALLINCKRODT	N/A¤	N19981 001 JUN 10, 1991

TEMAZEPAM

CAPSULE; ORAL

RESTORIL

SANDOZ	7.5MG¤	N18163 003	
		OCT 25, 1991	

TEMAZEPAM

/AB/	/BOLAR/	/15MG/	/N70383/001/	
			/MAR/23,/1987/	
/AB/		/30MG/	/N70384/001/	
			/MAR/23,/1987/	
	ə BOLAR	15MG	N70383 001	
			MAR 23, 1987	
	ə	30MG	N70384 001	
			MAR 23, 1987	
/AB/	/PHARM/BASICS/	/15MG/	/N70489/001/	
			/JUL/07,/1986/	
/AB/		/30MG/	/N70490/001/	
			/JUL/07,/1986/	
B*	PHARM BASICS	15MG	N70489 001	
			JUL 07, 1986	
B*		30MG	N70490 001	
			JUL 07, 1986	

TERCONAZOLE

CREAM; VAGINAL

TERAZOL 3

JOHNSON RW	0.8%¤	N19964 001
		FEB 21, 1991

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

/AO/	/LEMMON/	/100MG/ML/	/N84401/001/	
/AO/		/200MG/ML/	/N84401/002/	
>DLT >/AO/	/QUAD/	/100MG/ML/	/N89326/001/	
>DLT >			/OCT/28,/1988/	
>DLT >/AO/		/200MG/ML/	/N89327/001/	
>DLT >			/OCT/28,/1988/	
>ADD >	ə QUAD	100MG/ML	N89326 001	
>ADD >			OCT 28, 1988	
>ADD >	ə	200MG/ML	N89327 001	
>ADD >			OCT 28, 1988	
AO	STERIS	100MG/ML	N84401 001	
AO		200MG/ML	N84401 002	

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

TESTOSTERONE ENANTHATE

/AO/	/LEMMON/	/100MG/ML/	/N83667/001/	
/AO/		/200MG/ML/	/N83667/002/	
>DLT >/AO/	/QUAD/	/100MG/ML/	/N89324/001/	
>DLT >			/SEP/16,/1986/	
>DLT >/AO/		/200MG/ML/	/N89325/001/	
>DLT >			/SEP/16,/1986/	
>ADD >	ə QUAD	100MG/ML	N89324 001	
>ADD >			SEP 16, 1986	
>ADD >	ə	200MG/ML	N89325 001	
>ADD >			SEP 16, 1986	
AO	STERIS	100MG/ML	N83667 001	
AO		200MG/ML	N83667 002	

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

TESTOSTERONE PROPIONATE

/AO/	/LEMMON/	/25MG/ML/	/N85490/001/	
/AO/		/50MG/ML/	/N85490/002/	
/AO/		/100MG/ML/	/N83595/003/	
>DLT >/AO/	/QUAD/	/100MG/ML/	/N89283/001/	
>DLT >			/NOV/03,/1986/	
>ADD >	ə QUAD	100MG/ML	N89283 001	
>ADD >			NOV 03, 1986	
AO	STERIS	25MG/ML	N85490 001	
AO		50MG/ML	N85490 002	
AO		100MG/ML	N83595 003	

THEOPHYLLINE

CAPSULE; ORAL

/SOMOPHYLLIN-T/

/BX/	/FISONS/	/100MG/	/N87155/001/	
			/FEB/25,/1985/	
/BX/		/200MG/	/N87155/002/	
			/FEB/25,/1985/	
/BX/		/250MG/	/N87155/003/	
			/FEB/25,/1985/	
	ə FISONS	100MG	N87155 001	
			FEB 25, 1985	
	ə	200MG	N87155 002	
			FEB 25, 1985	
	ə	250MG	N87155 003	
			FEB 25, 1985	

THEOPHYLLINE

CAPSULE; ORAL
THEOPHYLLINE

/BX/	/SCHERER/	/100MG/	/N84731/002/ /NOV/07,/1986/
/BX/		/200MG/	/N84731/001/ /NOV/07,/1986/
/BX/		/250MG/	/N84731/003/ /NOV/07,/1986/
	ə SCHERER	100MG	N84731 002 NOV 07, 1986
	ə	200MG	N84731 001 NOV 07, 1986
	ə	250MG	N84731 003 NOV 07, 1986

CAPSULE, EXTENDED RELEASE; ORAL
THEOPHYL-SR

/BC/	/JOHNSON/RW/	/125MG/	/N86480/001/ /FEB/08,/1985/
	ə JOHNSON RW	125MG	N86480 001 FEB 08, 1985

THEOPHYLLINE

/BC/	/CENTRAL/PHARMS/	/125MG/	/N88654/001/ /FEB/12,/1985/
/BC/		/250MG/	/N88689/001/ /FEB/12,/1985/
	ə CENTRAL PHARMS	125MG	N88654 001 FEB 12, 1985
	ə	250MG	N88689 001 FEB 12, 1985

THEOPHYLLINE-SR

/BC/	/SCHERER/	/300MG/	/N88255/001/ /JUN/12,/1986/
	ə SCHERER	300MG	N88255 001 JUN 12, 1986

TABLET; ORAL
THEOCLEAR-100

/BD/	/CENTRAL/PHARMS/	/100MG/	/N85353/002/
	ə CENTRAL PHARMS	100MG	N85353 002

THEOCLEAR-200

/BD/	/CENTRAL/PHARMS/	/200MG/	/N85353/001/
	ə CENTRAL PHARMS	200MG	N85353 001

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HCL

/AP/	/LEMMON/	/100MG/ML/	/N83534/001/
/AP/		/200MG/ML/	/N83534/002/

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HCL

/AP/	/LYPHOMED/	/100MG/ML/	/N80509/001/
	ə LYPHOMED	100MG/ML	N80509 001
AP	STERIS	100MG/ML	N83534 001
AP		200MG/ML	N83534 002

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL
THIORIDAZINE HCL

/AB/	/BOLAR/	/10MG/	/N88412/001/ /SEP/12,/1983/
/AB/		/15MG/	/N88345/001/ /JUL/28,/1983/
/AB/		/25MG/	/N88296/001/ /JUL/28,/1983/
/AB/		/50MG/	/N88323/001/ /JUL/28,/1983/
/AB/		/100MG/	/N88284/001/ /AUG/25,/1983/
/AB/		/150MG/	/N88410/001/ /MAR/05,/1984/
/AB/		/200MG/	/N88381/001/ /MAR/14,/1984/
	ə BOLAR	10MG	N88412 001 SEP 12, 1983
	ə	15MG	N88345 001 JUL 28, 1983
	ə	25MG	N88296 001 JUL 28, 1983
	ə	50MG	N88323 001 JUL 28, 1983
	ə	100MG	N88284 001 AUG 25, 1983
	ə	150MG	N88410 001 MAR 05, 1984
	ə	200MG	N88381 001 MAR 14, 1984

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HCL

/AB/	/ROXANE/	/10MG/	/N88663/001/ /MAR/15,/1984/	
/AB/		/25MG/	/N88664/001/ /MAR/15,/1984/	
/AB/		/50MG/	/N88665/001/ /MAR/15,/1984/	
/AB/		/100MG/	/N89048/001/ /FEB/26,/1985/	
	∂ ROXANE	10MG	N88663 001 MAR 15, 1984	
	∂	25MG	N88664 001 MAR 15, 1984	
	∂	50MG	N88665 001 MAR 15, 1984	
	∂	100MG	N89048 001 FEB 26, 1985	

THIOTHIXENE

CAPSULE; ORAL

THIOTHIXENE

/AB/	/AM/THERAP/	/1MG/	/N71884/001/ /AUG/12,/1987/	
/AB/		/2MG/	/N71885/001/ /AUG/12,/1987/	
/AB/		/10MG/	/N71887/001/ /AUG/12,/1987/	
	∂ AM THERAP	1MG	N71884 001 AUG 12, 1987	
	∂	2MG	N71885 001 AUG 12, 1987	
	∂	10MG	N71887 001 AUG 12, 1987	

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

THIOTHIXENE HCL

/AA/	/PACO/	/EQ 5MG BASE/ML/	/N71939/001/ /DEC/16,/1988/	
		/EQ 1MG/BASE/ML/	/N71917/001/ /SEP/20,/1989/	
	∂ PACO	EQ 5MG BASE/ML	N71939 001 DEC 16, 1988	
		EQ 1MG BASE/ML	N71917 001 SEP 20, 1989	

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLID

	SYNTEX	250MG*	N19979 002 OCT 31, 1991	

TIMOLOL MALEATE

TABLET; ORAL

TIMOLOL MALEATE

/AB/	/BOLAR/	/5MG/	/N72269/001/ /MAR/14,/1989/	
/AB/		/10MG/	/N72270/001/ /MAR/14,/1989/	
/AB/		/20MG/	/N72271/001/ /MAR/14,/1989/	
	∂ BOLAR	5MG	N72269 001 MAR 14, 1989	
	∂	10MG	N72270 001 MAR 14, 1989	
	∂	20MG	N72271 001 MAR 14, 1989	
AB	DANBURY	5MG*	N72917 001 JUL 31, 1991	
AB		10MG*	N72918 001 JUL 31, 1991	
AB		20MG*	N72919 001 JUL 31, 1991	
/AB/	/PHARM/BASICS/	/5MG/	/N72001/001/ /JAN/10,/1989/	
/AB/		/10MG/	/N72002/001/ /JAN/10,/1989/	
/AB/		/20MG/	/N72003/001/ /JAN/10,/1989/	
B*	PHARM BASICS	5MG	N72001 001 JAN 10, 1989	
B*		10MG	N72002 001 JAN 10, 1989	
B*		20MG	N72003 001 JAN 10, 1989	

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

AP	ABBOTT	EQ 10MG BASE/ML¤	N63080 001 APR 30, 1991		
AP		EQ 10MG BASE/ML¤	N63112 001 APR 30, 1991		
AP		EQ 40MG BASE/ML¤	N63111 001 APR 30, 1991		
AP		EQ 40MG BASE/ML¤	N63161 001 MAY 29, 1991		
>ADD> AP	ELKINS SINN	EQ 10MG BASE/ML¤	N63128 001 NOV 27, 1991		
>ADD> AP		EQ 40MG BASE/ML¤	N63127 001 NOV 27, 1991		
AP	LEDERLE	EQ 10MG BASE/ML¤	N63113 001 APR 26, 1991		
AP		EQ 40MG BASE/ML¤	N63117 001 APR 26, 1991		
AP		EQ 40MG BASE/ML¤	N63118 001 JUL 29, 1991		

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

/AB/ /BOLAR/	/100MG/	/N70242/001/ /AUG/01,/1986/	
/AB/	/250MG/	/N70243/001/ /AUG/01,/1986/	
/AB/	/500MG/	/N70244/001/ /AUG/01,/1986/	
@ BOLAR	100MG	N70242 001 AUG 01, 1986	
@	250MG	N70243 001 AUG 01, 1986	
@	500MG	N70244 001 AUG 01, 1986	
/AB/ /CHELSEA/	/100MG/	/N70285/001/ /JAN/09,/1986/	
/AB/	/250MG/	/N70286/001/ /JAN/09,/1986/	
/AB/	/500MG/	/N70287/001/ /JAN/09,/1986/	
B* CHELSEA	100MG	N70285 001 JAN 09, 1986	
B*	250MG	N70286 001 JAN 09, 1986	
B*	500MG	N70287 001 JAN 09, 1986	

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

/AB/ /PHARM/BASICS/	/100MG/	/N71355/001/ /JAN/11,/1988/	
/AB/	/250MG/	/N70168/001/ /APR/02,/1986/	
/AB/	/500MG/	/N70169/001/ /APR/02,/1986/	
B* PHARM BASICS	100MG	N71355 001 JAN 11, 1988	
B*	250MG	N70168 001 APR 02, 1986	
B*	500MG	N70169 001 APR 02, 1986	

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE

@ ALRA	500MG	N86141 001	
/@/BANMAX/	/500MG/	/N86141/001/	
/AB/ /BOLAR/	/250MG/	/N89110/001/ /MAY/29,/1987/	
/AB/	/500MG/	/N89111/001/ /MAY/29,/1987/	
@ BOLAR	250MG	N89110 001 MAY 29, 1987	
@	500MG	N89111 001 MAY 29, 1987	

TOLMETIN SODIUM

CAPSULE; ORAL
TOLECTIN DS

>ADD> AB	JOHNSON RW	EQ 400MG BASE	N18084 001	
>ADD>	TOLMETIN SODIUM			
>ADD> AB	MUTUAL PHARM	EQ 400MG BASE¤	N73311 001 NOV 27, 1991	
>ADD> AB	NOVOPHARM	EQ 400MG BASE¤	N73290 001 NOV 27, 1991	

TABLET; ORAL
TOLECTIN

>ADD> AB	JOHNSON RW	EQ 200MG BASE	N17628 001	
>ADD>	TOLMETIN SODIUM			
>ADD> AB	MUTUAL PHARM	EQ 200MG BASE¤	N73310 001 NOV 27, 1991	

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HCL

/AB/	/BOLAR/	/50MG/	/N71112/001/	/NOV/17,/1986/
/AB/		/100MG/	/N71113/001/	/NOV/17,/1986/
	ə BOLAR	50MG	N71112 001	NOV 17, 1986
	ə	100MG	N71113 001	NOV 17, 1986
/AB/	/CHELSEA/	/50MG/	/N70568/001/	/OCT/10,/1986/
/AB/		/100MG/	/N70569/001/	/OCT/10,/1986/
B*	CHELSEA	50MG	N70568 001	OCT 10, 1986
B*		100MG	N70569 001	OCT 10, 1986
AB	MYLAN	50MG¤	N71405 001	FEB 27, 1991
AB		100MG¤	N71406 001	FEB 27, 1991
/AB/	/PHARM/BASICS/	/50MG/	/N70491/001/	/APR/29,/1987/
/AB/		/100MG/	/N70492/001/	/APR/29,/1987/
B*	PHARM BASICS	50MG	N70491 001	APR 29, 1987
B*		100MG	N70492 001	APR 29, 1987

TRETINOIN

GEL; TOPICAL

RETIN-A

/AT/	/JOHNSON/RW/	/0.01%/	/N17579/003/

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; NASAL

NASACORT

RHONE POULENC RORER	55UGM/INH¤	N19798 001 JUL 11, 1991

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

/KENAG/

/AT/	/NMC/	/0.025%/	/N87797/001/ /JUN/07,/1982/
/AT/		/0.1%/	/N87798/001/ /JUN/04,/1982/

TRIAMCINOLONE ACETONIDE

AT	G AND W	0.025%¤	N89797 001 MAY 31, 1991
AT		0.1%¤	N89798 001 MAY 31, 1991
AT	NMC	0.025%	N87797 001 JUN 07, 1982
AT		0.1%	N87798 001 JUN 04, 1982
/AT/	/PHARM/BASICS/	/0.025%/	/N88094/001/ /SEP/01,/1983/
/AT/		/0.1%/	/N88095/001/ /SEP/01,/1983/
/AT/		/0.5%/	/N88096/001/ /SEP/01,/1983/
	ə PHARM BASICS	0.025%	N88094 001 SEP 01, 1983
	ə	0.1%	N88095 001 SEP 01, 1983
	ə	0.5%	N88096 001 SEP 01, 1983

/GEL;/TOPICAL/

/ARISTOGEL/

	/LEDERLE/	/0.1%/	/N83380/001/
	ə LEDERLE	0.1%	N83380 001

OINTMENT; TOPICAL

ARISTOCORT A

/AT/	/LEDERLE/	/0.5%/	/N88781/001/ /OCT/05,/1984/
	ə LEDERLE	0.5%	N88781 001 OCT 05, 1984

/KENAG/

/AT/	/NMC/	/0.1%/	/N87799/001/ /JUN/07,/1982/

TRIAMCINOLONE ACETONIDE

AT	NMC	0.1%	N87799 001 JUN 07, 1982

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE

/AT/	/PHARM/BASICS/	/0.025%/	/N88090/001/ /SEP/01,/1983/
/AT/		/0.1%/	/N88091/001/ /SEP/01,/1983/
/AT/		/0.5%/	/N88092/001/ /SEP/01,/1983/
	ə PHARM BASICS	0.025%	N88090 001 SEP 01, 1983
	ə	0.1%	N88091 001 SEP 01, 1983
	ə	0.5%	N88092 001 SEP 01, 1983

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION
TRIAMCINOLONE DIACETATE

/BP/	/LEMMON/	/40MG/ML/	/N85529/001/
BP	STERIS	40MG/ML	N85529 001

TRICHLORMETHIAZIDE

TABLET; ORAL
TRICHLORMETHIAZIDE

/BP/	/BOLAR/	/4MG/	/N83462/001/
	ə BOLAR	4MG	N83462 001

TRIFLUOPERAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
STELAZINE

>DLT >/AP/	/SKF/	/EQ 2MG BASE/ML/	/N11552/005/
>ADD >	SKF	EQ 2MG BASE/ML	N11552 005
>DLT >	/TRIFLUOPERAZINE HCL/		
>DLT >/AP/	/QUAD/	/EQ 2MG BASE/ML/	/N89893/001/ /OCT/17,/1988/
>DLT >			
>ADD >	ə QUAD	EQ 2MG BASE/ML	N89893 001 OCT 17, 1988
>ADD >			

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL

/AB/	/BOLAR/	/EQ 1MG BASE/	/N85975/001/ /JUN/23,/1988/
/AB/		/EQ 2MG BASE/	/N85976/001/ /JUN/23,/1988/
/AB/		/EQ 5MG BASE/	/N85973/001/ /JUN/23,/1988/
/AB/		/EQ 10MG BASE/	/N88710/001/ /JUN/23,/1988/
	ə BOLAR	EQ 1MG BASE	N85975 001 JUN 23, 1988
	ə	EQ 2MG BASE	N85976 001 JUN 23, 1988
	ə	EQ 5MG BASE	N85973 001 JUN 23, 1988
	ə	EQ 10MG BASE	N88710 001 JUN 23, 1988
/AB/	/DURAMED/	/EQ 1MG BASE/	/N88967/001/ /APR/23,/1985/
/AB/		/EQ 2MG BASE/	/N88968/001/ /APR/23,/1985/
/AB/		/EQ 5MG BASE/	/N88969/001/ /APR/23,/1985/
/AB/		/EQ 10MG BASE/	/N88970/001/ /APR/23,/1985/
B*	DURAMED	EQ 1MG BASE	N88967 001 APR 23, 1985
B*		EQ 2MG BASE	N88968 001 APR 23, 1985
B*		EQ 5MG BASE	N88969 001 APR 23, 1985
B*		EQ 10MG BASE	N88970 001 APR 23, 1985

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL
TRIHEXYPHENIDYL HCL

/AA/	/BOLAR/	/2MG/	/N85117/001/
/AA/		/5MG/	/N85105/001/
	ə BOLAR	2MG	N85117 001
	ə	5MG	N85105 001

TRIMEPRAZINE TARTRATE

SYRUP; ORAL

	TEMARIL				
/AA/	/HERBERT/	/EQ 2.5MG BASE/5ML/	/N11316/003/		
	HERBERT	EQ 2.5MG BASE/5ML	N11316 003		
	/TRIMEPRAZINE TARTRATE/				
/AA/	/PHARM BASICS/	/EQ 2.5MG BASE/5ML/	/N88285/001/ /APR 11, 1985/		
	∂ PHARM BASICS	EQ 2.5MG BASE/5ML	N88285 001 APR 11, 1985		

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

	TRIMETHOBENZAMIDE HCL				
/AP/	/SOLOPAK/	/100MG/ML/	/N89043/001/ /APR 04, 1986/		
	∂ SOLOPAK	100MG/ML	N89043 001 APR 04, 1986		

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

	TRIMIPRAMINE MALEATE				
/AB/	/PHARM BASICS/	/EQ 25MG BASE/	/N71283/001/ /DEC 08, 1987/		
/AB/		/EQ 50MG BASE/	/N71284/001/ /DEC 08, 1987/		
/AB/		/EQ 100MG BASE/	/N71285/001/ /DEC 08, 1987/		
B*	PHARM BASICS	EQ 25MG BASE	N71283 001 DEC 08, 1987		
B*		EQ 50MG BASE	N71284 001 DEC 08, 1987		
B*		EQ 100MG BASE	N71285 001 DEC 08, 1987		

TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

	TRIPROLIDINE HCL				
/AA/	/DANBURY/	/2.5MG/	/N85094/001/		
	DANBURY	2.5MG	N85094 001		
/AA/	/VITARINE/	/2.5MG/	/N85610/001/		
	∂ VITARINE	2.5MG	N85610 001		

TRISULFAPYRIMIDINES

SUSPENSION; ORAL

	/SULFOSE/				
/AB/	/WYETH AYERST/	/500MG/5ML/	/N80013/002/		
	∂ WYETH AYERST	500MG/5ML	N80013 002		

TABLET; ORAL

	/SULFOSE/				
/AB/	/WYETH AYERST/	/500MG/	/N80013/001/		
	∂ WYETH AYERST	500MG	N80013 001		

VALPROIC ACID

CAPSULE; ORAL

	VALPROIC ACID				
AB	SCHERER	250MG¤	N73229 001 OCT 29, 1991		

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

	/CALAN/				
/AP/	/SEARLE/	/2.5MG/ML/	/N18925/001/ /MAR 30, 1984/		
	∂ SEARLE	2.5MG/ML	N18925 001 MAR 30, 1984		
	VERAPAMIL HCL				
/AP/	/QUAD/	/2.5MG/ML/	/N70672/001/ /MAR 07, 1986/	> DLT >	
	∂ QUAD	2.5MG/ML	N70672 001 MAR 07, 1986	> DLT >	
/AP/	/SOLOPAK/	/2.5MG/ML/	/N70697/001/ /JUL 31, 1987/	> ADD >	
	∂ SOLOPAK	2.5MG/ML	N70697 001 JUL 31, 1987	> ADD >	

TABLET; ORAL

	VERAPAMIL HCL				
B*	CHELSEA	80MG	N70421 001 SEP 17, 1986		
B*		120MG	N70422 001 SEP 17, 1986		
/BX/		/80MG/	/N70421/001/ /SEP 17, 1986/		
/BX/		/120MG/	/N70422/001/ /SEP 17, 1986/		

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ISOPTIN SR			
KNOLL	120MG#	N19152 003	MAR 06, 1991

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

>DLT >/AP/	/LYPHOMED/	/1MG/ML/	/N89515/001/	/APR/29,/1987/
>DLT >				
>ADD >	LYPHOMED	1MG/ML	N89515 001	APR 29, 1987
>ADD >				
>DLT >/AP/	/QUAD/	/1MG/ML/	/N89311/001/	/MAR/23,/1987/
>DLT >				
>DLT >/AP/		/10MG/VIAL/	/N89365/001/	/AUG/07,/1986/
>DLT >				
>ADD >	@ QUAD	1MG/ML	N89311 001	MAR 23, 1987
>ADD >				
>ADD >	@	10MG/VIAL	N89365 001	AUG 07, 1986
>ADD >				

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE

>DLT >/AP/	/BULL/	/1MG/VIAL/	/N71559/001/	/APR/11,/1988/
>DLT >				
>DLT >/AP/		/2MG/VIAL/	/N71560/001/	/APR/11,/1988/
>DLT >				
>ADD >	BULL	1MG/VIAL	N71559 001	APR 11, 1988
>ADD >				
>ADD >		2MG/VIAL	N71560 001	APR 11, 1988
>ADD >				

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE

>DLT >/AP/	/QUAD/	/1MG/ML/	/N70777/001/	/APR/29,/1986/
>DLT >				
>DLT >/AP/		/1MG/ML/	/N70778/001/	/MAY/01,/1986/
>DLT >				
>DLT >/AP/		/1MG/VIAL/	/N71222/001/	/MAR/07,/1988/
>DLT >				
>DLT >/AP/		/2MG/VIAL/	/N71223/001/	/MAR/07,/1988/
>DLT >				
>DLT >/AP/		/5MG/VIAL/	/N71937/001/	/MAR/07,/1988/
>DLT >				
>ADD >	@ QUAD	1MG/ML	N70777 001	APR 29, 1986
>ADD >				
>ADD >	@	1MG/ML	N70778 001	MAY 01, 1986
>ADD >				
>ADD >	@	1MG/VIAL	N71222 001	MAR 07, 1988
>ADD >				
>ADD >	@	2MG/VIAL	N71223 001	MAR 07, 1988
>ADD >				
>ADD >	@	5MG/VIAL	N71937 001	MAR 07, 1988
>ADD >				

VITAMIN A PALMITATE

CAPSULE; ORAL

/VITAMIN A/

/AA/	/MILES/	/EQ 50,000 UNITS BASE/	/N80972/001/	
@ MILES		EQ 50,000 UNITS BASE	N80972 001	

WARFARIN SODIUM

TABLET; ORAL
WARFARIN SODIUM

/BX/	/BOLAR/	/2MG/	/N86123/001/ /AUG/17,/1982/
/BX/		/2.5MG/	/N86120/001/ /AUG/17,/1982/
/BX/		/5MG/	/N86119/001/ /AUG/17,/1982/
/BX/		/7.5MG/	/N86118/001/ /AUG/17,/1982/
/BX/		/10MG/	/N86122/001/ /AUG/17,/1982/
	ə BOLAR	2MG	N86123 001 AUG 17, 1982
	ə	2.5MG	N86120 001 AUG 17, 1982
	ə	5MG	N86119 001 AUG 17, 1982
	ə	7.5MG	N86118 001 AUG 17, 1982
	ə	10MG	N86122 001 AUG 17, 1982

XYLOSE

POWDER; ORAL
XYLO-PFAN

AA	ADRIA	25GM/BOT /25GM/BOT/	N17605 001 /N17605/001/

XYLOSE

AA	LYNE	25GM/BOT	N18856 001 MAR 26, 1987
/ə/		/25GM/BOT/	/N18856/001/ /MAR/26,/1987/

ACETAMINOPHEN

SUPPOSITORY; RECTAL		
/TYLENOL/		
/MCNEIL/	/120MG/	/N17756/002/
	/650MG/	/N17756/001/
@ MCNEIL	120MG	N17756 002
@	650MG	N17756 001

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL		
EXIDINE		
/3/XTTRIUM/	/2%/	/N19422/001/
		/DEC/17,/1985/
XTTRIUM	2%	N19422 001
		DEC 17, 1985
MICRODERM		
JOHNSON AND JOHNSON	4%¤	N72255 001
		APR 15, 1991
SPONGE; TOPICAL		
MICRODERM		
JOHNSON AND JOHNSON	4%¤	N72295 001
		FEB 28, 1991

CLOTRIMAZOLE

CREAM; TOPICAL		
MYCELEX		
MILES	1%¤	N18183 002
		APR 01, 1991
SOLUTION; TOPICAL		
MYCELEX		
MILES	1%¤	N18181 002
		APR 01, 1991

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL		
DISOBROM		
GENEVA	6MG;120MG¤	N70770 001
		SEP 30, 1991

DOXYLAMINE SUCCINATE

TABLET; ORAL		
DOXYLAMINE SUCCINATE		
COPLEY	25MG¤	N88900 002
		FEB 12, 1988

HYDROCORTISONE

/OINTMENT;/TOPICAL/		
/HC/(HYDROCORTISONE)/		
/C/AND/M/	/0.5%/	/N80481/001/
@ C AND M	0.5%	N80481 001

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL		
ADVIL COLD AND SINUS		
WHITEHALL	200MG;30MG	N19771 001
		SEP 19, 1989
/COADVIL/		
/WHITEHALL/	/200MG;30MG/	/N19771/001/
		/SEP/19,/1989/

INSULIN BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION		
NOVOLIN R		
NOVO NORDISK	100UNITS/ML¤	N19938 001
		JUN 25, 1991

INSULIN BIOSYNTHETIC HUMAN; INSULIN SUSP ISOPHANE BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION		
NOVOLIN 70/30		
NOVO NORDISK	30UNITS/ML;70UNITS/ML¤	N19991 001
		JUN 25, 1991

INSULIN PORK

INJECTABLE; INJECTION		
INSULIN		
/NOVO/NORDISK/	/40/UNITS/ML/	/N17926/001/
@ NOVO NORDISK	40 UNITS/ML	N17926 001

INSULIN SUSP ISOPHANE BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
NOVOLIN N
NOVO NORDISK 100UNITS/ML¤ N19959 001
JUL 01, 1991

INSULIN ZINC SUSP BEEF

INJECTABLE; INJECTION
LENTE INSULIN
/NOVO/NORDISK/ /40/UNITS/ML/ /N17998/001/
@ NOVO NORDISK 40 UNITS/ML N17998 001

INSULIN ZINC SUSP BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
NOVOLIN L
NOVO NORDISK 100UNITS/ML¤ N19965 001
JUN 25, 1991

MICONAZOLE NITRATE

CREAM; VAGINAL
MONISTAT 7
JOHNSON RW 2%¤ N17450 002
FEB 15, 1991

SUPPOSITORY; VAGINAL
MONISTAT 7
JOHNSON RW 100MG¤ N18520 002
FEB 15, 1991

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
SUDAFED 12 HOUR
BURROUGHS WELLCOME 120MG¤ N73585 001
OCT 31, 1991

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

>ADD< TABLET, EXTENDED RELEASE; ORAL
>ADD< TRIPROLIDINE AND PSEUDOEPHEDRINE HCL
>ADD< KV 120MG;5MG¤ N72758 001
>ADD< NOV 25, 1991

>_ADD_> TABLET, EXTENDED RELEASE; ORAL
>_ADD_> TRIPROLIDINE AND PSEUDOEPHEDRINE HCL
>_ADD_> KV 120MG;5MG N72758 001
>_ADD_> NOV 25, 1991

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE DIVISION OF BLOOD AND BLOOD PRODUCTS LIST
CUMULATIVE SUPPLEMENT NUMBER 10 / JAN '91 - NOV '91

HETASTARCH 6% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

INJECTABLE; INJECTION
HESPAN
DUPONT MERCK PHARM 6GM/100ML;0.9GM/100ML N890105
APR 04, 1991

PENTASTARCH 10% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

INJECTABLE; INJECTION
PENTASPAN
DUPONT MERCK PHARM 10GM/100ML;0.9GM/100ML N890104
APR 04, 1991

ORPHAN DRUG PRODUCT DESIGNATIONS

SECTION 526 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT CONTAINS PROVISIONS WHEREBY FDA MAY DESIGNATE A SPONSOR'S DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT AS A "DESIGNATED ORPHAN DRUG." SECTION 527 OF THE ACT ESTABLISHES A PROCESS WHEREBY A SPONSOR MAY RECEIVE SEVEN YEARS OF EXCLUSIVE APPROVAL STATUS IF THAT SPONSOR IS THE FIRST TO ACHIEVE NEW DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT APPROVAL FOR A DESIGNATED ORPHAN DRUG FOR THE DESIGNATED INDICATION(S). THE EXCLUSIVE APPROVAL MAY BE REVOKED BY WRITTEN CONSENT OF THE SPONSOR OR BY FDA ACTION AFTER FINDING THAT THE SPONSOR HOLDING EXCLUSIVE APPROVAL CANNOT ASSURE THE AVAILABILITY OF SUFFICIENT QUANTITIES OF THE DRUG TO MEET THE NEEDS OF PATIENTS WITH THE DESIGNATED ORPHAN INDICATION(S).

WHEN A PRODUCT IS GRANTED ORPHAN DRUG DESIGNATION, IT WILL APPEAR IN THIS SECTION. ONCE A BIOLOGICAL OR DRUG PRODUCT IS LICENSED/APPROVED FOR MARKETING, IT WILL BE LISTED IN THIS SECTION AND ASTERISKED, AS APPROPRIATE, TO DENOTE MARKETING/EXCLUSIVE APPROVAL STATUS. IN ADDITION, THE EXCLUSIVITY EXPIRATION DATE WILL BE DISPLAYED FOLLOWING THE APPROVED DESIGNATED INDICATION(S).

THE FOLLOWING DRUGS AND BIOLOGICALS HAVE BEEN GRANTED ORPHAN DRUG DESIGNATION PURSUANT TO SECTION 526 OF THE FOOD, DRUG, AND COSMETIC ACT AS AMENDED BY THE ORPHAN DRUG ACT [PUBLIC LAW 97-414].

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: ALPHA-GALACTOSIDASE A TRADE: CC-GALACTOSIDASE	TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY. (FABRY'S DISEASE).	DAVID H. CALHOUN, PH.D. CITY COLLEGE OF NEW YORK
GENERIC: ANTIVENOM (CROTALIDAE) PURIFIED (AVIAN) TRADE: NOT ESTABLISHED	TREATMENT OF ENVENOMATION BY POISONOUS SNAKES BELONGING TO THE CROTALIDAE FAMILY.	OPHIDIAN PHARMA
GENERIC: BOTULINUM TOXIN TYPE A TRADE: OCULINUM*/**	TREATMENT OF STRABISMUS ASSOCIATED WITH DYSTONIA IN ADULTS (PATIENTS 12 YEARS OF AGE AND ABOVE).*/** [DEC 29, 1996] TREATMENT OF BLEPHAROSPASM ASSOCIATED WITH DYSTONIA IN ADULTS (PATIENTS 12 YEARS OF AGE AND ABOVE).*/** [DEC 29, 1996] TREATMENT OF CERVICAL DYSTONIA.	ALLERGAN

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: CLOSTRIDIUM BOTULINUM TYPE F NEUROTOXIN TRADE: NOT ESTABLISHED	TREATMENT OF SPASMODIC TORTICOLLIS.	PORTON PRODUCTS LIMITED
GENERIC: CHIMERIC M-T412 (HUMAN-MURINE) IGG MONOCLONAL ANTI-CD4 ANTIBODY TRADE: NOT ESTABLISHED	TREATMENT OF MULTIPLE SCLEROSIS.	CENTOCOR, INC
GENERIC: CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) TRADE: NOT ESTABLISHED	USE IN CONJUNCTION WITH GANCICLOVIR SODIUM FOR THE TREATMENT OF CYTOMEGALOVIRUS PNEUMONIA IN BONE MARROW TRANSPLANT PATIENTS.	MILES, INC
GENERIC: EPOETIN ALPHA (RECOMBINANT-HUMAN) TRADE: EPOGEN*/**	TREATMENT OF ANEMIA ASSOCIATED WITH HIV INFECTION OR HIV TREATMENT. [TREATMENT OF AZT-INDUCED ANEMIA IN HIV INFECTED PATIENTS.*/**] [DEC 31, 1997]	AMGEN
GENERIC: FILGRASTIM TRADE: NEUPOGEN	TREATMENT OF PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) WHO, IN ADDITON, ARE AFFLICTED WITH CYTOMEGALOVIRUS RETINITIS (CMV RETINITIS) AND ARE BEING TREATED WITH GANCICLOVIR.	AMGEN, INC
GENERIC: HUMAN MONOCLONAL ANTIBODY AGAINST HEPATITIS B VIRUS TRADE: NOT ESTABLISHED	PROPHYLAXIS OF HEPATITIS B REINFECTION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION SECONDARY TO END-STAGE CHRONIC HEPATITIS B INFECTION.	SANDOZ PHARMACEUTICALS CORPORATION
GENERIC: INSULIN-LIKE GROWTH FACTOR-1 TRADE: MYOTROPHIN	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	CEPHALON, INC
GENERIC: INTERFERON (RECOMBINANT, BETA) TRADE: R-IFN-BETA	SYSTEMIC TREATMENT OF METASTATIC RENAL CELL CARCINOMA. SYSTEMIC TREATMENT OF CUTANEOUS T-CELL LYMPHOMA. SYSTEMIC TREATMENT OF CUTANEOUS MALIGNANT MELANOMA. INTRALESIONAL AND/OR SYSTEMIC TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA.	BIOGEN

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: INTERLEUKIN-1 ALPHA, HUMAN RECOMBINANT TRADE: NOT ESTABLISHED	FOR THE PROMOTION OF EARLY ENGRAFTMENT IN BONE MARROW TRANSPLANTATION. FOR HEMATOPOIETIC POTENTIATION IN APLASTIC ANEMIA.	IMMUNEX CORPORATION
GENERIC: INTERLEUKIN-1 RECEPTOR ANTAGONIST, HUMAN RECOMBINANT TRADE: ANTRIL	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	SYNERGEN, INC
GENERIC: INTERLEUKIN-3, RECOMBINANT HUMAN TRADE: NOT ESTABLISHED	PROMOTION OF ERYTHROPOIESIS IN DIAMOND-BLACKFAN ANEMIA (CONGENITAL PURE CELL RED APLASIA).	IMMUNEX CORPORATION
GENERIC: MONOCLONAL ANTIBODY PM-81 TRADE: NOT ESTABLISHED	ADJUNCTIVE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA.	MEDAREX, INC
GENERIC: LIPOSOME ENCAPSULATED RECOMBINANT INTERLEUKIN-2 TRADE: NOT ESTABLISHED	TREATMENT OF BRAIN AND CNS TUMORS.	ONCOTHERAPEUTICS, INC
GENERIC: MUCOID EXOPOLYSACCHARIDE PSEUDOMONAS HYPERIMMUNE GLOBULIN TRADE: MEPIG	TREATMENT OF PULMONARY INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA IN PATIENTS WITH CYSTIC FIBROSIS.	UNIVAX BIOLOGICS, INC
GENERIC: MYELIN TRADE: NOT ESTABLISHED	TREATMENT OF MULTIPLE SCLEROSIS.	AUTOIMMUNE, INC
GENERIC: POLY I: POLY $C_{12}U$ TRADE: AMPLIGEN	TREATMENT OF RENAL CELL CARCINOMA.	HEM RESEARCH, INC
GENERIC: RECOMBINANT HUMAN DEOXYRIBONUCLEASE (RHDNASE) TRADE: NOT ESTABLISHED	TO REDUCE MUCOUS VISCOSITY AND ENABLE CLEARANCE OF AIRWAY SECRETIONS IN PATIENTS WITH CYSTIC FIBROSIS.	GENENTECH, INC
GENERIC: RECOMBINANT SECRETORY LEUCOCYTE PROTEASE INHIBITOR TRADE: NOT ESTABLISHED	TREATMENT OF CONGENITAL ALPHA-1 ANTITRYPSIN DEFICIENCY. TREATMENT OF CYSTIC FIBROSIS.	SYNERGEN, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: RICIN (BLOCKED) CONJUGATED MURINE MONOCLONAL ANTIBODY (ANTI-B4) TO B CELL (CD 19) TRADE: NOT ESTABLISHED	FOR THE EX-VIVO PURGING OF LEUKEMIC CELLS FROM THE BONE MARROW OF NON-T CELL ACUTE LYMPHOCYTIC LEUKEMIA PATIENTS WHO ARE IN COMPLETE REMISSION.	IMMUNOGEN, INC
GENERIC: RICIN (BLOCKED) CONJUGATED MURINE MONOCLONAL ANTIBODY (N901) TO CD56 POSITIVE CELLS TRADE: NOT ESTABLISHED	TREATMENT OF SMALL CELL LUNG CANCER.	IMMUNOGEN, INC
GENERIC: SARGRAMOSTIM TRADE: LEUKINE*/**	TREATMENT OF NEUTROPENIA ASSOICATED WITH BONE MARROW TRANSPLANTS IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA, HODGKIN'S DISEASE AND ACUTE LYMPHOBLASTIC LEUKEMIA. [MAR 5, 1998]	IMMUNEX
GENERIC: SDZ MSL-109 TRADE: NOT ESTABLISHED	PROPHYLAXIS OF CYTOMEGALOVIRUS DISEASE IN PATIENTS UNDERGOING SOLID ORGAN TRANSPLANTATION. TREATMENT OF CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME.	SANDOZ PHARMACEUTICALS CORP
GENERIC: THYMOSIN ALPHA-1 TRADE: NOT ESTABLISHED	ADJUNCTIVE TREATMENT OF CHRONIC ACTIVE HEPATITIS B.	ALPHA 1 BIOMEDICALS, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: ALGLUCERASE TRADE: CEREDASE*/**	REPLACEMENT THERAPY IN PATIENTS WITH GAUCHER'S DISEASE TYPE I. [APR 5, 1998]	GENZYME
GENERIC: BERACTANT TRADE: SURVANTA*/**	PREVENTION OF NEONATAL RESPIRATORY DISTRESS SYNDROME (RDS).*/** [JUL 1, 1998] TREATMENT OF NEONATAL RESPIRATORY DISTRESS SYNDROME (RDS).*/** [JUL 1, 1998]	ROSS
GENERIC: CALCIUM GLUCONATE GEL TRADE: H-F GEL	EMERGENCY TOPICAL TREATMENT OF HYDROGEN FLUORIDE (HYDROFLUORIC ACID) BURNS.	LTR PHARMACEUTICALS, INC
GENERIC: CYCLOSPORINE 2% OPHTHALMIC OINTMENT TRADE: SANDIMMUNE	TREATMENT OF PATIENTS AT HIGH RISK OF GRAFT REJECTION FOLLOWING PENETRATING KERATOPLASTY. USE IN CORNEAL MELTING SYNDROMES OF KNOWN OR PRESUMED IMMUNOLOGIC ETIOPATHOGENESIS INCLUDING MOOREN'S ULCER.	SANDOZ PHARMACEUTICALS CORP
GENERIC: CYSTEAMINE HCL TRADE: NOT ESTABLISHED	TREATMENT OF NEPHROPATHIC CYSTINOSIS.	WARNER-LAMBERT COMPANY
GENERIC: DEFEROXAMINE AND DEXTRAN TRADE: BIO-RESCUE	TREATMENT OF ACUTE IRON POISONING.	BIOMEDICAL FRONTIERS, INC
GENERIC: DESMOPRESSIN ACETATE TRADE: DDAVP HIGH CONCENTRATION	TREATMENT OF MILD HEMOPHILIA A AND VON WILLEBRAND'S DISEASE.	RORER PHARMACEUTICAL CORP
GENERIC: DRONABINOL TRADE: MARINOL	STIMULATION OF APPETITE AND PREVENTION OF WEIGHT LOSS IN PATIENTS WITH A CONFIRMED DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS).	UNIMED, INC
GENERIC: ETIDRONATE DISODIUM TRADE: DIDRONEL	PREVENTION OF DEGENERATIVE METABOLIC BONE DISEASE OCCURRING IN PATIENTS WHO REQUIRE LONG TERM (6 MONTHS OR GREATER) TOTAL PARENTERAL NUTRITION. TREATMENT OF DEGENERATIVE METABOLIC BONE DISEASE OCCURRING IN PATIENTS WHO REQUIRE LONG TERM (6 MONTHS OR GREATER) TOTAL PARENTERAL NUTRITION.	MGI PHARMA, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: FLUDARABINE PHOSPHATE TRADE: FLUDARA*/**	TREATMENT OF REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA. [APR 18, 1998]	BERLEX
GENERIC: FOSPHENYTOIN TRADE: NOT ESTABLISHED	ACUTE TREATMENT OF PATIENTS WITH STATUS EPILEPTICUS OF THE GRAND MAL TYPE.	WARNER-LAMBERT COMPANY
GENERIC: GALLIUM NITRATE TRADE: GANITE*/**	TREATMENT OF HYPERCALCEMIA OF MALIGNANCY. [JAN 17, 1998]	FUJISAWA PHARM
GENERIC: GENTAMICIN IMPREGNATED PMMA BEADS ON SURGICAL WIRE TRADE: SEPTOPAL	TREATMENT OF CHRONIC OSTEOMYELITIS OF POST-TRAUMATIC, POSTOPERATIVE OR HEMATOGENOUS ORIGIN.	E. MERCK, DARMSTADT
GENERIC: HALOFANTRINE TRADE: HALFAN	TREATMENT OF MILD TO MODERATE ACUTE MALARIA CAUSED BY SUSCEPTIBLE STRAINS OF P. FACIPARUM AND P. VIVAX.	SMITHKLINE BEECHAM PHARMACEUTICALS
GENERIC: HISTRELIN TRADE: NOT ESTABLISHED	TREATMENT OF ACUTE INTERMITTENT PORPHYRIA, HEREDITARY COPROPORPHYRIA, AND VARIEGATE PORPHYRIA.	KARL E. ANDERSON, M.D. UNIVERSITY OF TEXAS
GENERIC: IDARUBICIN HCL TRADE: IDAMYCIN	TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN PEDIATRIC PATIENTS.	ADRIA
GENERIC: KETOCONAZOLE TRADE: NOT ESTABLISHED	FOR USE WITH CYCLOPORIN A TO DIMINISH THE NEPHROTOXICITY INDUCED BY CYCLOSPORIN IN ORGAN TRANSPLANTATION.	PHARMEDIC COMPANY
GENERIC: L-LEUCOVORIN CALCIUM TRADE: ISOVORIN	USE IN CONJUNCTION WITH HIGH-DOSE METHOTREXATE IN THE TREATMENT OF OSTEOSARCOMA.	LEDERLE LABORATORIES
GENERIC: LODOXAMIDE TROMETHAMINE TRADE: ALOMIDE	TREATMENT OF VERNAL KERATOCONJUNCTIVITIS.	ALCON LABORATORIES, INC
GENERIC: METRONIDAZOLE TRADE: METROGEL	TREATMENT OF PERIORAL DERMATITIS.	CURATEK PHARMACEUTICALS MEDICAL CENTER

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: NIFEDIPINE TRADE: NOT ESTABLISHED	TREATMENT OF INTERSTITIAL CYSTITIS.	JONATHAN FLEISCHMANN, M.D. CLEVELAND METROHEALTH
GENERIC: OFLOXACIN TRADE: NOT ESTABLISHED	TREATMENT OF BACTERIAL CORNEAL ULCERS.	ALLERGAN, INC
GENERIC: OM 401 TRADE: DREPANOL	PROPHYLACTIC TREATMENT OF SICKLE CELL DISEASE.	OMEX INTERNATIONAL, INC
GENERIC: OXANDROLONE TRADE: OXANDRIN	ADJUNCTIVE THERAPY FOR AIDS PATIENTS SUFFERING FROM HIV-WASTING SYNDROME.	GYNEX, INC
GENERIC: PENTOSTATIN TRADE: NIPENT*/**	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. TREATMENT OF HAIRY CELL LEUKEMIA. (SINGLE AGENT TREATMENT FOR ADULT PATIENTS WITH ALPHA-INTERFERON-REFRACTORY HAIRY CELL LEUKEMIA.*/** [OCT 11, 1998])	PARKE-DAVIS
GENERIC: POLOXAMER 331 TRADE: PROTOX	INITIAL THERAPY OF TOXOPLASMOSIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYDROME (AIDS).	BURROUGHS WELLCOME COMPANY
GENERIC: PRAMIRACETAM SULFATE TRADE: NOT ESTABLISHED	FOR THE MANAGEMENT OF COGNITIVE DYSFUNCTION AND ENHANCEMENT OF ANTIDEPRESSANT ACTIVITY ASSOCIATED WITH ELECTROCONVULSIVE THERAPY.	CAMBRIDGE NEUROSCIENCE, INC
GENERIC: RECOMBINANT BETA-GLUCOCEREBROSIDASE TRADE: NOT ESTABLISHED	FOR REPLACEMENT THERAPY IN PATIENTS WITH TYPES I, II, AND III GAUCHER'S DISEASE.	GENZYME CORPORATION
GENERIC: RECOMBINANT HUMAN SUPEROXIDE DISMUTASE TRADE: NOT ESTABLISHED	PREVENTION OF BRONCHOPULMONARY DYSPLASIA IN PREMATURE NEONATES WEIGHING LESS THAN 1500 GMS.	BIO TECHNOLOGY GENERAL CORP
GENERIC: RIBAVIRIN TRADE: VIRAZOLE	TREATMENT OF HEMORRHAGIC FEVER WITH RENAL SYNDROME.	ICN PHARMACEUTICALS, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: SOMATROPIN TRADE: SAIZEN	TREATMENT OF AIDS-ASSOCIATED CATABOLISM/WEIGHT LOSS.	SERONO LABORATORIES, INC
GENERIC: SUCCIMER TRADE: CHEMET*/**	TREATMENT OF LEAD POISONING IN CHILDREN.*/** [JAN 30, 1998] TREATMENT OF MERCURY INTOXICATION.	MCNEIL
GENERIC: SUCRALFATE TRADE: NOT ESTABLISHED	TREATMENT OF ORAL ULCERATIONS AND DYSPHAGIA IN PATIENTS WITH EPIDERMOLYSIS BULLOSA.	NASKA PHARMCAL CO
GENERIC: TESTOSTERONE PROPIONATE TRADE: NOT ESTABLISHED	TREATMENT OF VULVAR DYSTROPHIES.	STAR PHARMACEUTICALS, INC
GENERIC: TESTOSTERONE SUBLINGUAL TRADE: NOT ESTABLISHED	TREATMENT OF CONSTITUTIONAL DELAY OF GROWTH AND PUBERTY IN BOYS.	GYNEX, INC
GENERIC: TIRATRICOL TRADE: TRIACANA	USE IN COMBINATION WITH LEVO-THYROXINE TO SUPPRESS THYROID STIMULATING HORMONE (TSH) IN PATIENTS WITH WELL-DIFFERENTIATED THYROID CANCER WHO ARE INTOLERANT TO ADEQUATE DOSES OF LEVO-THYROXINE ALONE.	MEDGENIX GROUP
GENERIC: TOREMIFENE TRADE: NOT ESTABLISHED	HORMONAL THERAPY OF METASTATIC CARCINOMA OF THE BREAST.	ADRIA LABORATORIES, INC
GENERIC: URSODEOXYCHOLIC ACID TRADE: ACTIGALL	MANAGEMENT OF THE CLINICAL SIGNS AND SYMPTOMS ASSOCIATED WITH PRIMARY BILIARY CIRRHOSIS.	CIBA GEIGY
GENERIC: URSODEOXYCHOLIC ACID TRADE: URSOFALK	TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS.	INTERFALK U.S., INC

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: 3,4 DIAMINOPYRADINE TRADE: DYNAMINE	TREATMENT OF HEREDITARY MOTOR AND SENSORY NEUROPATHY TYPE I (CHARCOT-MARIE-TOOTH DISEASE).	MAYO CLINIC
GENERIC: 6-METHYLENANDROSTA-1,4-DIENE-3,17-DIONE TRADE: NOT ESTABLISHED	HORMONAL THERAPY OF METASTATIC CARCINOMA OF THE BREAST.	ADRIA LABORATORIES, INC
GENERIC: 566C80 TRADE: NOT ESTABLISHED	PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP) IN HIGH-RISK, HIV-INFECTED PATIENTS DEFINED BY ONE OR BOTH OF THE FOLLOWING CRITERIA: (1) A HISTORY OF ONE OR MORE EPISODES OF PCP, (2) A PERIPHERAL CD4+ (T4 HELPER/INDUCER) LYMPHOCYTE COUNT LESS THAN OR EQUAL TO 200/MM^3.	BURROUGHS WELLCOME COMPANY

DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO NOVEMBER 1991 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR IN VIVO BIOEQUIVALENCE STUDIES AND IN VITRO DISSOLUTION TESTING AVAILABLE FROM THE DIVISION OF BIOEQUIVALENCE, HFD-650, MPN-2 ROOM 278, 5600 FISHERS LANE, ROCKVILLE, MD 20857. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 11TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
ESTROGENS, CONJUGATED (TABLET)	AUG 21, 1991	

ANDA SUITABILITY PETITIONS

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 11TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
CARBAMAZEPINE SUSPENSION; ORAL	200MG/5ML	89 P-0399/CP	GUIDELINES	NEW DOSAGE FORM	APPROVED MAY 16, 1991
CLOBETASOL PROPIONATE LOTION; TOPICAL	0.05%	90 P-0198/ CP1	KROSS	NEW DOSAGE FORM	APPROVED MAR 14, 1991
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	100MG/VIAL	90 P-0250/ CP1	PHARMACHEMIE	NEW DOSAGE FORM	APPROVED MAY 07, 1991
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	200MG/VIAL	90 P-0250/ CP2	PHARMACHEMIE	NEW DOSAGE FORM	APPROVED MAY 07, 1991
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	500MG/VIAL	90 P-0250/ CP3	PHARMACHEMIE	NEW DOSAGE FORM	APPROVED MAY 07, 1991
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	1GM/VIAL	90 P-0250/ CP4	PHARMACHEMIE	NEW DOSAGE FORM	APPROVED MAY 07, 1991
CYTARABINE INJECTABLE; INJECTION	20MG/ML (100ML/CONTAINER)	86 P-0428/ CP005	ADRIA	NEW DOSAGE FORM	APPROVED OCT 28, 1991
DOPAMINE HYDROCHLORIDE INJECTABLE; INJECTION	5MG/ML	90 P-0137/ CP1	ABBOTT	NEW STRENGTH	APPROVED APR 10, 1991

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (25ML/VIAL)	91 P-0041/ CP1	ADRIA	NEW STRENGTH	APPROVED MAY 22, 1991
ESTRADIOL FILM, EXTENDED RELEASE; TRANSDERMAL	0.067MG/24HR	90 P-0125/ CP1	NOVEN PHARMS	NEW STRENGTH	APPROVED MAR 14, 1991
ESTRADIOL FILM, EXTENDED RELEASE; TRANSDERMAL	0.084MG/24HR	90 P-0125/ CP2	NOVEN PHARMS	NEW STRENGTH	APPROVED MAR 14, 1991
NIFEDIPINE CAPSULE, EXTENDED RELEASE; ORAL	30MG 60MG 90MG	90 P-0436/ CP1	KV	NEW DOSAGE FORM	APPROVED OCT 23, 1991
PANCURONIUM BROMIDE INJECTABLE; INJECTION	0.1MG/ML	91 P-0006/ CP1	LYPHOMED	NEW STRENGTH	APPROVED OCT 28, 1991
TECHNETIUM TC99 MEDRONATE KIT INJECTABLE; INJECTION	N/A	91 P-0040/ CP1	ABARIS	NEW STRENGTH	APPROVED OCT 28, 1991
TERFENADINE CAPSULE; ORAL	60MG	91 P-0087 CP1	ARTHUR A. CHECCHI	NEW DOSAGE FORM	APPROVED OCT 28, 1991

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
FUROSEMIDE INJECTABLE; INJECTION	1MG/ML	90 P-0313/ CP1	LYPHOMED	NEW STRENGTH	DENIED OCT 28, 1991

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 11TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES
NEW INDICATION

I-55	HYPERTENSION
I-56	EROSIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58	INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
I-59	ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60	SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61	FEMALE ANDROGENETIC ALOPECIA
I-62	PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-63	ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
I-64	PREVENTION OF SUPRAVENTRICULAR ARRHYTHMIAS
I-65	PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS

REFERENCES
PATENT USE CODE

U-44	RELIEF OF NAUSEA AND VOMITING
U-45	TREATMENT OF INFLAMMATION AND ANALGESIA
U-46	TREATMENT OF PANIC DISORDER
U-47	STIMULATION OF THE RELEASE OF GROWTH HORMONE
U-48	ANALGESIA

EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODE

U-49	SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
U-50	USE IN TREATING INFLAMMATORY DERMATOSES
U-51	BLOOD POOL IMAGING, INCLUDING FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
U-52	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-53	HYPERCALCEMIA OF MALIGNANCY
U-54	REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20089 001	ACYCLOVIR; ZOVIRAX	4199574	APR 22, 1997		NCE	MAR 29, 1992
>ADD>						I-45	APR 26, 1993
>ADD>	20089 002	ACYCLOVIR; ZOVIRAX	4199574	APR 22, 1997		NCE	MAR 29, 1992
>ADD>						I-45	APR 26, 1993
	20057 003	ALGLUCERASE; CEREDASE				NCE	APR 05, 1996
						ODE	APR 05, 1998
	18276 001	ALPRAZOLAM; XANAX	4508726	APR 02, 2002	U-46		
	18276 002	ALPRAZOLAM; XANAX	4508726	APR 02, 2002	U-46		
	18276 003	ALPRAZOLAM; XANAX	4508726	APR 02, 2002	U-46		
	18276 004	ALPRAZOLAM; XANAX	4508726	APR 02, 2002	U-46		
			3980789	SEP 14, 1993			
	19926 001	ALTRETAMINE; HEXALEN				ODE	DEC 26, 1997
	19155 001	AMMONIUM LACTATE; LAC-HYDRIN	4105783	OCT 26, 1995			
	18700 001	AMRINONE LACTATE; INOCOR	4072746	APR 23, 1998	U-7	NCE	JUL 31, 1994
>ADD>	19677 001	ATROPINE SULFATE; ENLON-PLUS	4952586	AUG 28, 2007	U-54	NC	NOV 06, 1994
>ADD>	19678 001	ATROPINE SULFATE; ENLON-PLUS	4952586	AUG 28, 2007	U-54	NC	NOV 06, 1994
	19851 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2000		NCE	JUN 25, 1996
	19851 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2000		NCE	JUN 25, 1996
	19851 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2000		NCE	JUN 25, 1996
	19851 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2000		NCE	JUN 25, 1996
	20032 001	BERACTANT; SURVANTA	4397839	AUG 10, 2000		NCE	JUL 01, 1996
	18709 001	CAPTOPRIL; CAPOZIDE 25/15				I-63	OCT 24, 1994
	18709 002	CAPTOPRIL; CAPOZIDE 25/25				I-63	OCT 24, 1994
	18709 003	CAPTOPRIL; CAPOZIDE 50/25				I-63	OCT 24, 1994
	18709 004	CAPTOPRIL; CAPOZIDE 50/15				I-63	OCT 24, 1994
	19856 001	CARBIDOPA; SINEMET CR	4900755	MAY 23, 2006			
			4832957	MAY 23, 2006			
			3830827	AUG 20, 1991		NDF	MAY 30, 1994
	19880 001	CARBOPLATIN; PARAPLATIN	4140707	AUG 25, 1998		I-58	JUL 05, 1994
	19880 002	CARBOPLATIN; PARAPLATIN	4140707	AUG 25, 1998		I-58	JUL 05, 1994
	19880 003	CARBOPLATIN; PARAPLATIN	4140707	AUG 25, 1998		I-58	JUL 05, 1994
	20044 001	CETYL ALCOHOL; EXOSURF NEONATAL	4312860	NOV 23, 2001		NC	AUG 02, 1993
	17920 002	CIMETIDINE; TAGAMET	3950333	APR 13, 1993		I-56	MAR 07, 1994
	17920 003	CIMETIDINE; TAGAMET	3950333	APR 13, 1993		I-56	MAR 07, 1994
	17920 004	CIMETIDINE; TAGAMET	3950333	APR 13, 1993		I-56	MAR 07, 1994
	17920 005	CIMETIDINE; TAGAMET	3950333	APR 13, 1993		I-56	MAR 07, 1994
	17924 001	CIMETIDINE HYDROCHLORIDE; TAGAMET	3950333	APR 13, 1993		I-56	MAR 07, 1994
>ADD>	17939 002	CIMETIDINE HYDROCHLORIDE; TAGAMET				I-65	NOV 13, 1994

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19849 001	DAPIPRAZOLE HYDROCHLORIDE; REV-EYES	4252721	FEB 24, 1998		NCE	DEC 31, 1995
	19082 001	DEZOCINE; DALGAN	4605671	AUG 12, 2003			
			4001331	JAN 04, 1996		NCE	DEC 29, 1994
			3836670	SEP 09, 1991	U-48		
	19082 002	DEZOCINE; DALGAN	4605671	AUG 12, 2003			
			4001331	JAN 04, 1996		NCE	DEC 29, 1994
			3836670	SEP 09, 1991	U-48		
	19082 003	DEZOCINE; DALGAN	4605671	AUG 12, 2003			
			4001331	JAN 04, 1996		NCE	DEC 29, 1994
			3836670	SEP 09, 1991	U-48		
	20037 001	DICLOFENAC SODIUM; VOLTAREN	4960779	OCT 02, 2007			
			3652762	MAR 28, 1991		NDF	MAR 28, 1994
	20154 002	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
	20154 003	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
	20154 004	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
	20154 005	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
	20155 003	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
	20155 004	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
	20155 005	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
	20155 006	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
	20156 001	DIDANOSINE; VIDEX	4861759	AUG 29, 2006	U-52	NCE	OCT 09, 1996
	20027 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM				NDF	OCT 24, 1994
	20027 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM				NDF	OCT 24, 1994
	18723 001	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008			
	18723 002	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008			
	18723 003	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008			
	19680 001	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008			
	19794 001	DIVALPROEX SODIUM; DEPAKOTE CP	4988731	JAN 29, 2008			
	19794 002	DIVALPROEX SODIUM; DEPAKOTE CP	4988731	JAN 29, 2008			
	19946 001	DOXACURIUM CHLORIDE; NUROMAX	4701460	OCT 20, 2004		NCE	MAR 07, 1996
	19668 001	DOXAZOSIN MESYLATE; CARDURA	4188390	FEB 12, 1999		NCE	NOV 02, 1995
	19668 002	DOXAZOSIN MESYLATE; CARDURA	4188390	FEB 12, 1999		NCE	NOV 02, 1995
	19668 003	DOXAZOSIN MESYLATE; CARDURA	4188390	FEB 12, 1999		NCE	NOV 02, 1995
	19668 004	DOXAZOSIN MESYLATE; CARDURA	4188390	FEB 12, 1999		NCE	NOV 02, 1995
	19080 001	ESTAZOLAM; PROSOM	3987052	OCT 19, 1995			
	19080 002	ESTAZOLAM; PROSOM	3987052	OCT 19, 1995			
	19081 002	ESTRADIOL; ESTRADERM				I-62	OCT 24, 1994
>ADD>	19081 003	ESTRADIOL; ESTRADERM				I-62	OCT 24, 1994
>DLT>	~~19081 003~~	~~ESTRADIOL; ESTRADERM~~				~~I-62~~	~~OCT 24, 1994~~
	19653 001	ETHINYL ESTRADIOL; ORTHO CYCLEN-21	4027019	MAY 31, 1996		NC	DEC 29, 1992
	19653 002	ETHINYL ESTRADIOL; ORTHO CYCLEN-28	4027019	MAY 31, 1996		NC	DEC 29, 1992

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	18922 002	ETODOLAC; LODINE	4076831	FEB 28, 1997	U-45		
>DLT>			~~4076831~~	~~FEB 28, 1997~~	~~U-45~~		
			3939178	FEB 17, 1993		NCE	JAN 31, 1996
>ADD>	18922 003	ETODOLAC; LODINE	4076831	FEB 28, 1997	U-45		
>DLT>			~~4076831~~	~~FEB 28, 1997~~	~~U-45~~		
			3939178	FEB 17, 1993		NCE	JAN 31, 1996
	19834 001	FELODIPINE; PLENDIL	4264611	APR 28, 1998		NCE	JUL 26, 1996
	19834 002	FELODIPINE; PLENDIL	4262611	APR 28, 1998		NCE	JUL 26, 1996
	18830 001	FLECAINIDE ACETATE; TAMBOCOR				I-64	OCT 23, 1994
	18830 003	FLECAINIDE ACETATE; TAMBOCOR				I-64	OCT 23, 1994
	18830 004	FLECAINIDE ACETATE; TAMBOCOR				I-64	OCT 23, 1994
	19949 001	FLUCONAZOLE; DIFLUCAN	4404216	OCT 16, 2003		NCE	JAN 29, 1995
	19949 002	FLUCONAZOLE; DIFLUCAN	4404216	OCT 16, 2003		NCE	JAN 29, 1995
	19949 003	FLUCONAZOLE; DIFLUCAN	4404216	OCT 16, 2003		NCE	JAN 29, 1995
	19950 001	FLUCONAZOLE; DIFLUCAN	4404216	OCT 16, 2003		NCE	JAN 29, 1995
	20038 001	FLUDARABINE PHOSPHATE; FLUDARA	4357324	NOV 02, 1999		NCE	APR 18, 1996
						ODE	APR 18, 1998
	20101 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001		NCE	DEC 29, 1992
	19957 001	FLUTICASONE PROPIONATE; CUTIVATE	4335121	MAR 16, 2002			
	19958 001	FLUTICASONE PROPIONATE; CUTIVATE	4335121	MAR 16, 2002			
	20068 001	FOSCARNET SODIUM; FOSCAVIR				NCE	SEP 27, 1996
	19915 002	FOSINOPRIL SODIUM; MONOPRIL	4384123	MAY 17, 2000			
			4337201	JUN 29, 1999		NCE	MAY 16, 1996
	19915 003	FOSINOPRIL SODIUM; MONOPRIL	4384123	MAY 17, 2000			
			4337201	JUN 29, 1999		NCE	MAY 16, 1996
>ADD>	19961 002	GALLIUM NITRATE; GANITE	4529593	JAN 17, 2005	U-49	NCE	JAN 17, 1996
>DLT>			~~4529593~~	~~JUL 16, 2002~~	~~U-49~~	~~NCE~~	~~JAN 17, 1996~~
						ODE	JAN 17, 1998
	19967 001	HALOBETASOL PROPIONATE; ULTRAVATE	4619921	DEC 17, 2004		NCE	DEC 17, 1995
	19968 001	HALOBETASOL PROPIONATE; ULTRAVATE	4619921	DEC 17, 2004		NCE	DEC 17, 1995
	19784 001	IBUPROFEN; RUFEN				NDF	SEP 19, 1992
	19580 001	IOTROLAN; OSMOVIST	4239747	DEC 16, 1999		NCE	DEC 07, 1994
	19580 002	IOTROLAN; OSMOVIST	4239747	DEC 16, 1999		NCE	DEC 07, 1994
	19546 001	ISRADIPINE; DYNACIRC	4466972	AUG 21, 2001	U-3	NCE	DEC 20, 1995
	19546 002	ISRADIPINE; DYNACIRC	4466972	AUG 21, 2001	U-3	NCE	DEC 20, 1995

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
18686 001	LABETALOL HYDROCHLORIDE; NORMODYNE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
18687 001	LABETALOL HYDROCHLORIDE; NORMODYNE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
18687 002	LABETALOL HYDROCHLORIDE; NORMODYNE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
18687 003	LABETALOL HYDROCHLORIDE; NORMODYNE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
18687 004	LABETALOL HYDROCHLORIDE; NORMODYNE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
18716 001	LABETALOL HYDROCHLORIDE; TRANDATE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
18716 002	LABETALOL HYDROCHLORIDE; TRANDATE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
18716 003	LABETALOL HYDROCHLORIDE; TRANDATE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
18716 004	LABETALOL HYDROCHLORIDE; TRANDATE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
19425 001	LABETALOL HYDROCHLORIDE; TRANDATE	4012444	AUG 02, 1998		NCE	AUG 01, 1994
20035 001	LEVAMISOLE HYDROCHLORIDE; ERGAMISOL	4584305	JUN 19, 2004	U-42	NCE	JUN 18, 1995
20088 001	LEVONORGESTREL; NORPLANT SYSTEM	3850911	NOV 26, 1991		NP	DEC 10, 1993
19753 001	MORICIZINE HYDROCHLORIDE; ETHMOZINE	3864487	FEB 04, 1994		NCE	JUN 19, 1995
19753 002	MORICIZINE HYDROCHLORIDE; ETHMOZINE	3864487	FEB 04, 1994		NCE	JUN 19, 1995
19753 003	MORICIZINE HYDROCHLORIDE; ETHMOZINE	3864487	FEB 04, 1994		NCE	JUN 19, 1995
19886 001	NAFARELIN ACETATE; SYNAREL	4234571	NOV 18, 1999		NCE	FEB 13, 1995
18612 001	NICOTINE POLACRILEX; NICORETTE	3901248	AUG 26, 1992		NCE	JAN 13, 1994
19684 001	NIFEDIPINE; PROCARDIA XL	4783337	SEP 16, 2003		I-55	SEP 06, 1992
		4765989	SEP 16, 2003		D-2	SEP 06, 1992
19684 002	NIFEDIPINE; PROCARDIA XL	4783337	SEP 16, 2003		I-55	SEP 06, 1992
		4765989	SEP 16, 2003		D-2	SEP 06, 1992
19684 003	NIFEDIPINE; PROCARDIA XL	4783337	SEP 16, 2003		I-55	SEP 06, 1992
		4765989	SEP 16, 2003		D-2	SEP 06, 1992
19508 001	NIZATIDINE; AXID	4382090	MAY 03, 2000	U-18	I-59	JUL 26, 1994
19508 002	NIZATIDINE; AXID	4382090	MAY 03, 2000	U-18	I-59	JUL 26, 1994
19757 001	NORFLOXACIN; CHIBROXIN	4551456	NOV 05, 2002			
		4146719	MAR 27, 1998		NDF	JUN 17, 1994
19735 001	OFLOXACIN; FLOXIN	4382892	MAY 10, 2002			
19735 002	OFLOXACIN; FLOXIN	4382892	MAY 10, 2002			
19735 003	OFLOXACIN; FLOXIN	4382892	MAY 10, 2002			
19715 001	OLSALAZINE SODIUM; DIPENTUM	4559330	AUG 04, 2004		NCE	JUL 31, 1995
19810 001	OMEPRAZOLE; PRILOSEC	4255431	MAR 10, 2000		I-57	JUN 12, 1994
20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 28, 2005	U-44	NCE	JAN 04, 1996
>ADD>		4695578	JAN 03, 2005			
>DLT>		~~4695578~~	~~SEP 22, 2004~~			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20036 001	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004		NCE	OCT 31, 1996
			3962432	JUN 08, 1993	U-53		
	20122 001	PENTOSTATIN; NIPENT	3923785	DEC 02, 1992		ODE	OCT 11, 1998
						NCE	OCT 11, 1996
	18631 001	PENTOXIFYLLINE; TRENTAL	3737433	APR 03, 1997		NCE	AUG 30, 1994
	19456 001	PINACIDIL; PINDAC	RE31244	NOV 08, 1996	U-3	NCE	DEC 28, 1994
	19456 002	PINACIDIL; PINDAC	RE31244	NOV 08, 1996	U-3	NCE	DEC 28, 1994
	19797 001	POLYETHYLENE GLYCOL 3350; NULYTELY				NP	APR 22, 1994
	19898 002	PRAVASTATIN SODIUM; PRAVACHOL	4346227	AUG 24, 1999		NCE	OCT 31, 1996
	19898 003	PRAVASTATIN SODIUM; PRAVACHOL	4346227	AUG 24, 1999		NCE	OCT 31, 1996
	19568 001	PREDNICARBATE; DERMATOP	4242334	DEC 30, 1997	U-50	NE	SEP 23, 1994
	19627 001	PROPOFOL; DIPRIVAN	4056635	NOV 01, 1996		NCE	OCT 02, 1994
	19664 001	PSEUDOEPHEDRINE HYDROCHLORIDE; SELDANE-D	3878217	APR 15, 1994		NC	AUG 19, 1994
>ADD>	19885 001	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005			
>ADD>			4344949	AUG 17, 1999	U-3	NCE	NOV 19, 1996
>ADD>	19885 002	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005			
>ADD>			4344949	AUG 17, 1999	U-3	NCE	NOV 19, 1996
>ADD>	19885 003	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005			
>ADD>			4344949	AUG 17, 1999	U-3	NCE	NOV 19, 1996
>ADD>	19885 004	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005			
>ADD>			4344949	AUG 17, 1999	U-3	NCE	NOV 19, 1996
	19901 001	RAMIPRIL; ALTACE	4587258	MAY 06, 2003		NCE	JAN 28, 1996
	19901 002	RAMIPRIL; ALTACE	4587258	MAY 06, 2003		NCE	JAN 28, 1996
	19901 003	RAMIPRIL; ALTACE	4587258	MAY 06, 2003		NCE	JAN 28, 1996
	19901 004	RAMIPRIL; ALTACE	4587258	MAY 06, 2003		NCE	JAN 28, 1996
>ADD>	19863 001	SERMORELIN ACETATE; GEREF	4703035	DEC 28, 2004	U-47	NCE	DEC 28, 1995
>DLT>			~~4703035~~	~~MAY 14, 2002~~	~~U-47~~	~~NCE~~	~~DEC 28, 1995~~
			4517181	MAY 14, 2002		NCE	DEC 28, 1995
	19998 002	SUCCIMER; CHEMET				NCE	JAN 30, 1996
						ODE	JAN 30, 1998
	19981 001	TECHNETIUM TC-99M RED BLOOD CELL KIT; ULTRATAG	4755375	JUL 05, 2005	U-51	NC	JUN 10, 1994
	19785 001	TECHNETIUM TC-99M SESTAMIBI KIT; CARDIOLITE	4452774	SEP 09, 2004		NCE	DEC 21, 1995
	19785 002	TECHNETIUM TC-99M SESTAMIBI KIT; CARDIOLITE	4452774	SEP 09, 2004		NCE	DEC 21, 1995

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	18163 001	TEMAZEPAM; RESTORIL				NS	OCT 25, 1994
>ADD>	18163 002	TEMAZEPAM; RESTORIL				NS	OCT 25, 1994
>ADD>	18163 003	TEMAZEPAM; RESTORIL				NS	OCT 25, 1994
	19979 001	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	MAY 27, 2003			
			4051141	SEP 27, 1994		NCE	OCT 31, 1996
	19979 002	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	MAY 27, 2003		NCE	OCT 31, 1996
			4051141	SEP 27, 1994			
	19798 001	TRIAMCINOLONE ACETONIDE; NASACORT				NR	JUL 11, 1994

*U.S. Government Printing Office: 1992 — 312-211/40005

New 12th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

12TH EDITION

Superintendent of Documents Supscriptions Order Form

Order Processing Code
* 6126

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** please send me the following indicated subscriptions:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $95.00 per year.

1. The total cost of my order is $_____. All prices include regular domestic postage and handling and are subject to change. International customers please add 25%.

Please Type or Print

2. _____
(Company or personal name)

_____
(Additional address/attention line)

_____
(Street address)

_____
(City, State, ZIP Code)

(_____) _____
(Daytime phone including area code)

3. **Please choose method of payment.**

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
(Signature)

(10/91)

4. **Mail To:** Superintendent of Documents, Government Printing Office, Washington, DC 20402-9371.
To **FAX** your charge order, call (202) 512-0019.
To charge your subscription call (202) 783-3238.